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Abstract
The peroxisomal proliferator activator receptors (PPARs) are ligand-activated transcription 
factors that play important roles in the regulation of lipid metabolism. Three PPAR isoforms 
have been identified: PPARα, PPARβ/δ, and PPARγ. Each isoform has specific functions 
determined by their relative abundance in a cell and regulation of specific target genes. 
A highly sensitive PPAR target gene is represented by Angiopoietin-like 4 (ANGPTL4), 
which was discovered by three independent groups in 2000. ANGPTL4 is produced in 
a number of organs including liver and adipose tissue, where its expression is governed 
by PPARα and PPARγ, respectively. Upon secretion, ANGPTL4 is cleaved into N- and 
C-terminal fragments that have divergent functions. nANGPTL4 is known to function as 
an inhibitor of lipoprotein lipase, whereas cANGPTL4 is involved in a number of processes 
including tumorigenesis and wound healing, and is known to interact with integrins β1 
and β5.
In this thesis we set out to expand our knowledge on the molecular function of ANGPTL4 
in the regulation of lipid metabolism. We performed animal experiments, cell culture, 
biochemical assays, and other functional measurements to zoom in on previously unexplored 
aspects of ANGPTL4.
Feeding mice deficient in ANGPLT4 a diet rich in long-chain saturated fatty acids elicited 
a complex phenotype and Angptl4–/– mice ultimately died from fibrinopurulent peritonitis. 
In contrast, the lethal phenotype was not observed when the fat component of the high-fat 
diet was changed to medium-chain fatty acids, suggesting a role for increased chyle flow via 
the lymphatic system. Indeed, Angptl4–/– mice had dramatically enlarged mesenteric lymph 
nodes which contained numerous lipid laden macrophages. In vitro experiments showed 
that PPARβ/δ-mediated induction of ANGPTL4 results in inhibition of macrophage LPL. 
In the absence of ANGPTL4, lipid uptake in mesenteric lymph node resident macrophages 
is increased, leading to ER stress and subsequent pro-inflammatory response. 
Additionally, Angptl4–/– mice initially gain more weight when fed a high-fat diet. The 
increased body weight and adiposity was unrelated to food intake, activity, or energy 
expenditure. Remarkably, we observed decreased fecal lipid excretion in Angptl4–/– mice, 
which coincided with increased lipase activity in the intestinal lumen. Using biochemical 
assays we reveal that ANGPTL4 inhibits pancreatic lipase.
In the second part of this thesis we identify a novel PPAR target gene named hypoxia 
inducible lipid droplet associated (HILPDA). We observed Hilpda expression to be increased 
in liver slices exposed to a synthetic PPARα ligand. Additionally, oral dosing of similar 
ligand induced a marked increase in HILPDA expression in livers of wild-type mice but 
not Ppara–/– mice. Induction of HILPDA expression by PPAR was found to be mediated 
by a conserved and functional PPAR response element located 1200 base pair upstream of 
the transcription start site of Hilpda. Functional characterization of HILPDA in liver was 
performed via adeno-associated virus-mediated overexpression. Interestingly, increased 
hepatic expression of HILPDA was associated with the development of a fatty liver, which 
could be attributed to a decrease in hepatic very low-density lipoprotein (VLDL) production. 
HILPDA was also found to be highly expressed in both human and mouse adipose tissue, 
where its expression is under the control of PPARγ and β-adrenergic receptor. Moreover, 
adipose tissue HILPDA expression was increased with fasting but decreased with high-fat 
feeding. HILPDA did not affect 3T3-L1 adipogenesis. Furthermore, adipose tissue specific 
Hilpda knock-out mice showed no major metabolic perturbations upon fasting. However, 
overexpression of HILPDA in adipocytes significantly reduced the release of NEFAs upon 
β-adrenergic receptor activation. Induction of HILPDA by β-adrenergic receptor stimulation 
may be part of feedback mechanism to regulate adipocyte lipolysis.
In conclusion, in thesis we have extended the current knowledge on the function of 
ANGPTL4. We show that ANGPTL4 serves as an important regulator in the process of 
lipid digestion and in the protection of macrophages that reside in mesenteric lymph nodes. 
HILPDA is a novel PPAR target that is involved in hepatic VLDL secretion and adipocyte 
lipolysis. Future research will focus on elucidating the mechanistic aspects of the regulation 
and function of HILPDA in liver and adipose tissue.
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Lipid digestion
Our diet contains three major macronutrients that can provide energy: carbohydrates, 
lipids, and proteins. Carbohydrates and proteins yield 4 kcal of energy per gram whereas 
lipids contribute 9 kcal of energy per gram. Around 34% of the energy in the current diet 
of the Dutch population is derived from lipids, which corresponds to 70-105 gram of fat 
per day, depending on age and gender (1). Dietary fat mainly consists of triglycerides (TGs) 
(95%), with minor fractions of phospholipids and cholesteryl esters. The human body is 
able to extract > 90% of these TGs with the aid of several lipases. 
Digestion of TGs starts in the mouth by the enzyme lingual lipase followed by 
contractions of the stomach to mix lipids with water, gastric acid, and gastric lipase 
secreted by the chief cells of the stomach (2). However, the major fraction of dietary lipids 
is digested in the small intestine (3). In the duodenum, the predigested food is emulsified 
with bile acids to allow for efficient digestion. At the same time, the pancreas releases 
several digestive enzymes including lipases such as pancreatic lipase (PL), carboxyl ester 
hydrolase, and pancreatic lipase-related protein 2 (3). Among those PL is the major lipase 
involved in the digestion of dietary lipids and hydrolyzes the ester bonds at the sn-1 and 
sn-3 positions of TGs (3). 
PL is a carboxyl esterase that is part of the family of extracellular lipases that includes 
lipoprotein lipase (LPL), hepatic lipase, and endothelial lipase (4). Inhibition of PL by 
pharmacological inhibitors such as Orlistat lowers the amount of lipid that is digested 
and subsequently absorbed by 30% and is used in the treatment of obesity (5). Similarly, 
many plant-derived components have been found to inhibit PL (6). Following PL mediated 
hydrolysis, 2-monoacylglycerol (2-MG) and fatty acids mix with bile acids to form 
micelles that subsequently migrate to the apical membrane of enterocytes (7). The precise 
mechanisms by which 2-MG and fatty acids enter enterocytes are not completely understood 
and several mechanism including passive diffusion and active transport via transporters 
such as CD36 and fatty acid binding proteins (FABPs) have been postulated (7, 8).
Chylomicron formation and secretion
Once taken up by enterocytes, 2-MG and fatty acids are re-esterified into TGs catalyzed by 
several monoacylglycerol acyltransferase (MGAT) and acyl-coenzyme A: diacylglycerol 
acyltransferase (DGAT) enzymes localized at the surface of the endoplasmic reticulum 
(ER) (9-11). Within the rough ER, apolipoprotein B48 (APOB48) is lipidated by the 
enzyme microsomal triglyceride transfer protein (MTTP) to form a primordial particle 
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(12, 13). These particles fuse with intraluminal ER-associated lipid droplets to form 
pre-chylomicrons that are subsequently transported to the Golgi via transport vesicles 
(14). After maturation in the Golgi, the chylomicrons are subsequently secreted into 
intercellular space by exocytosis after which the chylomicrons enter the intestinal lacteals 
(15, 16). Lacteals transporting chylomicrons merge into the mesenteric lymph duct, then 
into the thoracic duct. Chylomicrons ultimately enter the circulation in the subclavian 
vein. Following a high-fat meal the production and secretion of chyle and chylomicrons 
increases and TG concentrations in the mesenteric lymph duct can reach concentrations 
up to 55 mM (17). During the transport of chyle in the mesenteric lymphatics numerous 
mesenteric lymph nodes (MLNs) are encountered. MLNs contain a variety of immune 
cells including T cells and macrophages that sample chyle for the presence of antigens 
(18). As a consequence of their localization, mesenteric lymph node resident immune cells 
are exposed the high concentration of TGs as mentioned above. In contrast to long-chain 
fatty acids, short- and medium-chain fatty acids (SCFA/MCFA) are absorbed apically 
and secreted basolateral without being incorporated into chylomicrons. Instead, SCFA 
and MCFA are secreted in the portal vein and transported to the liver directly (19, 20). 
Uptake of non-esterifi ed fatty acids from lipoproteins via LPL
Chylomicrons that have entered the circulation deliver their TGs to peripheral tissues 
to serve as energy source of for storage. In the circulation chylomicrons acquire several 
additional apoliproteins such as APOC2 and APOE that aid in the clearance of TGs (21, 
22). In order for peripheral tissues to efficiently hydrolyze fatty acids from chylomicrons, 
the presence of LPL is required (23). Expression of LPL is found in numerous tissues that 
are characterized by elevated uptake of lipids such as skeletal muscle, adipose tissue and 
heart (23). Production of LPL takes place in the parenchymal cells after which the enzyme 
is secreted and transported to the luminal surface of capillary endothelial cells. Here, LPL 
is anchored to heparin sulfate proteoglycans (HSPG) and glycosylphosphatidylinositol 
anchored high density lipoprotein binding protein 1 (GPIHBP1) (24, 25). Interestingly, 
GPIHBP1 is responsible for LPL translocation across the endothelial cells and prevents LPL 
from being inactivated by ANGPTL4 (see below) (26, 27). LPL functions as a homodimer 
and requires cofactors including APOC2 to catalyze the lipolysis of TGs from chylomicrons 
(21, 23, 28). The resulting products of LPL mediated hydrolysis, glycerol and non-esterified 
fatty acids (NEFAs) are then taken up by the parenchymal cells to be used in a variety of 
processes such as β-oxidation, synthesis of lipid derived components, or storage in lipid 
droplets after re-esterification to triglycerides. 
Chapter 1
12
NEFAs activate PPARS 
Additionally, lipids that are taken up can activate transcription factors of the peroxisomal-
proliferator activated receptor (PPAR) family (29). PPARs are part of a larger family of 
nuclear hormone receptors that includes additional members such as the glucocorticoid 
receptor, vitamin D receptor, and the liver X receptor (30, 31). To date, three PPAR isoforms 
have been identified: PPARα, PPARβ/δ and PPARγ, all of which function as a heterodimer 
with the retinoid X receptor (RXR) (32, 33). Similar to most nuclear receptors, PPARs 
contain several distinct domains: an N-terminal activation function 1 (AF1), a DNA 
binding domain (DBD), a ligand binding domain (LBD), and an activation function 2 (AF2) 
located within the LBD (34). Upon ligand activation PPARs dismiss several corepressors 
such as nuclear receptor co-repressor (NCoR) and silencing mediator of retinoic acid 
and thyroid hormone receptor (SMRT) and simultaneously recruit coactivators including 
CREB binding protein (CBP/p300) and peroxisome proliferator activated receptor gamma 
coactivator 1 alpha (PGC-1α) (35-37). Together, these actions initiate the binding of PPARs 
to specific loci in the DNA called PPAR response elements (PPREs) that are present in 
promoter regions but also in introns and intergenic regions (34, 38). Each PPAR displays 
a distinct expression profile: PPARα is mainly expressed in liver, brown adipose tissue, 
skeletal muscle, and heart, PPARβ/δ is expressed ubiquitously, while PPARγ expression 
is primarily localized to adipose tissue (34, 39-41). These differential expression profiles 
together with inherent biochemical properties and ligand specificity determine the genes 
that are regulated by each PPAR and consequently their specific function. PPARα regulates 
many genes that are involved in the oxidation of fatty acids, although it is increasingly 
recognized as an important regulator of other metabolic processes such as gluconeogenesis 
and bile metabolism (42). The function of PPARβ/δ is less well characterized though 
accumulating data suggest that it induces β-oxidation in skeletal muscle and heart (40). 
PPARγ was identified in adipose tissue where it plays a role in the development as well is in 
the maintenance of adipose tissue (43). Although all PPARs can be activated by fatty acids 
and fatty acid-derived components, the specific ligands are poorly defined. High affinity 
ligands such as fibrates and thiazolidinediones are used in the treatment of hyperlipidemia 
and type 2 diabetes and act via PPARα and PPARγ, respectively (44-46).
Induction of ANGPTL4 via PPARs
One of the genes that is under the control of the family of PPAR receptors is angiopoietin-
like 4 (ANGPTL4). ANGPTL4 was identified as PPAR target when livers from wild-type 
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and Ppara–/– mice were analyzed for differentially expressed genes (47). In later years, the 
PPAR dependent regulation was confirmed with the identification of a PPRE located within 
intron 3 (48). The Angptl4 gene contains 6 introns and 7 exons that encode a protein of 406 
amino acids. Expression of ANGPTL4 is ubiquitous with high expression levels in liver, 
adipose tissue, heart, and intestine (47, 49, 50). ANGPTL4 is subjected to several post-
translational modifications that take place upon secretion, such as cleavage, glycosylation 
and sialylation (51-55). Proteolytic processing of ANGPTL4 yields an N-terminal fragment 
containing a coiled-coil domain and a C-terminal fragment that comprises a fibrinogen-
like domain (56). cANGPTL4 circulates as a monomer, serves as a ligand for β1 and β5 
integrins, and is involved in numerous processes including angiogenesis, wound healing, 
and tumorigenesis (56-58). In contrast, nANGPTL4 forms oligomers and plays an 
important role in the regulation of lipid uptake via regulation of LPL in a number of tissues 
and cells in an autocrine and endocrine manner (59). For instance, lipid accumulation 
in cardiomyocytes via LPL mediated hydrolysis of chylomicrons leads to the activation 
of PPARβ/δ, induction of Angptl4 expression and ultimately inhibition of LPL activity by 
secreted ANGPTL4 (60). Hence, induction of ANGPTL4 by ligand-activated PPAR serves 
as a feedback mechanism to prevent aberrant lipid accumulation. The precise mechanism by 
which ANGPTL4 inhibits LPL is unclear. Several lines of evidence suggest that ANGPTL4 
inhibits LPL by non-reversible degradation of LPL homodimers (61, 62). More recently 
an additional mechanism has been proposed in which ANGPTL4 reversibly inhibits LPL 
in the subendothelial space by forming a complex (63). In addition to the PPARs, several 
other transcription factors have been implicated in the regulation of ANGPTL4, including 
the glucocorticoid receptor and hypoxia-inducible factor (64-66).
Uptake of chylomicron remnants in liver and production of VLDL
After delivery of the vast majority of their TGs to peripheral tissues, chylomicron remnant 
particles are taken up by the liver via LDL receptor, LDL receptor related protein, and HSPG 
mediated pathways (67-70). The liver does not store major quantities of lipids although 
several conditions including obesity, cancer cachexia, and fasting are associated with an 
increase in hepatic lipid accumulation (71-73). Indeed, the majority of lipids in liver are 
secreted back in to the circulation incorporated in VLDL, a process that is generally believed 
to be largely driven by substrate availability (74). Assembly and secretion of VLDL in liver 
and chylomicrons in the intestine share many similarities and both processes rely on the 
lipidation process initiated by MTTP (75, 76). Nevertheless, there are some key differences. 
For instance, chylomicron synthesis starts with the lipidation of APOB48, whereas VLDL 
Chapter 1
14
synthesis starts with APOB100. Both apolipoproteins are derived from the same gene, yet 
in the intestine a stop codon is introduced via RNA editing by APOBEC1 and APOBEC1 
complementation factor (ACF), resulting in the translation of a smaller protein (77, 78). 
It should be noted that rats and mice produce APOB48-containing particles in liver as 
well (79, 80). VLDL contains relatively more cholesterol and phospholipids compared to 
chylomicrons. Once secreted, VLDL redistributes TGs to LPL-expressing tissues including 
heart, muscle and adipose tissue. 
Outline of this thesis
The main aim of this thesis is to increase our understanding regarding the function of 
ANGPTL4 in lipid metabolism. In chapter 2 we present a contemporary overview of the 
knowledge on ANGPTL proteins and their role in triglyceride metabolism. Chapter 3 
uncovers the key role of ANGPTL4 in the regulation of lipid uptake by mesenteric lymph 
node resident macrophages. Using Angptl4–/– mice we show that a PPARβ/δ-ANGPTL4 
feedback mechanism in these macrophages protects them from an inflammatory response 
provoked by uncontrolled influx of saturated fatty acids. In chapter 4 we reveal a new role 
for ANGPTL4 in the regulation of lipid uptake in the intestine. Employing a combination 
of in vivo and in vitro experiments, we provide evidence for an ANGPTL4-mediated 
reduction in lipid harvest from dietary sources. As a result, Angptl4–/– animals are heavier 
and have increased fat mass. In chapter 5 we identify hypoxia inducible lipid droplet 
associated (HILPDA) as a novel PPAR target gene involved in the regulation of VLDL 
production. Chapter 6 describes the regulation and function of HILPDA in adipose tissue. 
We demonstrate that HILPDA plays a role as an inhibitor of β-adrenergic receptor induced 
lipolysis. Finally, in chapter 7 we discuss our findings, integrate the different chapters and 
provide a general conclusion.
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Abstract
Plasma triglyceride concentrations are determined by the balance between production 
of the triglyceride-rich lipoproteins VLDL and chylomicrons in liver and intestine, and 
their lipoprotein lipase-mediated clearance in peripheral tissues. In the last decade, the 
group of Angiopoietin-like proteins has emerged as important regulators of circulating 
triglyceride (TG) levels. Specifically, ANGPTL3 and ANGPTL4 impair TG clearance 
by inhibiting lipoprotein lipase (LPL). Whereas ANGPTL4 irreversibly inactivates LPL 
by promoting conversion of active LPL dimers into inactive monomers, ANGPTL3 
reversibly inhibits LPL activity. Studies using transgenic or knockout mice have clearly 
demonstrated the stimulatory effect of ANGPTL3 and ANGPTL4 on plasma TG, 
which is further supported by human genetic data including genome wide association 
studies. Whereas ANGPTL3 is mainly active in the fed state, ANGPTL4 is elevated 
by fasting and mediates fasting-induced changes in plasma TG and free fatty acid 
metabolism. Both proteins undergo oligomerization and are subject to proteolytic 
cleavage to generate N- and C-terminal fragments with highly divergent biological 
activities. Expression of ANGPTL3 is exclusive to liver and governed by the liver X 
receptor (LXR). In contrast, ANGPTL4 is expressed ubiquitously and under sensitive 
control of the Peroxisome proliferator-activated receptor (PPAR) family. Induction of 
ANGPTL4 gene expression by fatty acids via PPARs is part of a feedback mechanism 
aimed at protecting cells against lipotoxicity. So far there is very little evidence that 
other ANGPTLs directly impact plasma lipoprotein metabolism.
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Introduction
The extracellular lipase gene family represents one of the most robust gene families in 
living organisms. Members of the family, which include Hepatic Lipase (HL), Endothelial 
Lipase (EL), Lipoprotein Lipase (LPL), and Pancreatic Lipase (PL) share significant 
structural homology and are essential for maintaining lipid homeostasis. Pancreatic 
lipase is responsible for digesting dietary triglycerides, thereby permitting uptake of 
lipids from food. Hepatic lipase facilitates uptake of remnant lipoproteins, is involved in 
remodeling of HDL, and catalyzes conversion of IDL to LDL. Endothelial lipase targets 
circulating phospholipids and regulates plasma HDL levels. Finally, Lipoprotein lipase 
catalyzes breakdown of triglyceride-rich lipoproteins and as such is a major determinant 
of circulating TG levels. Given their importance in lipid homeostasis, the activity of 
extracellular lipases needs to be carefully controlled. In recent years it has become evident 
that the activity of some lipases is regulated by members of the family of Angiopoetin-
like proteins. To date seven Angiopoietin-like proteins have been identified named 
ANGPTL1 through ANGPTL7. All ANGPTLs contain an N-terminal signal peptide 
that directs the proteins towards secretion, an N-terminal coiled-coil domain, a linker 
region, and a C-terminal fibrinogen-like domain. Here we review the current knowledge 
on ANGPTL2-6 and their role in regulation of metabolism of plasma lipids, moving from 
human genetic data to transgenic animal and in vitro data. No metabolic function has 
thus far been attributed to ANGPTL1 or ANGPTL7, which therefore are not discussed 
in this review. 
ANGPTL2
No sequence variants in ANGPTL2 have been identified that are associated with alterations 
in plasma lipoprotein levels. Deletion of Angptl2 in mice leads to amelioration of adipose 
tissue inflammation and insulin resistance in obese mice, whereas Angptl2 overexpression 
promotes adipose tissue inflammation and systemic insulin resistance (1). However, unlike 
ANGPTL3 and ANGPTL4, there is no evidence that ANGPTL2 directly regulates plasma 
lipid levels. Administration of recombinant Angptl2 to diabetic db/db mice was recently 
shown to significantly reduce serum TG levels and free fatty acids. However, these changes 
are likely indirect via changes in insulin sensitivity in adipocytes (2). Expression of Angptl2 
is found in several tissues including adipose tissue where it follows a circadian rhythmicity 
(1, 2). Data on regulation of Angptl2 mRNA are scarce and remain ambiguous with respect 
to the effect of obesity and endoplasmic reticulum stress (1, 2). 
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ANGPTL3
Human genetic studies
ANGPTL3 represents one of the many genes that have been linked to circulating lipids in 
recent genome wide association studies (3-5). Several SNPs at loci near ANGPTL3 have 
been associated with plasma lipid concentrations. ANGPTL3 rs12130333 is associated 
with the Fredrickson hyperlipoproteinemia type 5, representing a mixed hyperlipidaemia 
characterized by elevated VLDL and chylomicrons levels (6). More recently, rs2131925 
was identified as the lead SNP in ANGPTL3 and was shown to be associated with a mean 
reduction in plasma TG of 4.94 mg/dL (7). rs2131925 is located within the DOCK7 
gene located upstream of the ANGPTL3 gene and impacts ANGPTL3 expression, likely 
by being situated within regulatory elements (7). In another report, the ANGPTL3 SNP 
rs12042319 was associated with lower LDL-C, TG, and IL-6 levels but counter-intuitively 
with increased risk for coronary heart disease (8). Re-sequencing of the seven exons of 
ANGPTL3 in the Dallas Heart Study has provided further evidence for a link between 
the ANGPTL3 gene and plasma TG levels in humans. A total of 35 non-synonymous 
sequence variants were identified and variants that yield a loss-of-function allele were 
all in the lowest quartile of TG levels. Fourteen out of 35 non-synonymous variants were 
in the lower quintile for TG, while 5 variations were found in the upper quintile. Variant 
M259T, which is mainly present in African Americans and rare among individuals of 
European descent, was associated with lower plasma TG levels in the Dallas Heart Study 
and among African Americans in the Atherosclerosis Risk in Communities study (9). 
Recently, exome sequencing of 15,994 genes of two individuals from a family with familial 
combined hypolipidemia led to the identification of two novel ANGPTL3 gene variants that 
introduce a stop codon at positions 17 and 129. Subsequent sequencing of the first exon 
in all family members identified 13 normal heterozygotes and 4 compound heterozygotes, 
with the latter exhibiting significantly lower plasma LDL-C and TG levels. The normal 
heterozygotes in turn had significantly lower plasma LDL-C and TG levels compared to 21 
non-mutant family members (10). Thus, human genetic studies clearly link the ANGPTL3 
gene to regulation of plasma lipid levels, with a primary effect on plasma TG.
Based on the above data, a positive association between plasma ANGPTL3 levels and 
plasma TG levels may be expected. However, in two Japanese studies, ANGPTL3 levels did 
not correlate with TG levels (11, 12). Also, no correlation between plasma ANGPTL3 and 
TG was found in a small group of 20 overweight and obese subjects (13). More recently, an 
inverse correlation between ANGPTL3 levels and TG concentration was found in a Finnish 
population. Interestingly, when HDL-C and ApoA-I were used as control variables, the 
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association between ANGPTL3 and TG was no longer apparent, indicating that the effect 
of ANGPTL3 on TG levels may be dependent on HDL concentration (14). It should be 
noted that the lack of a clear association between plasma ANGPTL3 and TG levels does 
not necessarily invalidate ANGPTL3 as a determinant of plasma TG in humans yet does 
raise questions about whether circulating ANGPTL3 represents the functional pool of 
protein. Proper interpretation of the data on circulating ANGPTL3 also requires additional 
information on what the ELISA actually detects, as ANGPTL3 undergoes cleavage to 
generate fragments that likely vary in their biological activity.
ANGPTL3 raises plasma triglycerides in mice via LPL inhibition
An abundance of data from animal studies supports an inhibitory effect of ANGPTL3 on 
plasma TG metabolism in mice. In an effort to explain the low plasma TG levels in the 
mutant KK/San mice, Koshi and colleagues discovered that the KK/San animals carry 
a 4 base pair insert in exon 6 of the Angptl3 gene creating a stop codon at position 347. 
Adenoviral-mediated delivery of either mouse or human ANGPTL3 in both KK/San and 
C57BL/6J mice raised plasma TG levels, as did injection of recombinant ANGPTL3 in 
KK/San animals (15). Consistent with these findings, targeted deletion of Angptl3 lowers 
plasma TG and cholesterol levels (16). The hypertriglyceridemic effect of ANGPTL3 is 
most prominent during the fed state, suggesting that ANGPTL3 mainly plays a role in 
regulation of peripheral lipid uptake after feeding (16).
Data abound indicating that the plasma TG raising effect of ANGPTL3 is mediated by 
inhibition of LPL activity (Figure 1). Low TG levels in the KK/San mice can be attributed to 
marked augmentation of the LPL-dependent clearance rate of VLDL-TG from the plasma, 
and not by changes in the hepatic VLDL triglyceride secretion rate (17). Consistent with 
these findings, absence of ANGPTL3 markedly increases post-heparin LPL activity, while 
HL activity is only mildly affected (17, 18). Despite its strong effects in vivo, recombinant 
ANGPTL3 only weakly inhibits LPL catalytic activity and does not cause permanent 
LPL inactivation in a biochemical assay (19). The discrepancy may be explained by the 
suggested stimulatory effect of ANGPTL3 on LPL cleavage mediated by endogenous 
FURIN and PCSK6, causing dissociation of LPL from the cell surface (20). Interestingly, 
while the inhibitory effect of ANGPTL3 on LPL activity in vitro and in vivo was found 
to be mitigated by heparin and the LPL anchor and transport protein GPIHBP1 (19, 21), 
ANGPTL3-induced LPL cleavage was unaffected by heparan-sulphate proteoglycans or 
GPIHBP1 in a cell based system (20). Inhibition of LPL activity by ANGPTL3 is dependent 
on a heparin-binding site and three polar residues located within the N-terminal coiled-
coil region: Asn46, Gln50, and His53 (18, 22). 
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Figure 1. Current model on regulation of LPL-mediated lipolysis by ANGPTL3 and ANGPTL4
ANGPTL3 is predominantly expressed in hepatocytes and is under transcriptional control of the 
Liver X Receptor. ANGPTL4 is expressed in multiple cell types including adipocytes, hepatocytes, and 
macrophages, and expression is governed by PPARs. ANGPTL3 and ANGPTL4 undergo several post-
translational modifications that include oligomerization, glycosylation and proprotein convertase 
(PCSK)-mediated cleavage. LPL inhibition by ANGPTL3 and ANGPTL4 is dependent on three polar 
residues on position 46, 50, and 53 within the N-terminal coiled-coil domain. ANGPTL4 permanently 
inactivates LPL at least partly by promoting the dissociation of LPL dimer into inactive LPL monomers. 
In contrast, ANGPTL3 reversibly inhibits LPL activity. The C-terminal fibrinogen-like domain (FLD) does 
not seem to have a direct function in regulation of TG metabolism.  
GPIHBP1 = glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1. HSPG = 
heparan-sulphate proteoglycan. SP = signal peptide. 
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Next to its role in regulation of TG homeostasis, ANGPTL3 is capable of inhibiting 
endothelial lipase (EL), leading to increased HDL cholesterol and phospholipids levels 
(12). It was suggested that hepatic proprotein convertases inhibit EL partly by promoting 
the activating cleavage of ANGPTL3, thus raising HDL levels (23).
Transcriptional and post-transcriptional regulation of ANGPTL3
Like many secreted proteins, ANGPTL3 is susceptible to numerous post-translational 
modifications including cleavage and glycosylation. The cleavage site has been located to 
amino acid sequence 221RAPR224, yielding an N-terminal fragment containing the coiled-
coil region and a C-terminal fragment containing the fibrinogen-like domain (18) (Figure 
1). Cleavage of ANGPTL3 is catalyzed by proprotein convertases and was found to be 
required to achieve a maximum increase in plasma TG upon injection of ANGPTL3 in mice 
(18, 23). Recently, it was shown that proprotein convertase-induced ANGPTL3 cleavage is 
blocked by GalNAc-T2 mediated O-glycosylation of Thr225/226 residues (24). Interestingly, 
variants in the GALNT2 gene are associated with increased TG levels in GWAS studies. 
Future research will have to reveal whether this effect might be due to altered GalNac-T2 
mediated O-glycosylation of ANGPTL3 (3, 4, 7). In addition to undergoing cleavage, 
ANGPTL3 forms higher order multi-subunit complexes, which does not seem to require 
formation of intermolecular disulfide bonds (25). It can be speculated that formation of 
oligomers may protect ANGPTL3 from degradation and/or glomerular filtration.
Expression of ANGPTL3 in mouse and human is predominant in liver, with minor 
expression in kidney, and is governed by a variety of signals. The nuclear receptor LXR 
induces ANGPTL3 mRNA via a LXR response element located within the promoter of 
ANGPTL3, possibly accounting for the stimulatory effect of LXR agonists on plasma TG 
levels (Figure 1) (26, 27). In contrast, the nuclear receptor PPARβ/δ inhibits Angptl3 mRNA 
expression, likely by dissociating the binding between of LXR and RXRα and thereby 
hampering activation of Angptl3 by LXR (28). More recently, hepatic ANGPTL3 mRNA 
was shown to be decreased upon treatment with atorvastatin, suggesting that ANGPTL3 
may play a role in VLDL-TG lowering by statins when used at high doses (29). In addition, 
insulin, leptin, thyroid hormone and LPS suppress hepatic Angptl3 expression (30-33).
ANGPTL4
Human genetic studies
Human genetic studies unequivocally support a role of ANGPTL4 in plasma TG 
homeostasis. Evidence was first provided by re-sequencing seven exons and intron-exon 
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boundaries of ANGPTL4 in a large number of individuals. One particular variant, which 
is carried by approximately 2% of Caucasians and causes a substitution of glutamine to 
lysine at position 40 (E40K) was associated with decreased plasma TG and increased 
plasma HDL-C concentrations (34, 35). The lower TG levels in E40K carriers compared 
to non-carriers persisted over a nine-year period during which TG concentrations went 
up in both groups (36).
Another ANGPTL4 gene variant, T266M, was also found to be associated with lower 
plasma TG. However, the effect disappeared once E40K carriers were removed from 
analysis, suggesting linkage disequilibrium between T266M and E40K (35). Others have 
been unable to replicate the association between T266M and plasma TG, possibly due to 
the low number of E40K carriers in their sample (37, 38). Recently, Smart-Halajko found 
that even after removal of E40K carriers from the analysis, T266M was associated with 
lower plasma TG levels in type 2 diabetic patients (39). In contrast, the same authors failed 
to find an association between T266M and plasma TG in a meta-analysis of 5 studies 
involving patients with cardiovascular disease (35). Interestingly, T266M raised plasma 
ANGPTL4 levels, possibly by influencing ANGPTL4 secretion (40). In summary, while 
the effect of the E40K variant on circulating TGs and HDL has been firmly established, 
the effect of T266M remains unclear and may depend on the specific population studied.
Surprisingly, none of the GWAS studies performed so far have linked SNPs in or near 
the ANGPTL4 gene to plasma TG levels. However, a significant association was found 
between rs2967605, which is located 30 kb downstream from ANGPTL4, and HDL-C 
levels. Why an association was found with HDL-C but not with TG is unclear and could 
be related to the more pronounced role of environmental factors in determining plasma 
TG compared to HDL-C. Alternatively, the rs2967605 SNP may mediate the effect of 
another gene located in proximity to ANGPTL4 (5). 
Whereas ANGPTL4 genotype clearly influences plasma TG, the relation between 
plasma levels of ANGPTL4 and plasma TG is less clear-cut. An early report found a 
positive correlation between the two parameters (41). However, more recent studies have 
not been able to replicate those initial findings (14, 40, 42, 43). Similar to ANGPTL3, the 
absence of a correlation between plasma ANGPTL4 and plasma TG does not necessarily 
invalidate ANGPTL4 as a determinant of plasma TG in humans yet does raise questions 
about: a) whether circulating ANGPTL4 represents the functional pool of protein involved 
in LPL inhibition, and b) what functional form of ANGPTL4 is in fact detected by the 
ELISA assay.
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ANGPTL4 raises plasma triglycerides in mice
Studies with mice lacking or overexpressing Angptl4 have clearly demonstrated the impact 
of ANGPTL4 on plasma TG metabolism. Mice deficient in Angptl4 exhibit low plasma TG 
levels coinciding with elevated post-heparin plasma LPL activity, while whole body Angptl4 
transgenic mice show high TG levels together with low plasma LPL activity (44). Similar 
to whole body Angptl4 overexpression, liver-specific Angptl4 overexpression raises plasma 
TG levels and decreases post-heparin plasma LPL activity, suggesting an endocrine effect 
of liver-derived ANGPTL4 (16). Interestingly, cardiac specific Angptl4 transgenic animals 
are characterized by elevated plasma TG together with decreased cardiac LPL activity yet 
do not exhibit any change in post-heparin plasma LPL activity or LPL activity in other 
tissues (45). Hence, ANGPTL4 produced in heart may primarily act locally to protect the 
heart from lipid overload and consequent lipotoxicity (46). It is unclear what accounts 
for the primary autocrine/paracrine versus endocrine function of ANGPTL4 in tissues. 
The hypertriglyceridemic effect of ANGPTL4 is unequivocally attributable to its 
N-terminus as injecting mice with an monoclonal antibody directed against the N-terminal 
portion of ANGPTL4 lowers plasma TG to levels comparable to Angptl4–/– animals (47). 
In support of this notion, mice homozygous for the E40K mutation, which alters a critical 
residue towards the N-terminus of ANGPTL4, have low plasma TG levels (48).
Besides raising circulating TG levels, ANGPTL4 potently increases plasma free fatty 
acids. Injection of recombinant ANGPTL4 acutely raises free fatty acids (49). In addition, 
whole body Angptl4 overexpression augments the fasting-induced increase in free fatty 
acids, whereas this response is completely blunted in Angptl4–/– mice (50). Studies in 
cultured adipocytes support a direct effect of ANGPTL4 on TG hydrolysis in adipocytes 
(50). How ANGPTL4 stimulates intracellular lipolysis is unknown but involvement of the 
adipose triglyceride lipase ATGL/PNPLA2 has been proposed (44).
ANGPTL4 is an endogenous inhibitor of lipoprotein lipase
Like all Angiopoietin-like proteins, ANGPTL4 is composed of several distinct regions 
including an N-terminus signal peptide, a coiled-coil domain and fibrinogen-like domain 
(Figure 1). Numerous studies have provided firm evidence that the N-terminal portion 
of ANGPTL4 irreversibly inhibits LPL activity, which is at least partially accounted for 
by promoting the conversion of active LPL dimers into inactive monomers (22, 51, 52). 
Inhibition of LPL by ANGPTL4 is suppressed by GPIHBP1 but not by heparin (19, 21). 
Besides inducing LPL dimer dissociation, ANGPTL4 may inhibit LPL by potentiating 
proprotein convertase-mediated cleavage of LPL (53). Similar to ANGPTL3, the LPL 
inhibitory effect of ANGPTL4 is largely conferred by the polar residues His46, Gln50, 
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and Gln53 located within the N-terminal coiled-coil domain (Figure 1). Consistent 
with this notion, injection of mice with a synthetic 12 amino acid peptide encompassing 
this particular region increased plasma TG levels by 164% compared to saline injected 
animals, although it was less potent compared to recombinant ANGPTL4 encompassing 
the entire N-terminus including the coiled-coil domain (22). ANGPTL4 effectively inhibits 
LPL produced by a variety of cells including (cardio)myocytes, adipocytes, and also 
macrophages. Recently, we demonstrated that macrophage ANGPTL4 is induced by fatty 
acids and inhibits LPL to reduce postprandial lipid uptake from chyle into macrophages 
present in mesenteric lymph nodes, thereby preventing macrophage activation and foam 
cell formation (54).
Post-transcriptional modifi cations of ANGPTL4
In analogy with ANGPTL3, ANGPTL4 is cleaved into an N-terminal (nANGPTL4) and 
a C-terminal (cANGPTL4) part, which occurs at the conserved proprotein convertase 
recognition sequence 161RRKR164 (53, 55-57). Whereas rat ANGPTL4 seems to require 
serum for in vitro cleavage, human ANGPTL4 can be cleaved in cultured cells in the absence 
of serum (57, 58). Recent work has found that proprotein convertases PCSK5, FURIN, 
and PCSK7 are able to cleave ANGPTL4 (53). Several studies have investigated whether 
cleavage of ANGPTL4 influences its ability to inhibit LPL. Conditioned medium from cells 
overexpressing the cleavage-resistant 161GSGS164 variant of ANGPTL4 markedly inhibited 
LPL activity, yet was less effective compared to wild-type ANGPTL4 conditioned medium. 
Surprisingly, adenoviral-mediated overexpression of the GSGS mutant in mice caused more 
pronounced hypertriglyceridemia compared to injection of wild-type ANGPTL4, possibly 
because of higher protein stability (57). In contrast, adenoviral-mediated overexpression 
of the cleavage-resistant mutant R161A resulted in less pronounced hypertriglyceridemia 
compared to wild-type ANGPTL4 overexpression, concurrent with less inhibition of LPL 
(53). Thus, the importance of ANGPTL4 cleavage for regulating LPL inhibition remains 
ambiguous. It should be emphasized that cANGPTL4 does not seem to play a role in lipid 
metabolism but rather regulates a variety of biological processes including angiogenesis, 
wound healing and tumor cell behavior by binding integrin β1 and β5 (59, 60). 
In addition to cleavage, ANGPTL4 is subject to a second post-translational modification 
via oligomerization (Figure 1), which takes place intracellularly and is dependent on 
disulfide bond-forming cysteine residues 76 and 80 (56-58, 61). Since these residues 
are located in the N-terminal portion, nANGPTL4 and full length ANGPTL4 but not 
cANGPTL4 form oligomers (57). ANGPTL4 mutated at both residues is much less effective 
at raising plasma TG levels upon adenoviral-mediated overexpression, concurrent with a 
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marked reduction in nANGPTL4 and full length ANGPTL4 oligomers but also monomers. 
The latter result suggests that oligomerization protects ANGPTL4 from degradation and 
thereby maintains its LPL inhibitory capacity (57, 61). Consistent with this notion, detailed 
kinetic analysis of LPL inhibition indicated that purified ANGPTL4 mutated at cysteine 76 
and 80 was equally effective at inhibiting LPL compared to wild-type ANGPTL4 (19). In 
contrast, disruption of disulfide mediated oligomerization by reducing agent was shown 
to reduce the capacity of ANGPTL4 to inhibit LPL independent of the absolute amount 
of ANGPTL4 protein (22). Thus, while it is clear that oligomerization is important for 
ANGPTL4 stabilisation to ensure an active pool of functional ANGPTL4 protein, it is 
unclear whether oligomerization is an actual prerequisite for effective LPL inhibition, for 
instance by creating the proper interface for LPL inhibition.
Another potential modification altering protein function is glycosylation. ANGPTL4 
contains several potential N- and O-glycosylation sites (62), and was found to be 
N-glycosylated in the fibrinogen-like domain at position 177, potentiating its anti-
angiogenic capacity (Figure 1) (55, 58). It is unclear whether glycosylation impacts the 
ability of ANGPTL4 to inhibit LPL. N-glycosylation at position 177 does not seem to affect 
cleavage of ANGPTL4 by proprotein convertases (53).
Regulation of ANGPTL4 expression
ANGPTL4 is ubiquitously expressed in both mouse and human. Highest expression 
levels in humans are found in liver, followed by small intestine, adipose tissue, and heart, 
whereas mouse Angptl4 mRNA is most highly expression in adipose tissue, followed by 
liver, intestine, heart, lung and ovary (9, 63-65). 
In these tissues, Angptl4 gene expression is regulated by many signals. ANGPTL4 was 
originally identified as a PPARα and -γ target gene in liver and adipose tissue, respectively 
(Figure 1) (64, 66). Although many studies have employed Angptl4 as marker gene for 
PPARβ/δ activation (67-70), it should be emphasized that the main PPAR isotype involved 
in Angptl4 regulation depends on the cell or tissue studied and can be either PPARα 
(liver, intestine), PPARβ/δ (skeletal muscle, heart, macrophages), or PPARγ (adipocytes, 
colonocytes). Regulation by PPAR is mediated by a composite PPAR-response element 
within intron 3 of the gene that consists of a number of adjacent direct repeat-1 elements 
(71-73). Recently, TGFβ was shown to either positively or negatively modulate PPARβ/δ-
induced ANGPTL4 regulation via interactions between additional transcription factor and 
the PPREs (73, 74). Consistent with fatty acids being potent activators of PPARs, Angptl4 
gene expression is strongly induced by free fatty acids in a variety of tissues (42, 46, 54, 63). 
In fact, microarray analysis has shown that Angptl4 is the most highly induced gene upon 
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fatty acid stimulation in several cell types (our unpublished observations). Accordingly, 
plasma ANGPTL4 levels in human are increased by conditions associated with elevated 
free fatty acid levels, including fasting, prolonged caloric restriction, and exercise (63, 
75). As a consequence, a positive correlation exists between fasting free fatty acids and 
ANGPTL4 levels (14, 42).
Interestingly, ANGPTL4 expression seems to be negatively regulated by insulin in 
cultured adipocytes and hepatocytes (76, 77). In agreement with these data, plasma 
ANGPTL4 levels were significantly reduced during a hyperinsulinemic clamp (77). 
Suppression of ANGPTL4 by insulin and induction by fasting may contribute to the switch 
in fuel utilization from lipoprotein derived fatty acids in the post-prandial state to free fatty 
acids in the fasting state. In addition to regulation by insulin, ANGPTL4 was found to be 
upregulated in hepatocytes and adipocytes by the glucocorticoid receptor via a binding 
site located at the 3’-untranslated region of Angptl4. Hence, ANGPTL4 may be a critical 
intermediate in the changes in triglyceride metabolism elicited by glucocorticoid treatment, 
including the hypertriglyceridemia in patients chronically treated with glucocorticoids (78). 
Similarly, ANGPTL4 may mediate the inhibitory effect of chronic intermittent hypoxia on 
clearance of TG-rich lipoproteins and adipose lipoprotein lipase activity (79).
Expression of ANGPTL4 in the small intestine is under control of the intestinal microbiota. 
Evidence was provided that the reduction in ANGPTL4 expression upon conventionalization 
of germ-free mice mediates the associated expansion of adipose tissue mass by stimulating 
adipose LPL activity (80). In contrast, it was also reported that absence of gut microbiota does 
not provide a general protection from diet-induced obesity and that intestinal ANGPTL4 
does not contribute to the effects of gut microbiota on fat storage (81). Currently, it is difficult 
to reconcile these obviously divergent reports. Interestingly, the probiotic Lactobacillus 
paracasei ssp paracasei F19 was found to increase the expression of ANGPTL4 in colonocytes 
and produce a trend towards elevated plasma TG in mice colonized with F19, indicating that 
regulation of ANGPTL4 by intestinal microbiota is strain dependent (82). 
ANGPTL5
Re-sequencing ANGPTL5 in the Dallas Heart Study indicated a significant excess of non-
synonymous sequence variations in the lower quartile of TG levels. One non-synonymous 
variant (T268M) in ANGPTL5 had a mean allele frequency exceeding 1% but no consistent 
association was found between this variant and plasma TG levels (9). Interestingly, 3 out 
of 7 missense mutations in ANGPTL5 found within the lower quartile of TG levels give 
rise to a protein that cannot be secreted into cell medium (9). Although these data may 
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hint at a potential role of ANGPTL5 in the regulation of TG metabolism, there has been 
no experimental follow up to explore these speculations. Specifically, the absence of a 
mouse ortholog makes it very difficult to perform functional studies in animals. In contrast 
to ANGPTL3, ANGPTL4, and ANGPTL6, ANGPTL5 is hardly expressed in liver yet is 
expressed in adipose tissue, heart, vena cava, epididymis, and bronchus (9). Unfortunately, 
no data are available regarding regulation of ANGPTL5.
ANGPTL6
Although multiple sequence variants of ANGPTL6 were found by re-sequencing of a large 
multiethnic population, none of them associated with plasma TG levels. A significant excess 
of variants was found in the upper quartile of plasma total cholesterol levels, though this 
was not the case when specifically examining LDL-C or HDL-C (9). In a French population, 
no association was apparent between any of the four SNPs that cover most of the genetic 
variability within ANGPTL6, and plasma TG levels (83). Hence, human genetic studies 
do not support a role for ANGPTL6 in regulation of plasma TG metabolism.
Serum ANGPTL6 levels did not correlate with TG levels in a Korean population while 
a positive correlation was found between ANGPTL6 levels and visceral fat, leptin, insulin, 
BMI and waist circumference (84). Moreover, ANGPTL6 levels were increased in diabetic 
patients compared to non-diabetic individuals (85).
Illustrating the importance of ANGPTL6 for basal development, more than 80% of 
Angptl6–/– mice die at about embryonic day 13 due to cardiovascular defects. Surviving 
Angptl6–/– mice develop obesity and increased hepatic TG content compared to wild-
type littermates (86). Moreover, Angptl6–/– mice show increased serum cholesterol and 
free fatty acid levels, whereas serum TG levels are comparable to control animals (86). 
Overexpression of Angptl6 generates a reverse phenotype characterized by lean and insulin 
sensitive animals showing decreased hepatic TG levels while serum TG levels are again 
comparable to wild-type animals (86). These effects are thought to be partially conveyed 
by a p38 MAPK/PGC-1α mediated increase in energy expenditure (87). Thus, there is 
currently no evidence linking ANGPTL6 to regulation of plasma TG metabolism and in 
contrast to ANGPTL3 and ANGPTL4, ANGPTL6 does not inhibit LPL (9). Whether the 
elevated serum cholesterol levels in Angptl6–/– mice reflect a direct effect of ANGPTL6 on 
lipoprotein metabolism requires further investigation.
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Perspectives
A major insight that has become apparent in recent years is that regulation of lipases is 
complex and involves many cooperating proteins. While the existence of an endogenous 
LPL inhibitor had been predicted by the Olivecrona group, many aspects of the structure, 
function, and regulation of ANGPTL3 and ANGPTL4 have been surprising, most notable 
the functional divergence between the N- and C-terminal fragments. It is tempting to 
speculate about proteins that may interact with ANGPTLs, including GPIHBP1, possibly 
directing them to specific targets or conferring site-specific roles. Identification of 
cooperating proteins will be challenging yet could provide important insights into the 
functioning of lipases and ANGPTLs. 
Cleavage of ANGPTLs has been considered a mechanism to create the functional 
endogenous lipase inhibitor. However, since full length ANGPTL3 and ANGPTL4 are 
able to inhibit lipases as well, the purpose of proteolytic processing of ANGPTLs remains 
somewhat ambiguous. It can be hypothesized that cleavage primarily serves to release 
the soluble monomeric C-terminal fragment, which otherwise would remain sequestered 
in a large multimeric complex of full length ANGPTL. Cleavage also enables separation 
between lipase inhibition and ANGPTL functions conferred by the C-terminal domain. 
The greatest mystery regarding ANGPTL3 and especially ANGPTL4 is why the proteins 
are so exceptionally regulated at the transcriptional level, given that the two cleavage 
fragments of ANGPTL3 and ANGPTL4 differ completely in their biological activities. 
Conceivably, proteolytic processing of ANGPTLs is cell-specific and yields different 
fragments depending on the expression of specific proprotein convertases. So far, there 
is no evidence of any regulation of ANGPTLs at the level of protein clearance and/or 
inactivation. 
In conclusion, data gathered in the last decade have clearly demonstrated a key function 
of several ANGPTLs in regulation of plasma TG metabolism. Effects of ANGPTL3 and 
ANGPTL4 on circulating lipoproteins can be almost entirely explained by inhibition of 
lipases, principally LPL. However, this observation does not exclude potential effects of 
ANGPTLs on lipid metabolism via other mechanisms. Currently, there is no evidence that 
any of the other ANGPTLs besides ANGPTL3 and ANGPTL4 function as inhibitors of 
lipases. While human genetic studies have provided preliminary data potentially linking 
ANGPTL5 to regulation of plasma lipid levels, biochemical follow-up analyses have been 
lacking.
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Abstract
Dietary saturated fat is linked to numerous chronic diseases, including cardiovascular 
disease. Here we study the role of the lipoprotein lipase inhibitor ANGPTL4 in the 
response to dietary saturated fat. Strikingly, in mice lacking Angptl4, saturated fat 
induces a severe and lethal phenotype characterized by fibrinopurulent peritonitis, 
ascites, intestinal fibrosis, and cachexia. These abnormalities are preceded by a massive 
acute phase response induced by saturated but not unsaturated fat or medium-chain fat, 
originating in mesenteric lymph nodes (MLNs). MLNs undergo dramatic expansion 
and contain numerous lipid-laden macrophages. In peritoneal macrophages incubated 
with chyle, ANGPTL4 dramatically reduced foam cell formation, inflammatory gene 
expression, and chyle-induced activation of ER stress. Induction of macrophage 
ANGPTL4 by fatty acids is part of a mechanism that serves to reduce postprandial 
lipid uptake from chyle into MLN-resident macrophages by inhibiting triglyceride 
hydrolysis, thereby preventing macrophage activation and foam cell formation and 
protecting against progressive, uncontrolled saturated fat-induced inflammation.
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Introduction
Studies indicate that elevated saturated fat consumption is associated with increased 
risk for chronic diseases, including cardiovascular disease and type 2 diabetes. However, 
the underlying mechanisms and why specifically saturated fat is harmful largely remain 
unknown. Consequently, there is a need to better understand the molecular mechanisms 
that govern the response to dietary (saturated) fat ingestion. 
After digestion of dietary fat, absorbed long-chain fatty acids are incorporated into 
chylomicrons as triglycerides (TGs) and released into the circulation after passage 
through the intestinal lymphatics. Hydrolysis of chylomicron-TG is catalyzed by the 
enzyme lipoprotein lipase (LPL), which is anchored to the capillary endothelium via 
heparin–sulphate proteoglycans and is a key determinant of cellular fatty acid uptake (1). 
LPL is expressed at high levels in tissues that depend on fatty acids as fuel (heart, skeletal 
muscle), or synthesize fats for storage or secretion (adipose tissue, mammary tissue), but 
high expression is also found in macrophages (2, 3).
Activity of LPL is governed via numerous mechanisms that act primarily at the 
posttranscriptional and posttranslational level. One important modulator of LPL activity is 
Angiopoietin-like protein 4 (ANGPTL4) (4). ANGPTL4 was discovered as transcriptional 
target of the peroxisome proliferator activated receptor alpha and gamma and is expressed 
in numerous cell types including adipocytes, hepatocytes, (cardio)myocytes and endothelial 
cells (5, 6). Studies using different transgenic mouse models of ANGPTL4 overexpression 
or deletion show that ANGPTL4 potently raises plasma TG levels by suppressing LPL-
mediated clearance of plasma TG-rich lipoproteins (7-9). 
Recently, it was shown that deletion of other members of the Angiopoietin-like protein 
family influences the development of obesity-related complications in the C57Bl/6 mouse 
high fat-induced obesity model. Specifically, surviving Angptl6–/– mice developed marked 
obesity, ectopic fat storage and insulin resistance. In contrast, mice over-expressing 
Angptl6 were leaner and had improved insulin sensitivity (10). Deletion of Angptl2 
ameliorated adipose tissue inflammation and insulin resistance in obese mice, whereas 
Angptl2 over-expression promoted adipose tissue inflammation and systemic insulin 
resistance (11). Given the role of ANGPTL4 in plasma clearance of dietary TGs, we set 
out to study the effect of ANGPTL4 deletion in the context of chronically elevated dietary 
fat intake.
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Results
Angptl4–/– mice fed HFD develop fi brinopurulent peritonitis and ascites
To examine the effect of ANGPTL4 on diet-induced obesity and its metabolic consequences, 
wild-type and Angptl4–/– mice were fed a high fat diet (HFD) containing saturated fat-rich 
palm oil and compared with mice fed low fat diet (LFD) (Table S1). As expected based 
on its ability to inhibit LPL, Angptl4–/– mice had decreased plasma TGs (Figure 1A) and 
showed faster initial weight gain (Figure 1B) (12). Remarkably, bodyweights of Angptl4–/– 
mice fed HFD reached a plateau after around 12 weeks and declined thereafter (Figure 
1B). The decrease in bodyweight was related to anorexia noticeable after about 10 weeks of 
HFD (Figure 1C). All Angptl4–/– mice fed HFD ultimately die anywhere between 15 and 25 
weeks. The cause of death was identified by an animal pathologist as severe fibrinopurulent 
peritonitis connected with ascites. 
Large amounts of fibrin exudate covered the abdominal organs in Angptl4–/– mice fed 
HFD (Figure 1D). Other macroscopic abnormalities included intestinal fibrosis (Figure 
1E), a compressed liver (Supplemental Figure 1A), and a hyperplasic spleen (data not 
shown). No such abnormalities were observed in Angptl4–/– mice fed LFD, even at high 
age (>1.5 years). Routine clinical tests were performed on the ascites fluid, which varied 
in color from purulent white to purulent red (Figure 1D, inset). Ascites white blood cell 
count was extremely high in all animals (25.5-34.1*109/l, diagnostic threshold: ≤0.5*109/l), 
as was the endotoxin concentration (50-120 EU/ml, zero threshold), strongly suggesting 
bacterial peritonitis. Ascites fluid of some animals tested positive for E. Coli. The high 
protein concentration (3.43-4.28 g/dl, diagnostic threshold: >2.5 g/dl) and low serum-
ascites albumin gradient (SAAG, 0.11-0.34 g/dl, diagnostic threshold: <1.1 g/dl) indicated 
exudative ascites, thereby excluding portal hypertension. The ascites TG concentration 
was highly variable but clearly elevated (4.8-75.5 mM, diagnostic threshold: ~1.25 mM). 
Analysis of chylous ascites fluid by lipoprotein profiling indicated an abundance of TG-rich 
Figure 1. Angptl4–/– mice chronically fed HFD develop fibrinopurulent peritonitis and ascites
(A) Four-hour fasting plasma TG levels during the course of chronic LFD or HFD intervention (Study 1). 
Differences between LFD and HFD within each genotype were not statistically significant (n = 10 per 
group). 
(B) Bodyweight changes in wild-type and Angptl4–/– mice fed LFD or HFD for 19 weeks. 
(C) Mean daily food intake in wild-type and Angptl4–/– mice fed LFD or HFD for 19 weeks. 
(D) Whole animal photographs taken immediately following sacrifice of representative wild-type and 
Angptl4–/– mice fed either LFD or HFD for 19 weeks. Pictures at far right were taken after removal of 
peritoneum. Ascites fluid collected from two Angptl4–/– mice fed HFD is shown at the bottom. 
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(E) Photograph of small intestine of wild-type and Angptl4–/– mouse fed LFD or HFD for 19 weeks. 
(F) FLPC lipoprotein profiling of ascites fluid of Angptl4–/– mice fed HFD for 19 weeks (n = 5). Inset: APOB 
immunoblot of FPLC fractions from ascites fluid of Angptl4–/– mice or mouse fasting plasma (FP). 
(G) Plasma endotoxin levels in wild-type and Angptl4–/– mice fed LFD or HFD for 19 weeks. 
(H) Lymph vessel area in jejunum of wild-type and Angptl4–/– mice fed LFD or HFD for 19 weeks determined 
after Lyve-1 staining. 
Error bars represent SEM. * indicates significantly different from corresponding wild-type mice according 
to Student’s t-test (P < 0.05).  
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lipoproteins representing chylomicrons, as shown by immunostaining for APOB (Figure 
1F), suggesting leakage of chyle from lymphatic vessels. Additionally, significant vascular 
leakage occurred, as shown by the much lower protein concentration in chyle (1.38-1.83 
g/dl) compared to ascites fluid (3.43-4.28 g/dl). 
Plasma endotoxin levels were significantly elevated in Angptl4–/– mice fed HFD for 19 
weeks (Figure 1G). Microscopic examination indicated that the fibrin exudate contained an 
abundance of foam cells, polynuclear giant cells, and other leukocytes (data not shown). The 
same cells as well as focal lymphocyte infiltrates were observed in the small intestine (Figure 
2A, inset) and mesenteric fat (Figure 2B), in the former encapsulated by collagen (Figure 
2C). Intestinal lymph vessels were dilated, suggesting mesenteric lymphatic obstruction 
(Figure 1H). Epididymal adipose tissue had a red appearance (Supplemental Figure 1C), 
and exhibited coagulation necrosis and steatitis as shown by presence of lymphocytes, 
granulocytes and other leukocytes (Supplemental Figure 1D, inset). 
Livers of Angptl4–/– mice fed HFD for 19 weeks were not fibrotic but resembled an 
ischemic liver. Portal triads, cords and sinusoids were poorly visible, and clumping of nuclei 
was seen, indicating collapse of liver (Supplemental Figures 1A and 1B). Focal infiltrates 
of neutrophils, eosinophils and macrophages were observed (Supplemental Figure 1B, 
inset), as were rod-shaped bacteria. Liver fat was almost absent, whereas it was elevated 
in Angptl4–/– mice on LFD (Supplemental Figure 1E). Weights of liver and epididymal fat 
pads were significantly lower in Angptl4–/– mice after 19 weeks of HFD (Supplemental 
Figures 1F and 1G), while epididymal fat pads were heavier in Angptl4–/– mice on the 
LFD. Taken together, Angptl4–/– mice chronically fed HFD develop a severe phenotype 
characterized by anorexia, cachexia, intestinal inflammation and fibrosis, chylous ascites, 
and fibrinopurulent peritonitis, leading to the death of the animal.
Ascites and other clinical abnormalities are not related to a primary lymph vessel defect
Angptl4–/– mice on a mixed genetic background were reported to die shortly after birth due 
to defective separation of intestinal lymphatic and blood microvasculature (13). Although 
we did not find these abnormalities in Angptl4–/– mice on pure C57Bl/6 background 
and adult mice in proper Mendelian ratios were obtained, there might be an underlying 
primary weakness in intestinal lymphatics that becomes manifest when chyle flow is 
increased as with HFD, causing leakage of chyle into intestinal lumen and peritoneal 
cavity. However, none of the clinical abnormalities including chylous ascites were observed 
in Angptl4–/– mice fed a safflower oil-based HFD rich in polyunsaturated fat (Table S2) 
(data not shown). Furthermore, if lymphatic vessels are intrinsically more permeable, 
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Figure 2. Severe intestinal inflammation in Angptl4–/– mice chronically fed HFD
(A and B) Representative H&E staining of small intestine (A) or mesenteric fat (B) of wild-type and 
Angptl4–/– mice fed HFD for 19 weeks (Study 1). Inset: high magnification image of lymphocyte infiltrate 
(top) or presence of granulocytes (bottom). 
(C) Sirius red staining of small intestine of wild-type and Angptl4–/– mice fed HFD for 19 weeks. Arrow 
indicates inflammatory infiltrate. 
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ascites and diarrhea, the latter due to loss of protein and fat from lymph into the intestinal 
lumen, should develop upon starting the HFD, which was not observed. Surprisingly, 
fecal fat excretion was markedly decreased in Angptl4–/– mice, indicating more efficient 
fat absorption (Supplemental Figure 2A). An acute intestinal lipid absorption test using 
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3H-triolein and 14C-palmitic acid failed to show any differences in rate of appearance of 
either label in blood between wild-type and Angptl4–/– mice (Supplemental Figures 2B 
and 2C), suggesting chylomicron formation and release is similar between wild-type and 
Angptl4–/– mice. In contrast, in all intestinal parts, accumulation of both labels 5 hours 
after lipid load was markedly higher in Angptl4–/– mice (Supplemental Figures 2D and 
2E). The similarity in results between 3H-triolein and 14C-palmitic acid argue against an 
effect of ANGPTL4 inactivation on TG digestion but suggest enhanced fatty acid uptake 
into enterocytes. This is supported by elevated expression of target genes of PPARα in 
small intestine of Angptl4–/– mice, suggesting enhanced gene regulation by fatty acids 
(Supplemental Figures 2F and 2G). Overall, the data argue against a primary lymph vessel 
defect forming the basis for the severe pathology. 
A massive acute phase response precedes ascites in Angptl4–/– mice fed HFD 
To investigate the cause of the severe pathology, wild-type and Angptl4–/– mice were 
studied before onset of anorexia and cachexia at 8 weeks of HFD (Figures 1A and 1B), 
and before ascites or other macroscopic abnormalities were observed. Strikingly, after 8 
weeks of HFD, plasma levels of serum amyloid A (SAA) and other inflammatory markers 
were dramatically increased in Angptl4–/– mice (Figures 3A and 3B). Whereas IL-6 was 
undetectable in plasma of wild-type mice, levels averaged 63±26 pg/ml in Angptl4–/– mice 
(normal values <15 pg/ml). These changes were paralleled by massive induction of hepatic 
mRNA for SAA2 and other acute phase proteins haptoglobin and lipocalin 2 (Figure 3C). 
Furthermore, increased expression of macrophage/Kupffer cell marker Cd68 (Figure 3D) 
and enhanced CD68 immunostaining was observed (Figure 3E). Consistent with these 
data, serum levels of negative acute phase protein albumin were decreased (Figure 3F). 
Thus, Angptl4–/– mice fed HFD exhibit systemic inflammation and a massive acute phase 
response several weeks prior to development of ascites and other clinical symptoms. 
Chronic HFD is known to induce adipose tissue inflammation, characterized by adipose 
infiltration of macrophages. However, no signs of enhanced macrophage or other leukocyte 
infiltration were observed in epididymal fat of Angptl4–/– mice after 8 weeks of HFD 
(Supplemental Figures 3A and 3B), suggesting that enhanced systemic inflammation does 
not originate in the adipose tissue.
Infl ammation in Angptl4–/– mice fed HFD originates in mesenteric lymph nodes
Interestingly, a trend towards increased plasma SAA levels in Angptl4–/– mice was already 
visible after one week of HFD (Figure 4A). HFD has been proposed to lead to inflammatory 
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Figure 3. High fat feeding provokes massive acute phase response in Angptl4–/– mice
(A) Plasma serum amyloid (SAA) levels in wild-type and Angptl4–/– mice fed LFD or HFD (Study 1). 
(B) Plasma levels of numerous cytokines in wild-type and Angptl4–/– fed HFD for 8 weeks. Values are 
expressed relative to wild-type. 
(C) Hepatic mRNA levels of SAA2, haptoglobin and lipocalin 2 determined by qPCR. Expression was 
normalized against 36b4. 
(D) Hepatic mRNA levels of macrophage marker Cd68. 
(E) CD68 immunostaining of liver sections of wild-type and Angptl4–/– mice fed HFD for 8 weeks. 
(F) Plasma serum albumin levels. 
Error bars represent SEM. * indicates significantly different from corresponding wild-type mice according 
to Student’s t-test (P < 0.05) (n = 4-11 mice per group). 
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Figure 4. Chyle containing saturated fat elicits massive mesenteric lymphadenitis in 
Angptl4–/– mice
(A) Kinetics of change in plasma SAA in wild-type and Angptl4–/– mice fed HFD (n = 6-7 per group). (B) 
Post-prandial endotoxin levels in portal plasma from wild-type and Angptl4–/– mice fed LFD or HFD for 
5 weeks (Study 2) (n = 6-7 per group). 
(C) Plasma SAA levels in wild-type and Angptl4–/– mice fed HFD for 5 weeks being given oral antibiotics 
or vehicle (Study 3) (n = 6-10 per group). 
(D) Relative abundance of total bacteria expressed per weight of colonic content in Angptl4–/– mice fed 
HFD and given oral antibiotics or vehicle. * indicates significantly different from corresponding wild-type 
mice according to Student’s t-test (P < 0.05). 
(E) Photograph of mesenteric fat of Angptl4–/– mouse fed HFD for 5 weeks (Study 2). Position of 
dramatically enlarged lymph node is indicated. 
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stress via changes in intestinal microflora and/or increased release of LPS (14). However, 
portal LPS levels were lowest in Angptl4–/– mice fed HFD (Figure 4B). Importantly, the 
increase in plasma SAA levels in Angptl4–/– mice by HFD was unaffected by chronic oral 
antibiotic treatment (Figure 4C), which effectively reduced intestinal bacterial counts 
(Figure 4D and Supplemental Figure 4A) and resulted in a severely enlarged caecum (data 
not shown). These data suggest that induction of systemic inflammation in Angptl4–/– mice 
by HFD is independent of the intestinal microbiota. 
Remarkably, we noticed that the mesenteric lymph nodes (MLNs) were dramatically 
enlarged in Angptl4–/– mice already after 5 weeks of HFD, indicating massive mesenteric 
lymphadenitis (Figures 4E and 4F). Inflammation extended to mesenteric fat which exhibited 
mesenteric panniculitis (Supplemental Figure 4B). High fat feeding is known to promote 
intestinal lymph flow and formation of chylomicrons, which pass through the MLNs as 
chyle before reaching the circulation. Hence, MLNs are exposed to extremely high TG 
concentrations, which reach 55 mM in rats fed HFD (mean 35±11 mM). To investigate 
the role of increased chyle flow, mice were fed for 5 weeks a diet rich in medium chain TGs 
(MCT) (Table S2), which are not processed via the lymph but enter the portal vein as free 
fatty acids. Remarkably, induction of plasma SAA and mesenteric lymphadenitis were absent 
in Angptl4–/– mice fed MCT (Figures 4G and 4H), suggesting the response is mediated by 
chylomicrons. A safflower oil-based HFD, which as mentioned previously did not provoke 
a clinical phenotype, also did not promote inflammation in Angptl4–/– mice, whereas a 
lard-based high saturated fat diet gave similar results as the palm-oil based HFD (Figures 
4G and 4H). Use of a palm oil-based diet with intermediate fat content supported a clear 
correlation between dietary saturated fat content and plasma SAA in Angptl4–/– mice (Figure 
4I). Consistent with a direct proinflammatory effect of saturated fat via chylomicrons, there 
(F) MLN of a wild-type and Angptl4–/– mouse fed HFD for 5 weeks after dissection and removal of adipose 
tissue. 
(G) Plasma SAA levels in wild-type and Angptl4–/– mice fed LFD or different types of HFD for 5 weeks 
(Study 2). HF-MCT = high fat medium-chain triglycerides, HF-lard = high fat lard-based, HF-palm = high 
fat palm oil-based, HF-safflower = high fat safflower oil-based. 
(H) Size of MLNs in wild-type and Angptl4–/– mice fed LFD or different types of HFD for 5 weeks (n = 
6-7 mice per group). Means of HF-palm and HF-lard groups were significantly different from the other 
groups as determined by one-way ANOVA followed by Tukey’s post-hoc test. 
(I) Close correlation between saturated fat content of the diet and the mean plasma level of SAA in 
Angptl4–/– mice after 3 weeks of feeding. 
(J) Expression of inflammatory marker genes in MLNs of wild-type and Angptl4–/– mice fed HFD for 24 
hours (Study 4). Error bars represent SEM (n = 3 per group). 
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was a clear trend towards increased expression of several inflammatory mediators in MLNs 
of Angptl4–/– mice already after one day of HFD (Figure 4J and Supplemental Figure 4C). 
These data indicate that in Angptl4–/– mice, a diet rich in saturated fat rapidly causes severe 
mesenteric lymphadenitis and panniculitis via chylomicrons, leading to a massive hepatic 
acute phase response via the connecting portal circulation.
Absence of ANGPTL4 stimulates foam cell formation and inflammation in MLN 
macrophages
MLNs are packed with numerous immune cells including macrophages. Microscopic 
examination of MLNs from Angptl4–/– mice but not wild-type mice fed HFD for 5 
weeks showed an abundance of multinucleated Touton giant cells (Figures 5A and 5B), 
originating from fusion of aberrant lipid-laden tissue macrophages as verified by F4/80 
immunostaining (Figure 5C). Formation of Touton cells is known to occur as reaction 
to lipid material in lymph nodes and is characteristic of lipid lymphadenopathy (15). 
Accumulation of neutral lipids in Touton cells was confirmed by Oil red O (Figure 5D) 
and Sudan Black staining (Figure 5E). Importantly, Touton cells were spotted in Angptl4–/– 
mice already after 1 day of HFD (Supplemental Figure 4D). The data suggest a major role 
of MLN macrophages in initiating inflammation in Angptl4–/– fed HFD. 
Previously, TG-rich VLDL particles were shown to stimulate foam cell formation and 
provoke release of cytokines by mouse peritoneal macrophages by serving as source of 
proinflammatory saturated fatty acids (16, 17). This effect required LPL, which is highly 
expressed in macrophages (2, 18, 19) and lymph nodes (http://biogps.gnf.org/) (20). 
Microarray analysis indicated that LPL was among the top 25 of genes with the highest 
microarray expression signal in peritoneal mouse macrophages (Table S3). Since ANGPTL4 
is also expressed in macrophages, is dramatically induced by chyle (Supplemental Figure 
5A), and can inhibit macrophage LPL (Supplemental Figure 5B), we hypothesized that 
ANGPTL4 minimizes lipolysis of chylomicrons by MLN macrophages and accordingly 
suppress uptake of proinflammatory saturated fatty acids. To test this hypothesis, peritoneal 
macrophages from Angptl4–/– mice were incubated with chyle obtained from the mesenteric 
lymph duct of rats fed palm oil-based HFD. Chyle dramatically increased lipid storage 
in macrophages leading to foam cell formation, which was strongly reduced by the LPL 
inhibitor orlistat (Supplemental Figure 5C). Increased lipid uptake was verified by elevated 
expression of PPAR-LXR target Abca1 and decreased expression of SREBP targets, as shown 
by whole genome expression profiling (Figure 6A) and qPCR (Supplemental Figure 5D). 
Importantly, increased lipid uptake was associated with pronounced induction of numerous 
inflammation and immune-related genes, as shown by significant over-representation of 
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Figure 6. ANGPTL4 inhibits macrophage foam cell formation and inflammatory gene 
expression
(A) Heat map showing changes in expression of selected genes in Angptl4–/– mouse peritoneal 
macrophages incubated for 6 hours with chyle (final TG concentration 2 mM) and/or Orlistat (20 μM), 
or with chyle and/or recombinant ANGPTL4 (2.5 μg/ml). Expression in untreated macrophages was set 
at 1. In parallel, expression changes are shown of same genes in peritoneal macrophages treated for 4 
hours with LPS (100ng/ml). All genes induced by chyle by at least 2.5-fold and which are labeled with 
“cytokine or chemokine activity” or “immune or inflammatory response” by Gene Ontology (Biological 
Process) or are involved in immunity/inflammation based on literature study were included. Also, SREBP 
target genes that were >75% suppressed by chyle were included. 
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GO-classes corresponding to those pathways and by Ingenuity Canonical Pathway analysis 
(Supplemental Figures 6A and 6B). Induction of inflammation, exemplified by Cxcl2, 
Gdf15, oncostatin M, Ptgs2 (COX-2) and other genes, was almost entirely blunted by orlistat, 
indicating lipolysis and LPL-dependency (Figure 6A). Some overlap in macrophage gene 
regulation was observed between chyle and LPS, but overall effects were mostly divergent 
(Supplemental Figure 6C). Specifically, typical targets of LPS such as Il1b were not induced 
by chyle, while numerous inflammatory genes upregulated by chyle were not induced by 
LPS, including Gdf15 and Vegfa. 
To examine whether ANGPTL4 can mimic the effect of orlistat on macrophage inflam-
mation, macrophages were loaded with chyle in the presence of recombinant ANGPTL4. 
ANGPTL4 did not influence cell viability, which was equally high in ANGPTL4- and 
PBS-treated cells (>85%). At a concentration that causes maximal inhibition of LPL 
(21), ANGPTL4 prevented lipid uptake from chyle (Figure 6B) and markedly reduced 
inflammation (Figures 6A and 6C), as shown by strongly blunted induction of 
inflammatory markers Ptgs2, Cxcl2, Ccr1 and Gdf15. Inhibitory effects of ANGPTL4 and 
orlistat on chyle-elicited changes in inflammatory gene expression were highly similar 
and support a common mechanism of action (Figure 6A). No clear differences in foam 
cell formation upon chyle loading were observed between wild-type and Angptl4–/– 
macrophages (Supplemental Figure 5C), likely because induction of ANGPTL4 protein 
by chyle in wild-type macrophages and subsequent feedback inhibition of lipid uptake 
via LPL lag behind the extremely rapid rate of lipid uptake.
ANGPTL4 abolishes chyle-induced ER stress in macrophages
To explore the mechanism mediating the proinflammatory effect of chyle, peritoneal 
macrophages were incubated with different chemical modulators including an inhibitor 
of LPS-induced TLR4 signaling (Polymyxin B), sphingolipid biosynthesis (Myriocin), and 
fatty acid translocase/Cd36 (Sulfosuccinimidyl oleate) (Figure 6D). None of the compounds 
(B) Oil red O staining of Angptl4–/– mouse peritoneal macrophages incubated for 6 hours with chyle 
(TG concentration 2 mM) and increasing concentrations of mouse recombinant ANGPTL4. Chyle was 
collected from rats fed palm oil-based HFD. Inset: high magnification image of macrophage foam cell. 
(C) qPCR expression of inflammatory genes in Angptl4–/– macrophages treated with chyle and/or ANGPTL4 
(2.5 μg/ml). * significantly different according to Student’s t-test (P < 0.05). 
(D) qPCR expression of inflammatory genes in Angptl4–/– macrophages treated with chyle and various 
pharmacologic inhibitors. SSO = Sulfosuccinimidyl oleate. Differences were evaluated for statistical 
significance by one-way ANOVA followed by Tukey’s post-hoc test. * significantly different from control-
treated cells (P < 0.05). Error bars represent SEM. 
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showed any repressive effect on chyle-induced inflammation, although the LPS inhibitor 
polymyxin B augmented expression of Gdf15 and Cxcl2. 
Since ER stress was one of the Canonical Pathways significantly altered by chyle (Table 
S6B), and is linked to activation of inflammation (22), we further focused our investigation 
on the ER stress pathway. The mammalian ER stress pathway consists of three major 
branches: IRE1α, PERK and ATF6. Upon ER stress activation, IRE1α and PERK undergo 
autophosphorylation and initiate downstream targets. IRE1α mediates the splicing of XBP1 
mRNA while PERK phosphorylates eIF2α, leading to attenuation of global translation and 
induction of expression of Atf4 and Ddit3 (CHOP). Remarkably, similar to the effect of ER 
stress inducers thapsigargin and tunicamycin, chyle significantly increased total IRE1α 
protein and IRE1α phosphorylation (Figure 7A), and dramatically stimulated XBP1 splicing 
(Figure 7B). Moreover, chyle stimulated phosphorylation of PERK and its target eIF2α, 
markedly increased CHOP protein, and upregulated expression of many ER stress target 
genes including XBP1s, CHOP, and Atf4 (Figure 7C). Importantly and consistent with its 
anti-lipolytic role, effects of chyle on ER stress marker genes were entirely abolished by 
ANGPTL4 (Figure 7D). Taken together, chyle induces ER stress in macrophages, which 
may account for the pronounced activation of inflammation. 
Saturated and unsaturated fatty acids diff erentially modulate Angptl4 mRNA and 
ER stress
As mentioned above, chyle dramatically increased Angptl4 mRNA in wild-type peritoneal 
macrophages (Figure 7E). Similarly, individual fatty acids markedly increased Angptl4 
mRNA in mouse peritoneal and human U937 macrophages (Figure 7F). Compared 
to unsaturated oleic and linoleic acid, the saturated palmitic acid was significantly less 
potent in inducing Angptl4. In contrast, expression of IRE1α, XBP1s, CHOP, Atf4, and 
Gdf15 and to a lesser extent Cxcl2 was specifically stimulated by palmitic acid (Figure 7G). 
Palmitic, oleic and linoleic acid represent 95% of fatty acids present in the various diets 
used, excluding the MCT diet.  
Figure 7. ANGPTL4 prevents chyle-induced ER stress
(A) Immunoblots of IRE1α, PERK, eIF2α and CHOP using regular gels or Phos-tag gels (IRE1α only) 
of Angptl4–/– macrophages treated with chyle (TG concentration 2 mM), thapsigargin (100 nM) or 
tunicamycin (2.5 μg/ml) for 6 hours. “P” represents phosphorylated form. 
(B) Regular RT-PCR of XBP1 processing revealing spliced and unspliced XBP1 mRNA. 
(C) qPCR expression of ER stress genes. Differences were evaluated for statistical significance by one-way 
ANOVA followed by Tukey’s post-hoc test. * significantly different from control-treated cells (P < 0.05). 
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(D) qPCR expression of selected genes involved in ER stress in Angptl4–/– mouse peritoneal macrophages 
incubated for 6 hours with chyle and/or recombinant ANGPTL4 (2.5 μg/ml). * significantly different 
according to Student’s t-test (P < 0.05). 
(E) Angptl4 mRNA expression in wild-type mouse peritoneal macrophages treated for 6 hours with chyle 
(TG concentration 1.3 mM). 
(F) Angptl4 mRNA expression in wild-type mouse peritoneal macrophages or human U937 macrophages 
treated for 6 hours with albumin-bound free fatty acids (500 μM). 
(G) qPCR expression of selected genes in wild-type mouse peritoneal macrophages treated with albumin-
bound free fatty acids (500 μM). Control-treated cells were treated with albumin only. Differences were 
evaluated for statistical significance by one-way ANOVA followed by Tukey’s post-hoc test. Bars with 
different letters are significantly different (P < 0.05). Error bars represent SEM. 
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Finally, to study which specific PPAR isotype is involved in Angptl4 regulation by 
fatty acids, three types of macrophages were treated with synthetic agonists for PPARα, 
PPARδ, and PPARγ. No induction of Angptl4 expression was observed with PPARα agonist 
Wy14643 (Supplemental Figure 7A). The PPARδ agonist GW501516 consistently induced 
Angptl4 mRNA in all three cell types, whereas the PPARγ agonist rosiglitazone increased 
Angptl4 mRNA in peritoneal macrophages and to a minor extent in U937 cells. These data 
suggest that PPARδ most likely mediates the effect of chylomicron-derived fatty acids on 
Angptl4 expression.
Taken together, these results demonstrate that ANGPTL4 protects MLN macrophages 
from uncontrolled lipid accumulation after high fat feeding, thereby preventing lipid-
induced ER stress and consequent inflammation.
Discussion
After a saturated fat-rich meal, MLNs are exposed to extremely high concentrations 
of chylomicrons via the chyle, which might lead to generation of large amounts of 
proinflammatory saturated fatty acids upon TG lipolysis. Our data indicate that MLNs 
and specifically resident macrophages are protected from the proinflammatory effect 
of saturated fatty acids via expression of ANGPTL4, which is strongly induced by chyle 
and fatty acids and which via inhibition of LPL prevents lipolysis of chylomicron-TG. 
In the absence of this protective autocrine mechanism, feeding a diet rich in saturated 
fat rapidly leads to enhanced lipid uptake into MLN-resident macrophages, triggering 
foam (Touton) cell formation and a massive inflammatory response characterized by 
severe mesenteric lymphadenitis. Concomitant induction of numerous cytokines leads 
to a massive hepatic acute phase response via the connecting portal circulation, further 
evolving into a progressive, uncontrolled inflammation that culminates in chylous ascites 
and fibrinopurulent peritonitis. The data thus show that ANGPTL4 is a key player in the 
protection against the severe proinflammatory effects of dietary saturated fat. Based on 
our data in mice, it can be hypothesized that human subjects homozygous for the E40K 
mutation in ANGPTL4, which has reduced ability to inhibit LPL and is associated with 
lower plasma TGs (23-25), may be particularly sensitive to the proinflammatory effects 
of dietary saturated fat.
According to microarray analysis, LPL was among the most highly expressed genes in 
mouse peritoneal macrophages. The ability of macrophage LPL to facilitate lipid uptake into 
macrophages is well recognized (2, 18). The locally released fatty acids may serve as energy 
source for active macrophages (26), but may also constitute a potential proinflammatory 
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stimulus. Consistent with this notion, fatty acids offered to macrophages as VLDL-TG 
are taken up and engage MAPK-mediated inflammatory pathways along with increased 
expression of several proinflammatory cytokines (17). Our data indicate that exposure 
of macrophages to elevated yet physiologically relevant concentrations of chylomicrons 
containing saturated fatty acids unleashes a vast inflammatory response characterized 
by marked induction of numerous chemokines and other inflammation-related genes, 
which is entirely dependent on TG-lipolysis. We propose that expression of ANGPTL4 
in macrophages and its potent induction by chylomicron-derived fatty acids are part of a 
feedback mechanism aimed at protecting MLN-resident macrophages against post-prandial 
lipid overload and associated inflammation. 
Ablation of ANGPTL4 is associated with decreased plasma TG levels caused by increased 
peripheral LPL activity (7). Recent data indicate that endothelium-bound LPL is stabilized 
by the protein GPIHBP1, which partially prevents LPL inhibition by ANGPTL4 (27). 
Perhaps the almost complete blockage of lipid uptake by ANGPTL4 in macrophages as 
opposed to its more modest effect in muscle and adipose tissue may be explained by the 
minimal expression of Gpihbp1 in macrophages (Supplemental Figure 7B) (27). Future 
studies will have to address this issue in more detail.
Feeding Angptl4–/– mice a diet rich in polyunsaturated fatty acids did not elicit an 
inflammatory response, consistent with data in peritoneal macrophages showing lack 
of induction of Gdf15 and Cxcl2 by oleic and linoleic acid. In contrast, oleic and linoleic 
acid were much more potent inducers of Angptl4 expression compared to palmitic 
acid, suggesting that the ANGPTL4-mediated feedback inhibition of lipid uptake and 
inflammation is disturbed in presence of saturated fatty acids.
An important question is how chyle induces inflammation in macrophages. Use of 
chemical inhibitors indicated that the response is not mediated by LPS, is not dependent on 
Cd36-mediated fatty acid transport, and does not require sphingolipid synthesis. Strikingly, 
chyle caused pronounced activation of different branches of the ER stress pathway. It has 
been shown that ER stress can promote inflammation by various mechanisms, including 
via IRE1α-mediated activation of stress kinases such as the c-Jun N-terminal kinase 
(28), and via PERK-mediated activation of NF-κB (29). We found that chyle stimulated 
IRE1α phosphorylation to promote XBP1 splicing, and activated PERK, eIF2α and their 
downstream targets. Activation of ER stress in peritoneal macrophages could be reproduced 
by free palmitic acid but not oleic or linoleic acid, suggesting the response is mediated by 
saturated fatty acids. 
The mechanism by which saturated fatty acids induce ER stress has been the subject 
of recent investigations. Palmitate but not palmitoleate induced ER stress in pancreatic 
Chapter 3
62
beta cells (30). In liver cells saturated fatty acids induced ER stress independently of 
ceramide synthesis (31). Stimulation of ER stress by palmitate may occur via increasing the 
saturated lipid content of ER membrane phospholipids and TGs, leading to compromised 
ER morphology and integrity and impaired function of protein-folding chaperones (32). 
Data also point to an important role for aP2 (FABP4) in linking saturated fatty acids to 
ER stress in macrophages via alterations in lipid composition (33). 
Several studies have attributed the proinflammatory effect of saturated fatty acids to 
activation of TLR4 (34-36). Recently, interplay between TLR4 (and TLR2) and the ER 
stress pathway was demonstrated (37). IRE1α was shown to be a positive regulator of the 
inflammatory response to TLR activation in macrophages, while the PERK pathway was 
not induced by TLR signaling (38). These data hint at a possible role for TLR signaling in 
the response to chyle in macrophages. However, unlike TLR signaling, chyle dramatically 
induced ER stress as evidenced by the activation of ER stress sensors IRE1α and PERK as 
well as their downstream targets. Additionally, whole genome analysis of gene regulation by 
chyle versus LPS revealed some overlap, but chyle clearly did not mimic LPS, as illustrated 
by the differential response of classic LPS/TLR4-target Il1b. Although these data do not 
rule out a role for TLR signaling in mediating the inflammatory effects of chyle, induction 
of ER stress seems a much more plausible mechanism.
A previous report briefly alluded to development of chylous ascites in Angptl4–/– mice 
after 20 weeks of HFD (39). In that study it was found that repeated injections of wild-type 
mice fed HFD with a monoclonal antibody recapitulated the phenotype of Angptl4–/– mice. 
Since the antibody is directed against the N-terminal portion of ANGPTL4 and abolishes 
its ability to inhibit LPL, the data support the notion that the clinical abnormalities 
in Angptl4–/– mice fed HFD are related to altered LPL activity, and are independent of 
C-terminal ANGPTL4.
Chylous ascites has been observed in mice heterozygous for the transcription factor 
prospero homeobox 1 (Prox1) as well as in mice lacking angiopoietin2 (Angpt2). Both 
proteins are essential for development of the lymphatic vasculature (40, 41). Accordingly, 
it is tempting to hypothesize a similar role for ANGPTL4. However, Prox1+/– and Angpt2–/– 
mice develop chylous ascites shortly after birth, reflecting a severe developmental 
defect. In contrast, Angptl4–/– mice do not exhibit ascites unless challenged with HFD 
for at least 12 weeks. Rather, the data indicate that ascites was secondary to progressive 
inflammation originating in MLN macrophages, leading to massive lymphadenitis and 
consequent obstruction in mesenteric lymph flow, which in turn caused dilation of 
intestinal lymphatic vessels. Furthermore, inflammation of MLNs and mesenteric fat led 
to increased local lymphatic and vascular permeability, as shown by chylous ascites and 
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low SAAG, respectively, which is indicative of exudative ascites. The more than two-fold 
higher protein concentration in ascites fluid compared to chyle supports an important 
contribution of vascular leakage next to leakage from chyle. Increased circulatory 
leakage caused fibrinogen extravasation, which after clotting accumulated as fibrin and 
covered abdominal organs. Chronic inflammation likely gave rise to impaired intestinal 
barriers function and translocation of enteric bacteria, causing peritonitis and death of 
the animals. 
In conclusion, ANGPTL4 protects against the severe proinflammatory effects of dietary 
saturated fat in MLNs by inhibiting macrophage LPL, thereby reducing lipolytic release 
of fatty acids, macrophage foam cell formation, ER stress, and initiation of a marked 
inflammatory response. The data illustrate how the unique anatomy of the intestinal 
lymphatic system in which immune cells residing in MLNs are exposed to excessive 
postprandial TG concentrations, requires activation of an effective cellular mechanism 
that protects against elevated lipid uptake and its complications. It can be speculated that 
the inability to effectively recruit this mechanism may contribute to proinflammatory 
changes related to elevated saturated fat consumption.
Methods
Animals
Animal studies were done using pure-bred wild-type and Angptl4–/– mice on C57Bl/6 background 
(7). In study 1, male 11-week old mice were fed LFD or HFD for 8 or 19 weeks, providing 10 or 45% 
energy percent as TGs (D12450B or D12451, Research Diets, Inc., Table S1) (Research Diets Services, 
Wijk bij Duurstede, Netherlands), after 3 weeks run-in (adaptation period) with LFD. In study 2, male 
10- to 18-week old mice were fed LFD or HFD for 5 weeks, after 2 weeks run-in with LFD. Fat source 
of the HFD was either palm oil (standard HFD used in study 1, 3 and 4, Table S1), lard, MCT oil, or 
safflower oil (Table S2). Blood was collected from tail vein at weekly intervals. In study 3, male 12-
week old mice were fed standard HFD for 5 weeks, after 2 weeks run-in with standardized low fat diet 
AIN93G (see http://testdiet.purina-mills.com/PDF/57W5.pdf and Table S2). The following antibiotics 
were provided in drinking water: ampicillin (1g/l), neomycin (1g/l), metronidazole (0.5g/l). Blood 
was collected from tail vein at weekly intervals. In study 4, mice were fed low fat AIN93G or standard 
HFD for 24 hours, after 1 week run-in with AIN93G. In the latter studies low fat AIN93G was chosen 
instead of D12450B to achieve minimal dietary saturated fat intake. Diet composition is provided in 
Table S1 and S2. At the end of each study, mice were anaesthetized with mixture of isoflurane (1.5%), 
nitrous oxide (70%) and oxygen (30%). Blood was collected by orbital puncture into EDTA tubes. 
Mice were killed by cervical dislocation, after which tissues were excised and directly frozen in liquid 
nitrogen or prepared for histology. 
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Wistar rats were fed palm-oil based HFD (D12451) overnight. The next morning, animals were 
anesthetized using isoflurane and mesenteric lymph ducts were cannulated. Chyle was collected for 
1-2 hours and stored at -20°C. Chyle TG concentrations averaged at 35±11 mM as determined by 
enzymatic assay (Instruchemie, Delfzijl, Netherlands). Animal studies were approved by the local 
animal ethics committee at Wageningen University.
Two terminally ill animals were transferred to the Small Animal Pathology laboratory of the Faculty 
of Veterinary Medicine at Utrecht University for formal autopsy by a licensed animal pathologist. 
Lipid excretion and absorption
During week 3-5 of high fat feeding, the amount of lipid excreted was measured in the faecal samples 
as previously described (42). Measurement of intestinal lipid absorption using 3H-labeled triolein and 
14C-labeled palmitic acid was carried out exactly as previously described (43).
Plasma and ascites analyses
All analyses were performed on non-fasting plasma unless specifically indicated. ELISA was used 
to determine plasma levels of serum amyloid A (Biosource International, Breda, Netherlands) and 
endotoxins (Limulus Amoebocyte Lysate, SanBio, Uden, Netherlands) following instructions from 
the manufacturer. Plasma concentrations of multiple inflammation markers were measured by 
multiplex immunoassay (RodentMAP) (Rules Based Medicine, Austin, TX). Plasma, ascites, and liver 
triglycerides were determined enzymatically as previously described (8). Plasma and ascites albumin 
concentration were determined by a photometric colorometric test according to the bromocresol green 
method (44) (Instruchemie, Delfzijl, Netherlands). Ascites protein concentration was determined 
using Bradford assay (45) (Biorad, Veenendaal, Netherlands). Ascites WBC was determined using 
a Sysmex XE-2100 haematology automated analyzer following instructions from the manufacturer. 
Lipoprotein profiling of the ascites fluid and mouse plasma was carried out by FPLC as previously 
described (21). Chylous ascites and plasma FPLC fractions were resolved by 6% SDS-PAGE and blotted 
onto PVDF membrane overnight (Millipore, Amsterdam, Netherlands). Membranes were blocked 
using 5% (w/v) milk powder in PBS with 0.1% Tween 20 and subsequently probed with rabbit anti-
mouse APOB48/APOB100 (Meridian Life Sciences Inc, Saco, ME) followed by HRP-conjugated goat 
anti-rabbit (Sigma, Zwijndrecht, Netherlands). Membranes were incubated with ECL (Amersham 
ECL Plus, GE Healthcare, Diegem, Belgium) and exposed to film.
Bacterial counts in feces
Colonic content was freeze-dried overnight and subsequently weighed. Feces were homogenized in 500 μl 
lysis buffer using FastPrep at 4°C and 5.5 ms for 3 minutes. 130 μl of 10 M ammonium acetate was added, 
followed by centrifugation. After transfer of the supernatant to a new tube, one volume of isopropanol 
was added. Samples were incubated on ice for 30 minutes, centrifuged, washed with 70% ethanol, and 
air-dried. The pellet was dissolved in 200 μl TE buffer. Genomic DNA was purified using QIAmp DNA 
Mini Kit to a final volume of 200 μl. Samples were diluted 100X before PCR analysis. DNA from all 
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bacteria was amplified by real-time PCR using primers: forward, ACTCCTACGGGAGGCAGCAG; 
reverse, ATTACCGCGGCTGCTGG. DNA from bacteroidetes was amplified using primers: forward, 
GGARCATGTGGTTTAATTCGATGAT; reverse, AGCTGACGACAACCATGCAG. Bacterial PCR-
based counts were normalized to the weight of fecal sample. 
Cell culture 
U937 human monocytes were differentiated into macrophages by 24 hours treatment with phorbol 
myristate acetate (10 ng/μl). U937 macrophages were subsequently incubated for 6 hours with fatty 
acids (C16:0, C18:1, C18:2) coupled to fatty acid free BSA to a final concentration of 500 μM as 
previously described (46).
To obtain peritoneal macrophages, wild-type and Angptl4–/– mice were injected intraperitoneally 
with 1 ml 4% thioglycollate. Three days later, animals were anesthesized with isoflurane, bled via 
orbital puncture, and peritoneal cavities washed using 10 ml ice-cold RPMI medium supplemented 
with 100 U/ml penicillin and 100 μg/ml streptomycin (Lonza, Verviers, Belgium). Cell pellets were 
incubated with RBC lysis buffer on ice for 5 minutes and subsequently washed with RPMI medium 
supplemented with 10% fetal bovine serum (FBS) (Lonza) and antibiotics, re-pelletized and seeded at 
density of 3×105 cells/cm2. Two hours later, cells were washed twice with PBS to remove non-adherent 
cells and provided with medium. Two days later, cells were exposed to chyle at TG concentration of 
2 mM for 6 hours preceded by preincubation with 20 μM Orlistat (Sigma Zwijndrecht, Netherlands) 
or 2.5 μg/ml mouse recombinant ANGPTL4 (R&D Systems, Abingdon, UK) for 1.5 hours. To explore 
mechanism of chyle, Angptl4–/– macrophages were preincubated with 10 μM myriocin, 10 μg/ml 
Polymyxin B or 0.5 mM Sulfosuccinimidyl oleate (SSO) for 30 minutes followed by exposure of cells 
to either PBS or chyle at TG concentration of 2 mM for 6 hours. In ER stress experiments, Angptl4–/– 
macrophages were exposed to 100 nM thapsigargin, 2.5 μg/ml tunicamycin or chyle (TG 2 mM) for 
6 hours. Analysis of ER stress in peritoneal macrophages was carried out as described (47).
Histology/Immunohistochemistry
Haematoxylin and Eosin staining of sections was performed using standard protocols. For detection 
of macrophages, immunohistochemistry was performed using antibody against CD68 (liver, adipose 
tissue) or F4/80 (lymph nodes) (Serotec, Oxford, UK). Paraffin-embedded sections were preincubated 
with 20% normal goat serum followed by overnight incubation at 4°C with primary antibody 
diluted 1:50 in PBS/1% BSA. After incubation with primary antibody, goat anti rat IgG conjugated 
to horseradish peroxidase (Serotec) was used as secondary antibody. Visualization was performed 
using AEC Substrate Chromogen (Cd68) or 3,3’-Diaminobenzidine (F4/80). Negative controls were 
prepared by omitting primary antibody.
For Sirius Red staining paraffin-embedded sections of small intestine were mounted on Superfrost 
microscope slides. Sections were dewaxed in xylene and rehydrated in series of graded alcohols. 
Slides were stained in picrosirius red 0.1% picric acid for 90 minutes and rinced in acidified H2O 
0.5% acetic acid.
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Oil red O stock solution was prepared by dissolving 0.5g Oil red O (Sigma, #O0625) in 500 ml 
isopropanol. Oil red O working solution was prepared by mixing 30 ml Oil red O stock with 20 ml 
dH2O, followed by filtration. 5μm sections were cut from frozen MLNs embedded in OCT. Sections 
were air dried for 30 minutes, rehydrated in dH2O, and fixated for 10 minutes in formal calcium (4% 
formaldehyde, 1% CaCl2). Sections were immersed in Oil red O working solution for 10 minutes, 
followed by two rinses with dH2O. Haematoxylin Nuclei staining was subsequently carried out for 5 
minutes followed by several rinses with dH2O. Sections were mounted in aqueous mountant (Imsol, 
Preston, UK).
For Sudan Black staining, 0.5 g Sudan black (Sigma, #86015) was dissolved in 100 ml warm 70% 
ethanol and subsequently filtered. Sections were fixed and rehydrated as above. After two 3 minutes 
rinses with 50% ethanol and two quick rinses with dH2O, sections were immersed in Sudan black 
solution for 10 minutes, followed by two rinses with dH2O. Sections were mounted in aqueous 
mountant (Imsol, Preston, UK).
LPL activity assay
Angptl4–/– macrophages were isolated and cultured as described in the main text. After extensive 
washing with PBS, cells were incubated in serum-free medium containing either PBS or recombinant 
mouse ANGPTL4 (5 μg/ml) (R&D Systems, Abingdon, United Kingdom) for 45 minutes. LPL was 
subsequently solubilized by adding 100 IU/ml heparin for 10 minutes. LPL activity was determined 
in 15 μl of medium using the Roar LPL Activity Assay Kit (Roar Biomedical, Inc, New York, USA).
Gene expression analysis
Isolation of RNA and subsequent analysis of gene expression by qPCR was carried out as previously 
described (48). Cyclophilin, 18S, or 36b4 were used as housekeeping genes. PCR primer sequences 
were taken from the PrimerBank and ordered from Eurogentec (Seraing, Belgium). Sequences of the 
primers used are available upon request.
RNA was isolated from mouse peritoneal macrophages using RNeasy mini columns (Qiagen, 
Venlo, The Netherlands). RNA quality was verified on an Agilent 2100 Bioanalyzer (Agilent 
Technologies, Amsterdam, The Netherlands) using 6000 Nano Chips according to manufacturer’s 
instructions. RNA was considered suitable for array hybridization only if RNA integrity number 
exceeded 8.0. RNA from 3 samples per group was pooled for microarray analysis. One hundred 
nanogram of RNA was used for Whole Transcript cDNA synthesis (Affymetrix, Santa Clara, CA). 
Hybridization, washing, and scanning of Affymetrix GeneChip Mouse Gene 1.0 ST Arrays were 
carried out according to standard Affymetrix protocols. Scans of the Affymetrix arrays were processed 
using packages from the Bioconductor project. Arrays were normalized using the Robust Multi-array 
Average method (49, 50). Probe sets were defined by assigning probes to unique gene identifiers, 
e.g. Entrez ID (51), which total 20985 on the Gene 1.0 ST arrays. Changes in gene expression were 
calculated as signal log ratios between treatment and control. These ratios were used to create 
heatmaps within Excel.
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Affymetrix GeneChip analysis was carried out on wild-type mouse peritoneal macrophages 
incubated with lipopolysaccharide (LPS, 100 ng/ml) for 4 hours (52). CEL files were downloaded from 
the internet via Gene Expression Omnibus (GSE14891) and processed as described above.
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Supplemental Figure 1. Micro- and macroscopic alteration in liver and adipose tissue
(A) Photograph of livers of wild-type and Angptl4–/– mouse fed LFD or HFD for 19 weeks. Livers of wild-
type mice fed HFD were enlarged and pale, indicating steatosis. Livers of Angptl4–/– mice fed HFD were 
rigid and compressed. 
(B) H&E staining of livers of wild-type and Angptl4–/– mouse fed HFD for 19 weeks. Staining reveals 
missing cords and sinusoids, poorly visible portal triads and lack of hepatic fat in Angptl4–/– mice fed HFD. 
Clumping of nuclei and focal infiltrates of neutrophils, eosinophils and macrophages were observed 
(insets). 
(C) Photograph of epididymal fat of wild-type and Angptl4–/– mouse fed LFD or HFD for 19 weeks. 
Adipose tissue of Angptl4–/– mice fed HFD had red appearance and was small in size compared to wild-
type mice fed HFD. 
(D) H&E staining of epididymal fat of wild-type and Angptl4–/– fed HFD for 19 weeks. Angptl4–/– mice reveal 
steatitis as shown by massive infiltration of granulocytes and lymphocytes around the periphery (insets). 
(E) Liver triglycerides after 19 weeks of LFD or HFD. 
(F and G) Weights of epididymal fat (F) and liver (G) after 19 weeks of LFD or HFD. 
Error bars represent SEM. * indicates significantly different according to Student’s t-test (P < 0.05). 
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Supplemental Figure 2. Absence of fat malabsorption in Angptl4–/– mice
(A) Fat excretion expressed as a percentage of dietary fat intake during week 2-5 of LFD or HFD. 
(B and C) Mice fasted for 5 hours were given 400 μl of olive oil containing 7μCi glycerol-tri[3H] oleate 
(triolein) and 2 μCi [14C]palmitate. Blood was collected every hour. 3H- (B) and 14C-radioactivity (C) are 
expressed as a percentage of total oral dose. 
(D and E) Five hours thereafter, small intestine was collected and cut into 3 parts. 3H- (D) and 
14C-radioactivity (E) are expressed as a percentage of total oral dose. 
(F) Heat map showing fold changes in expression of PPARα-target genes in small intestine of Angptl4–/– 
vs. wild-type mice. 
(G) mRNA expression of selected PPARα targets in small intestine of wild-type and Angptl4–/–  mice. 
Error bars represent SEM. * indicates significantly different between wild-type and Angptl4–/– mice 
according to Student’s t-test (P < 0.05).
?
?
??
??
??
??? ???
?
??
??
??
??
???
?
?
?
?
?
??
??
??
??
? ? ? ? ? ?
?????
?
??
??
??
??
??
??
???
??
??
??
?
?
??
??
??
??
? ? ? ? ? ?
?????
?
??
??
??
??
??
??
?
??
??
?
????
??
??
??
??????????
??????
?????
?????
?????
???????
??????
????
????
???????
??
??
?
??
??
???
?
???
???
???
???
???
???
???
????? ?? ?? ?? ??????
?
??
??
??
??
??
??
???
???
???
???
???
???
????? ?? ?? ?? ??????
?
??
?
??
??
??
??
??
?
?
?
?
?
?
?
?
?
?
????
??????
??????
??
?
?
?
?
?
?
?
?
??????? ??????
??
??
??
??
??
?
?
?
??
??????????
?? ?
????
?? ?
????? ??????????????????????????? ????? ???????????????????????????
73
ANGPTL4 protects MLN macrophages from saturated fat induced inflammation
3
Supplemental Figure 3. Epididymal adipose tissue does not show signs of enhanced 
inflammation in Angptl4–/– mice fed HFD
(A) H&E staining and CD68 immunostaining of epididymal adipose tissue of wild-type and Angptl4–/– 
fed HFD for 8 weeks. No signs of enhanced macrophage or other leukocyte infiltration were observed. 
(B) mRNA levels of macrophage marker Cd68 and F4/80 in epididymal adipose tissue of wild-type and 
Angptl4–/– mice fed LFD or HFD. * indicates significantly different between wild-type and Angptl4–/– mice 
according to Student’s t-test (P < 0.05). 
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Supplemental Figure 4. Inflammatory changes in Angptl4–/– mice fed HFD
(A) Relative abundance of bacterial phyla bacteroidetes and firmicutes per weight of colonic content in 
Angptl4–/– mice fed HFD and given oral antibiotics or vehicle. Error bars represent SEM. * = significantly 
different between mice given antibiotics or vehicle according to Student’s t-test (P < 0.05). 
(B) Mesenteric panniculitis in Angptl4–/– mice fed HFD for 5 weeks. 
(C) Expression of inflammatory genes in MLNs of wild-type and Angptl4–/– mice fed HFD for 24 hours. n 
= 3 per group. Error bars represent SEM. 
(D) High magnification (1000X) image of lipid-laden Touton giant cell in a MLN of an Angptl4–/– animal 
fed HFD for 24 hours.
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Supplemental Figure 5. The LPL inhibitor Orlistat prevents formation of lipid loaden 
macrophages
(A) Real-time PCR amplification plot of Angptl4 in wild-type peritoneal macrophages cultured in the 
absence of chyle (black lines, triplicates) and the presence of chyle (red lines, triplicates) (6 hours, final 
triglyceride concentration 2mM). 
(B) Heparin-releasable LPL activity in Angptl4–/– peritoneal macrophages treated with recombinant 
ANGPTL4 (5 μg/ml) 
(C) Oil red O staining of wild-type and Angptl4–/– peritoneal macrophages incubated for 6 hours with chyle 
(final triglyceride concentration 2 mM) and/or 20 μM Orlistat. Chyle was collected from rats provided 
with palm oil-based HFD overnight. Magnification 200X. 
(D) qPCR expression of selected genes in Angptl4–/– macrophages treated with chyle and/or Angptl4 
(2.5 μg/ml). * significantly different according to Student’s t-test (P < 0.05).
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Supplemental Figure 6. Chyle triggers inflammation in Angptl4–/– peritoneal macrophages
(A) Gene Ontology classes (Biological Processes) significantly overrepresented in Angptl4–/– mouse 
peritoneal macrophages treated with chyle (6 hours, triglyceride concentration 2 mM) compared to 
PBS-treated macrophages. Only GO classes with corrected P > 0.01 were included. 
(B) Ingenuity Canonical Pathways significantly altered in Angptl4–/– mouse peritoneal macrophages 
treated with chyle (6 hours, triglyceride concentration 2 mM) compared to PBS-treated macrophages. 
Only Canonical Pathways with P < 0.001 were included. 
(C) Venn diagram showing overlap in gene regulation by chyle (6 hours, 2 mM triglycerides) and LPS (4 
hours, 100 ng/ml) in primary mouse macrophages. Only genes present on both arrays and exceeding the 
minimal expression threshold (signal intensity >20 on at least one array) were included in the analysis 
(7517 genes in total). Overlap in gene induction (threshold 2.5-fold) by chyle and LPS was determined. 
The top 10 of most highly induced genes are shown. 
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Supplemental Figure 7. Regulation of Angptl4 and Gpihbp1 expression in macrophages
(A) Primary wild-type mouse peritoneal macrophages, human U937 and mouse RAW 264.7 macrophages 
were treated for 6 hours with synthetic agonists of PPARα (Wy14643, 1 μM), PPARβ/δ (GW501516, 0.5 
μM) and PPARγ (rosiglitazone, 0.5 μM). Angptl4 gene expression was determined by qPCR. 
(B) cDNA was prepared from whole mouse heart and mouse peritoneal macrophages. Real-time PCR 
amplification curves of Gpihbp1 were created using forward primer: ATGGGGCTAACTTGCCTAAGA and 
reverse primers: CTGAGCAGGGAGGGCTATATTAC. 
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Supplemental Table 1. Macronutrient and ingredient composition of the various diets
LFD- palm oil MFD-palm oil HFD-palm oil
Based on formula # D12450B D12451 D12451
  g% kcal% g% kcal% g% kcal%
Protein 19 20 21 20 24 20
Carbohydrate 67 70 54 51.3 41 35
Fat 4 10 13 27.7 24 45
Total   100   100   100
kcal/g 3.8   4.7   4.7  
Ingredient g kcal g kcal g kcal
Casein, lactic 200 800 200 800 200 800
L-Cystine 3 12 3 12 3 12
Corn Starch 427.2 1709 247.25 989 72.8 291
Maltodextrin 100 400 100 400 100 400
Sucrose 172.8 691 172.8 691 172.8 691
Cellulose, BW200 50 0 50 0 50 0
Soybean Oil 25 225 25 225 25 225
Palm oil 20 180 100 900 177.5 1598
Mineral Mix S10026 10 0 10 0 10 0
DiCalcium Phosphate 13 0 13 0 13 0
Calcium Carbonate 5.5 0 5.5 0 5.5 0
Potassium Citrate 16.5 0 16.5 0 16.5 0
Vitamin Mix V10001 10 40 10 40 10 40
Choline Bitartrate 2 0 2 0 2 0
Total (grams) 1055 4057 955.1 4057 858.15 4057
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Supplemental Table 2A. Fatty acid composition of the various diets expressed as percentage 
of total fatty acids
 % of total FAs Diet
LFD-
palm
MFD-
palm
HFD-
palm HFD-lard
HFD-
safflower
HFD-
MCT AIN93G
8:0 0.0 0.0 0.0 0.0 0.0 52.6 0.0
10:0 0.0 0.0 0.0 0.0 0.0 35.1 0.0
12:0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
14:0 0.5 0.8 0.9 1.3 0.0 0.0 0.1
16:0 25.5 38.0 40.7 23.2 6.5 1.2 10.0
16:1 0.0 0.0 0.0 2.2 0.0 0.0 0.0
18:0 4.0 4.0 4.0 14.5 3.1 0.5 4.0
18:1 30.3 36.5 37.8 40.5 13.3 2.8 22.5
18:2 35.0 19.0 15.5 14.2 75.2 6.8 55.0
18:3 4.2 1.5 0.9 2.7 0.9 0.9 7.5
Other 0.5 0.2 0.1 1.4 1.0 0.1 0.9
Total 100.0 100.0 100.0 100.0 100.0 100.0 100.0
Supplemental Table 2B. Fatty acid composition of the various diets expressed as percent 
by weight
g/100 g feed Diet
LFD-
palm
MFD-
palm
HFD-
palm HFD-lard
HFD-
safflower
HFD-
MCT AIN93G
8:0 0.0 0.0 0.0 0.0 0.0 12.4 0.0
10:0 0.0 0.0 0.0 0.0 0.0 8.3 0.0
12:0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
14:0 0.0 0.1 0.2 0.3 0.0 0.0 0.0
16:0 1.1 5.0 9.6 5.5 1.5 0.3 0.7
16:1 0.0 0.0 0.0 0.5 0.0 0.0 0.0
18:0 0.2 0.5 0.9 3.4 0.7 0.1 0.3
18:1 1.3 4.8 8.9 9.6 3.1 0.7 1.6
18:2 1.5 2.5 3.7 3.4 17.7 1.6 3.9
18:3 0.2 0.2 0.2 0.6 0.2 0.2 0.5
Other 0.0 0.0 0.0 0.3 0.2 0.0 0.1
Total 4.3 13.1 23.6 23.6 23.6 23.6 7.0
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Supplemental Table 3. Lipoprotein lipase (LPL) is among the most highly expressed genes 
in mouse peritoneal macrophages
Affymetrix microarray analysis was performed on mouse peritoneal macrophages using mouse Gene 
1.0 ST arrays. Arrays were normalized using the Robust Multi-array Average method. Genes were ranked 
according to expression signal.
Rank Expression
signal
Gene
symbol
Gene name
1 9618  Apoe apolipoprotein E
2 9178  Ctsd cathepsin D
3 8976  Psap prosaposin
4 8411  Gpnmb glycoprotein (transmembrane) nmb
5 8096  Fth1 ferritin heavy chain 1
6 8055  Ctss cathepsin S
7 7977  Lyz2 lysozyme 2
8 7898  Eef1a1 eukaryotic translation elongation factor 1 alpha 1
9 7601  Actb actin, beta
10 7423  Ctsb cathepsin B
11 7396  Spp1 secreted phosphoprotein 1
12 7354  Mmp12 matrix metallopeptidase 12
13 6916  Ctsz cathepsin Z
14 6786  Cd68 CD68 antigen
15 6387  Ctsl cathepsin L
16 6371  Cd36 CD36 antigen
17 6340  Gm13882 glyceraldehyde-3-phosphate dehydrogenase pseudogene
18 6235  Cst3 cystatin C
19 5908  Txn1 thioredoxin 1
20 5813  Lpl lipoprotein lipase
21 5810  Lgals3 lectin, galactose binding, soluble 3
22 5795  Akr1a4 aldo-keto reductase family 1, member A4 (aldehyde reductase)
23 5759  Cybb cytochrome b-245, beta polypeptide
24 5467  Vim vimentin
25 5464  Lipa lysosomal acid lipase A
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Abstract
Dietary triglycerides are hydrolyzed in the small intestine principally by pancreatic 
lipase. Following uptake by enterocytes and secretion as chylomicrons, dietary lipids 
are cleared from the bloodstream via lipoprotein lipase. Whereas lipoprotein lipase is 
inhibited by several proteins including Angiopoietin-like 4 (ANGPTL4), no endogenous 
regulator of pancreatic lipase has yet been identified. Here we present evidence that 
ANGPTL4 is an endogenous inhibitor of dietary lipid digestion. Angptl4–/– mice were 
heavier compared to their wild-type counterparts without any difference in food intake, 
energy expenditure or locomotor activity. However, Angptl4–/– mice showed decreased 
lipid content in the stools and increased accumulation of dietary triglycerides in the 
small intestine, which coincided with elevated luminal lipase activity in Angptl4–/– mice. 
Furthermore, recombinant ANGPTL4 reduced the activity of pancreatic lipase as well 
as the lipase activity in human ileostomy output. In conclusion, our data suggest that 
ANGPTL4 is an endogenous inhibitor of intestinal lipase activity.
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Introduction
Dietary triglycerides (TGs) contribute a major portion of our daily energy requirement. 
TGs are digested in the gastrointestinal tract through the action of several lipases including 
lingual lipase and gastric lipase (1, 2). However, the far majority of dietary TGs are digested 
in the small intestine by pancreatic lipase (PL) assisted by pancreatic colipase, pancreatic 
lipase-related protein 2, and carboxyl ester lipase (3, 4). To increase the accessibility of 
PL to dietary TGs at the oil-water interphase, dietary lipids are emulsified by the action 
of bile acids, which are produced in the liver, stored in the gallbladder, and subsequently 
released upon ingestion of a high-fat meal (2, 5). The resulting mono-acylglycerol and 
free fatty acids are taken up by enterocytes and resynthesized into TGs, followed by the 
lipidation of apolipoproteins to yield chylomicrons that are subsequently secreted into the 
lacteals (6-8). After traveling through the splanchnic lymphatic system and the thoracic 
duct, chylomicrons are released into the blood stream and ultimately reach the heart, 
skeletal muscle and adipose tissue as their primary target organs.
Clearance of circulating chylomicrons is mediated by lipoprotein lipase (LPL), which 
is anchored to the capillary endothelium via the protein GPIHBP1 (9-11). LPL catalyzes 
the hydrolysis of TGs to free fatty acids, which are taken up by the parenchymal cells to 
serve as energy source, building blocks for membranes, or to be used for storage. LPL 
is thought to function as an active homodimer and its activity in tissues is profoundly 
influenced by various physiological stimuli, including nutritional status, exercise and 
cold (9). In the last decade it has become evident that the activity of LPL is carefully 
controlled by three proteins belonging to the Angiopoietin-like protein family: ANGPTL3, 
ANGPTL4, and ANGPTL8 (12, 13). All three proteins have been shown to inhibit LPL 
activity in vitro and in vivo and accordingly raise circulating TG levels (12, 14, 15). 
ANGPTL3 is produced primarily by the liver and its expression is regulated by the Liver 
X Receptor (16, 17). ANGPTL8, a paralog of ANGPTL3, was recently identified as the 
latest member of the ANGPTL family (13). Deletion of ANGPTL8 results in decreased 
plasma TG levels due to decreased hepatic VLDL production and elevated LPL activity (14). 
ANGPTL4 has previously been shown to potently inhibit LPL in several tissues and cells 
under a variety of circumstances. Indeed, we and others have identified ANGPTL4 as an 
important regulator of LPL in adipose tissue, heart, and macrophages (18-22). ANGPTL4 
forms higher order oligomers and is subject to proteolytic cleavage to yield C- as well as 
N-terminal ANGPTL4. The precise mechanism by which ANGPTL4 inhibits LPL as well 
as the localization of the inhibitory effect are not fully understood. It was reported that 
ANGPTL4 inhibits LPL by promoting the irreversible conversion of active homodimeric 
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units into inactive monomers (23), whereas recent data suggest that ANGPTL4 functions 
as a reversible noncompetitive inhibitor of LPL (24). The expression of Angptl4 is governed 
by a multitude of dietary and hormonal cues including fatty acids and glucocorticoids via 
peroxisome proliferator-activated receptors (PPARs) and glucocorticoid receptor (GR), 
respectively (25-27).
LPL is part of the same family of extracellular lipases as PL, which also include 
endothelial lipase and hepatic lipase (28). However, little is known about regulation of the 
activity of PL. Here we report that ANGPTL4 reduces intestinal lipase activity by inhibition 
of PL. As a result, Angptl4–/– animals harvest more lipids from ingested food resulting in 
increased fat mass and body weight.
Results
ANGPTL4 deletion leads to increased bodyweight independent of food intake, energy 
intake, or locomotor activity
We observed that chow-fed Angptl4–/– mice have a significantly higher bodyweight than 
age-matched wild-type mice (Figure 1A). Body composition analysis by DEXA indicated 
that the difference in body weight can be attributed to a higher amount of body fat (Figure 
1B). In contrast, no difference in lean mass was observed between the two sets of mice, 
which was supported by the weight of major organs including liver, heart, and various 
muscles (Supplemental Figures 1A-1F). Also, no differences in food intake could be 
recorded (Figure 1C). Supporting a role of ANGPTL4 in dietary fat-induced weight gain, 
Angptl4–/– mice gained weight much faster compared to wild-type mice when switched 
to a high fat diet (Figure 1D), which again was independent of food intake (Figure 1E). 
A difference in body weight can be explained by several mechanisms including 
differences in locomotor activity and/or energy expenditure. To explore these options 
we determined the total energy balance of wild-type and Angptl4–/– mice using indirect 
calorimetry. For 1 week prior to and during the measurements the mice were given access 
to HFD. The metabolic phenotyping revealed no differences in food intake (Figures 2A and 
2B) and energy expenditure (Figures 2C and 2D), which was confirmed with ANCOVA 
analysis. Respiratory exchange ratios for wild-type and Angptl4–/– animals were equal 
at 0.85, indicative of the combustion of a mixture of fat and carbohydrates (Figure 2E). 
Moreover, locomotor activity did not differ between wild-type and Angptl4–/– animals 
(Figure 2F). These data indicate that the enhanced fat mass in Angptl4–/– mice is not due 
to increased food intake or decreased energy expenditure. 
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4Figure 1. Angptl4–/– mice are heavier despite equal food intake(A-D) Body weight (A), fat mass as determined with DEXA scan (B), average food intake per day over 
a 2-week period (C) of wild-type and Angptl4–/– mice on a standard chow diet (n = 10-11 per group). 
(D and E) Body weight development (D) and food intake (E) of wild-type and Angptl4–/– mice after a 
switch to HFD (n = 4-5 per group).
Data are mean ± SEM. Asterisks indicate significant differences according to Student’s t-test; *P < 0.05, 
**P < 0.01.
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To examine if lipid absorption is elevated in Angptl4–/– mice, we determined the amount 
of fat in the feces in mice fed low fat diet or high fat diet. Strikingly, the amount of fat 
in the feces was significantly lower in Angptl4–/– mice as compared to wild-type mice 
(Figure 2G), indicating enhanced lipid absorption. Thus, the data suggest that Angptl4–/– 
mice harvest more lipids from the ingested food, pointing to the intestine as a key site of 
ANGPTL4 action.
Although ANGPTL4 is known to be produced by a number of intestinal cell lines (29, 
30), little is known about intestinal ANGPTL4 expression in vivo. In mouse small intestine, 
Angptl4 mRNA levels were highest at the top of the villi and lowest in the crypts (Figure 
3A). Expression of Angptl4 did not vary much along the longitudinal axis of the murine 
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Figure 2. Metabolic phenotyping reveals no differences in energy expenditure, food intake 
or locomotor activity between wild-type and Angptl4–/– mice
(A and B) Food intake per 2 hours (A) or accumulated over 2 days (B) of wild-type and Angptl4–/– mice 
on a 45en% HFD diet (n = 11-12 per group). 
(C) Energy expenditure as determined every 13 minutes over the course of 2 days (n = 11-12 per group)
(D) Average energy expenditure over 2 days of wild-type and Angptl4–/– animals (n = 11-12 per group) 
(E) RER of wild-type and Angptl4–/– animals (n = 11-12 per group).
(F) Locomotor activity of wild-type and Angptl4–/– animals (n = 7-8 group).
(G) Fecal fat content in wild-type and Angptl4–/– mice after a 3-week HFD intervention (n = 4-5 group).
Data are mean ± SEM. Asterisk indicates significant differences according to two-way ANOVA with 
Bonferroni post-hoc test; *P < 0.05.
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4small intestine (Figure 3B). Interestingly, except in the most proximal portion of the small 
intestine, Angptl4 mRNA levels were 2-3 fold elevated by high fat feeding (Figure 3B). 
To explore the possible cause for the increased harvesting of dietary fat we carried out 
a lipid absorption test via oral dosing of 3H-triolein. No difference was observed in the 
rate of appearance of 3H-tracer in the circulation between wild-type and Angptl4–/– mice 
(Figure 4A), indicating that chylomicron synthesis and secretion, which are rate-limiting 
for dietary TG entry into the blood, are not different between the two sets of mice. 
However, a significant increase in tracer abundance was observed in small intestinal tissue 
of Angptl4–/– mice (Figure 4B), suggesting a higher rate of fatty acid uptake and possibly 
digestion. This finding was confirmed by higher TG levels in small intestine of Angptl4–/– 
mice after a 1-day HFD intervention (Figure 4C). In accordance with activation of the 
lipid-sensitive transcription factor PPARα by dietary fat, HFD or lipid gavage caused 
marked induction of numerous PPARα target genes in the small intestine. Consistent with 
enhanced lipid uptake in Angptl4–/– mice, induction of PPARα targets by HFD or lipid 
gavage was markedly augmented in Angptl4–/– mice in comparison with wild-type mice 
(Figures 5A and 5B). These data suggest that ANGPTL4 regulates the amount of luminal 
TG entering the enterocytes while having no effect on the amount of TG released from 
the intestine into the circulation.
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Figure 3. Increased intestinal Angptl4 mRNA expression after a HFD intervention
(A) Villin and Angptl4 expression in isolated epithelial fractions enriched for villi (n = 2).
(B) Angptl4 expression in 10 parts of the small intestine after 2 weeks HFD intervention, determined 
with Affymetrix Microarray (n = 3). 
Data are mean ± SEM. Asterisks indicate significant differences according to Student’s t-test; *P < 0.05, 
**P < 0.01.
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Figure 4. Angptl4–/– mice accumulate fat in their intestine
(A and B) 3H-triolein appearance in plasma (A) and intestine (B) after gavage with 3H-triolein in fasted 
wild-type and Angptl4–/– mice (n = 8-10 per group).
(C) Triglyceride content of wild-type and Angptl4–/– intestine after one day HFD intervention (n = 6-7 
per group).
Data are mean ± SEM. Asterisk indicates significant differences according to Student’s t-test; *P < 0.05.
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Increased lipid digestion in Angptl4–/– mice is independent of intestinal length, gas-
trointestinal transit time, and bile acid secretion or composition
An increase in intestinal lipid uptake might be explained by several factors, including a 
decrease in gastrointestinal (GI) transit time, allowing more time for lipases to digest dietary 
TGs and causing a higher overall rate of lipid digestion. To explore this possibility we fed 
overnight fasted mice a semi-synthetic diet colored with Fast Green FCF and recorded 
the time until arrival of the first dropping. No difference was observed in GI transit time 
between wild-type and Angptl4–/– mice (Figure 6A). In addition, total length of the small 
intestinal was unchanged between wild-type and Angptl4–/– mice (Figure 6B). 
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Figure 6. Increased lipid uptake in Angptl4–/– mice is independent of transit time or bile acid 
secretion
(A and B) GI transit time (A) and intestinal length (B) of wild-type and Angptl4–/– mice (n = 8-9 per group). 
(C-E) Fecal bile acids in wild-type and Angptl4–/– mice expressed as CA vs. CDCA (C), primary vs. secondary 
(D), or total (E) bile acids (n = 8-9 per group). 
Data are mean ± SEM. 
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Bile acids play an important role in lipid digestion by emulsifying lipids and thereby 
allowing for increased efficiency of lipid harvesting. Hence, a difference in the composition 
or in the total amount of bile acids may contribute to increased lipid uptake. We found 
no difference in the fecal amount of cholic- or deoxycholic acid (Figure 6C), nor in the 
amount of primary-, secondary-, or total bile acids between wild-type and Angptl4–/– mice 
(Figure 6D and E). Together, these observations indicate that enhanced lipid uptake in 
intestine of Angptl4–/– mice is unrelated to changes in intestinal transit time, intestinal 
length or bile acid composition/secretion.
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ANGPTL4 inhibits pancreatic lipase 
ANGPTL4 serves as an endogenous inhibitor of LPL and there is evidence that it inhibits 
hepatic lipase as well (31). Since PL, which serves as the principal intestinal lipase, belongs 
to the same family of extra-cellular lipases, we asked whether increased lipid uptake in 
Angptl4–/– mice may be explained by enhanced lipid digestion due to a lack of ANGPTL4-
mediated inhibition of intestinal lipase activity. To test this hypothesis we collected the 
luminal content from (refed) wild-type and Angptl4–/– mice and assayed fecal water for 
lipase activity. Consistent with our hypothesis, Angptl4–/– mice had a significantly higher 
luminal lipase activity in comparison to wild-type mice (Figure 7A). 
Inasmuch as PL is responsible for the major portion of intestinal lipase activity, we 
determined the direct effect of ANGPTL4 on PL by assaying the activity of recombinant 
PL in the presence of increasing amounts of recombinant ANGPTL4. As shown in Figure 
7B, ANGPTL4 inhibited PL activity in a dose-dependent manner. To extend these findings 
we collected ileostomy output from three otherwise healthy humans. Similar to mouse 
intestinal content, human material contained high lipase activity, which was repressed by 
the PL inhibitor Orlistat (Figure 7C). Importantly, adding recombinant human ANGPTL4 
significantly decreased the luminal lipase activity (Figure 7C). Together, these data indicate 
that ANGPTL4 inhibits intestinal lipase activity.
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Figure 7. ANGPTL4 inhibits pancreatic lipase
(A) Luminal lipase activity in fecal water derived from wild-type and Angptl4–/– mice (n = 9 per group).
(B) Recombinant PL activity in the presence of increasing concentrations of Orlistat or recombinant 
ANGPTL4.
(C) Lipase activity in stoma output of human volunteers in the absence or presence of Orlistat 25 μM) 
or recombinant human ANGPTL4 (10 μg/ml) (n = 3). 
Data are mean ± SEM. Asterisks indicate significant differences according to Student’s t-test (A) or one-
way ANOVA with Tukey’s post-hoc test (C); *P < 0.05, **P < 0.01.
Chapter 4
94
Discussion
Our results indicate that ANGPTL4 serves as an endogenous inhibitor of dietary lipid 
digestion via inhibition of PL, reducing the amount of energy that is harvested from dietary 
fat. As a result, mice lacking Angptl4 have less fat in their feces and gain more weight over 
time. Loss of ANGPTL4 does not appear to have any effect on energy expenditure or food 
intake. A key question elicited by our study is: what is the physiological relevance of an 
endogenous intestinal lipase inhibitor, production of which is increased by dietary fat? 
It is generally accepted that chylomicron secretion is rate limiting for lipid absorption, 
as evidenced by the constant rate of TG entry into the blood during an oral lipid loading 
test. Following consumption of a copious fat-rich meal, absence of any regulation on TG 
digestion may be expected to lead to excess fatty acid uptake into enterocytes, exceeding the 
capacity for re-esterification and chylomicron secretion and thus leading to lipid overload. 
To avoid such a scenario, production of ANGPTL4 is quickly stimulated upon entry of 
dietary fatty acids into enterocytes, putting a brake on dietary TG digestion. We propose 
that ANGPTL4 is an essential component of a feedback mechanism aimed at matching 
lipid uptake into enterocytes to the capacity for TG secretion. Previously, a similar role 
for ANGPTL4 in protection against lipid overload was demonstrated in cardiomyocytes 
and macrophages (19, 20).
The mechanism by which ANGPTL4 inhibits PL at the biochemical level requires further 
investigation. While we present a compelling case for direct inhibition of PL by ANGPTL4 
as the underlying mechanism accounting for enhanced fat uptake in Angptl4–/– mice, we 
cannot completely exclude a potential effect of Angptl4 deletion on total PL secretion. 
Indeed, an increase in PL secretion in Angptl4–/– mice would lead to increased lipid uptake 
and decreased fat secretion in the stools. However, recombinant ANGPTL4 was able to 
inhibit pancreatic lipase, pointing to a direct effect on PL. Since PL does not function 
as a homodimer, ANGPTL4 cannot inhibit PL by promoting the irreversible dimer to 
monomer conversion, as has been proposed for LPL (23). Interestingly, recent data suggest 
that ANGPTL4 may reversibly inhibit LPL independent of dimer dissociation by forming 
an inhibitory complex with LPL that regains lipase activity upon dissociation (24). It can 
be hypothesized that a similar mechanism may underlie inhibition of PL by ANGPTL4. It 
should be noted that ANGPTL4 was able to inhibit PL in the absence of colipase, and we 
therefore believe it is unlikely that the inhibitory effect is attributable to interference of the 
interaction between PL and colipase. Although the ANGPTL4 concentrations required for 
in vitro PL inhibition were relatively high, in vitro inhibition of LPL by ANGPTL4 under 
similar conditions also requires relatively high concentrations of ANGPTL4, yet there 
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is unequivocal evidence that ANGPTL4 serves as physiological inhibitor of LPL in vivo 
(18, 23, 32). It can be hypothesized that the high concentrations of ANGPTL4 required 
for in vitro LPL and PL inhibition may be related to absence of specific factors that shift 
the dose response curve.
Whereas numerous exogenous intestinal lipase inhibitors have been characterized, 
mainly representing plant derived components such as saponins, polyphenols, and 
terpenes (33, 34), to our knowledge we have identified the first endogenous inhibitor of 
PL. Interestingly, several endogenous inhibitors of the major protein digestive enzymes 
including trypsin and chemotrypsin have been described (35, 36). Although the majority 
is thought to function in the pancreas to prevent premature activation of zymogens (35), 
expression of some of these inhibitors is found in the intestine (37, 38), suggesting a role 
in controlling luminal protease activity.
In recent years, the gut microbiota has received much attention as alleged critical 
contributor to weight gain and obesity (39, 40). In this context, a role of ANGPTL4 
in linking gut microbiota to fat storage has been proposed. Specifically, introducing 
microbiota into germ-free mice or zebrafish was found to markedly reduce intestinal 
Angptl4 expression (41, 42). Furthermore, whereas wild-type and Angptl4–/– mice have 
similar amounts of body fat on a germ-free background, introducing microbiota leads 
to a much smaller increase in body fat in Angptl4–/– mice compared to wild-type mice, 
suggesting that microbial suppression of ANGPTL4 contributes to increased fat deposition. 
Suppression of ANGPTL4 was suggested to promote fat storage by loss of inhibition 
of LPL activity in adipose tissue and reduction in expression of Pgc1α and fatty acid 
oxidation enzymes in liver and skeletal muscle (43). Based on our data, it can be envisaged 
that microbial suppression of ANGPTL4 may also promote weight gain via loss of local 
action of ANGPTL4 in the gut, leading to elevated intestinal lipase activity and increased 
harvesting of dietary TGs. In apparent conflict with the decrease in Angptl4 expression 
upon colonization of germ-free animals, recent data suggest that short-chain fatty acids 
derived from microbial fermentation of dietary fibers induce Angptl4 expression in 
intestinal cells via PPARγ (29). Although most of the short-chain fatty acids are produced 
in the colon, relatively high concentrations are also found in the small intestine (29). It 
can be speculated that induction of ANGPTL4 may play a role in mediating the repressive 
effect of dietary fibers on lipid absorption (44, 45). ANGPTL4 undergoes cleavage to form 
N-terminal and C-terminal ANGPTL4 fragments. Recently, we found that C-terminal 
ANGPTL4, which is unable to inhibit lipase activity, is produced by entero-endocrine cells 
in human intestine, suggesting secretion towards the bloodstream (46). We hypothesize 
that N-terminal ANGPTL4, which is able to inhibit lipase activity, is released selectively by 
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enterocytes towards the lumen to inhibit PL. Future experiments will have to clarify both 
the exact site of N-terminal ANGPTL4 production as well as its presence in the lumen.
We have previously shown that Angptl4–/– mice develop a progressive and ultimately 
lethal inflammatory condition when chronically fed a HFD containing mainly saturated 
fatty acids (19). However, it is highly unlikely that the enhanced intestinal lipid uptake in 
Angptl4–/– mice is related to underlying inflammatory processes, as enhanced weight gain 
is already apparent on a LFD and becomes more pronounced very quickly upon shifting 
to a HFD. Furthermore, the effect of ANGPTL4 on luminal lipase activity is apparent in 
mice fed a LFD or with tests that last only a few hours. 
Recently, Kim and colleagues postulated that Angptl4 deletion leads to increased body 
weight due to an inhibitory effect of ANGPTL4 on hypothalamic AMPK and a subsequent 
increase in energy expenditure (47). In our study we were unable to find a difference in energy 
expenditure when comparing wild-type and Angptl4–/– mice after 1 week acclimatization to 
HFD, when the difference in weight gain between the two sets of mice is the most pronounced. 
Additionally, Kim and colleagues found that Angptl4–/– mice have increased food intake 
during fasting-refeeding, but not under ad libitum conditions (47). Similarly, we have never 
observed any differences in food intake between ad libitum-fed wild-type and Angptl4–/– 
mice, either on chow diet, semi-synthetic LFD or a HFD. Interestingly, the Angptl4–/– mice 
employed in the studies by Kim et al. were resistant to diet induced obesity, while we have 
found several times that mice lacking Angptl4 gain more weight on a HFD, at least during 
the first 2 months. A potential explanation for the difference is that the development of the 
previously reported dietary saturated fat-induced inflammation in Angptl4–/– mice was greatly 
accelerated in the study by Kim and colleagues due to extremely high saturated fat content 
of the diet, leading to reduced food intake as described previously (19).
Collectively, we describe a novel function of ANGPTL4 in the regulation of lipid 
metabolism. By acting as a gatekeeper in the regulation of intestinal lipid uptake, ANGPTL4 
decreases the amount of lipid being harvested from the ingested food and protects against 
enterocyte lipid overload.
Methods
Animal studies
Animals used for all experiments were pure-bred male wild-type and Angptl4–/– animals on a C57BL/6 
background (48). Body composition was determined by DEXA (Lunar, PIXImus) on chow-fed 24 
weeks old wild-type and Angptl4–/– mice. Food intake was recorded over a  2-week period. Animals were 
sacrificed by cervical dislocation after being anesthetized using isoflurane and several organs were excised. 
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Eleven-week-old wild-type and Angptl4–/– animals were given access to HFD providing 45en% 
fat (D12451, Research Diets Services, Wijk bij Duurstede, The Netherlands). Food intake and body 
weight were recorded weekly for a period of 3 weeks. 
Wild-type and Angptl4–/– animals (28 weeks old) were analyzed in an open-circuit LabMaster 
Metabolism Research Platform (TSE systems GmbH, Bad Homburg, Germany) as described 
previously (49), with minor adaptations. Animals were acclimatized for 24 hours followed by 48-hour 
measurements. Eight of the 12 cages were also equipped for locomotor activity measurements. Body 
composition analysis (Echo-MRI, Houston, USA) was performed immediately before and after the 
indirect calorimetric analyses, which showed similar lean mass between wild-type and Angptl4–/– mice. 
One week before the actual metabolic phenotyping, the animals were switched to HFD. During the 
analysis, mice were kept on the same HFD. Fecal fat was extracted from feces of 11-week-old wild-type 
and Angptl4–/– animals after a 3-week HFD intervention using published methods (50). Fatty acids were 
subsequently measured using an enzymatic assay (NEFA-HR(2), Wako Chemicals, Neuss, Germany). 
Intestinal lipid absorption tests were performed using 3H-labeled triolein according to published 
methods (51). For determination of intestinal TG content, wild-type and Angptl4–/– animals were fed 
a HFD for 24 hours after a 1-week run in with LFD. Mice were killed by cervical dislocation and the 
small intestine was collected, washed with ice-cold PBS and snap frozen. Samples were homogenized 
in sucrose buffer (10 mM Tris, 2 mM EDTA, 0.25 M sucrose, pH 7.5) with a Qiagen TissueLyser II 
(Qiagen, Hilden, Germany) and subsequently analyzed for TGs using a Triglycerides liquicolormono 
kit (HUMAN, Wiesbaden, Germany). 
qPCR analysis of PPARα target genes was performed in proximal small intestine of 10- to 15-week-
old wild-type and Angptl4–/– mice fed LFD or a safflower oil-based HFD for 6 weeks. qPCR analysis of 
PPARα target genes was also performed on small intestine of 4-months-old wild-type and Angptl4–/– 
animals fasted for 4 hours and subsequently intragastrically gavaged with 400 μl carboxymethyl cellulose 
(CMC) or synthetic trilinolenin. Proximal small intestines were excised, washed with ice-cold PBS, 
and subsequently snap frozen in liquid nitrogen. 
To assess intestinal transit time, wild-type and Angptl4–/– mice (16 weeks old) were fed AIN-93W 
low fat semi-purified diet (Research Diets Services, Wijk bij Duurstede, Netherlands) for 3 days prior 
to the experiment. Next, the mice were fasted for 16 hours and subsequently given access to AIN-93W 
diet which was colored with 60 mg/kg Fast Green FCF (Sigma-Aldrich, Schnelldorf, Germany). The 
time until the first green dropping appeared was recorded. Feces from 12- to 15-week-old wild-type 
and Angptl4–/– mice on standard chow were collected and analyzed for several bile acids as described 
previously (52).
Animal studies were performed according to protocols approved by the local animal ethics 
committee of Wageningen University.
Gene expression analysis
Proximal intestine samples from wild-type and Angptl4–/– animals after HFD or lipid gavage were 
homogenized in TRIzol® (Life Technologies Europe BV, Bleiswijk, The Netherlands) using a Qiagen 
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TissueLyser II (Qiagen, Hilden, Germany) for RNA isolation. cDNA was synthesized with the First 
Strand cDNA synthesis kit (Thermo Scientific, Landsmeer, The Netherlands). qPCR was performed 
using SensiMix (Bioline, GC biotech, Alphen aan den Rijn, The Netherlands) and primers from the 
Harvard PrimerBank on a CFX384 platform (BioRad, Veenendaal, The Netherlands). For normalization 
36b4 was used as a housekeeping gene. 
Affymetrix GeneChip analysis was performed on 10 longitudinal small intestine fragments 
collected along the total length of the small intestine of C57BL/6 mice fed LFD or HFD for 2 weeks. 
RNA was extracted as described above and subsequently purified using the RNeasy Minikit (Qiagen, 
Venlo, The Netherlands). RNA quality was assessed on RNA 6000 Nano chips with the Agilent 2100 
Bioanalyzer (Agilent Technologies, Amsterdam, the Netherlands). Labeled RNA was hybridized to 
Affymetrix Mouse Gene 1.1 ST array plate on the Affymetrix GeneTitan platform, and scans were 
processed using Bioconductor followed by RMA normalization (53, 54). Probe sets were generated 
based on published methods (55) using chip definition file (CDF) version 15 derived from the Entrez 
gene database. Analysis of Villin and Angptl4 mRNA levels along the crypt-villus axis was performed 
according to published methods (56) using qPCR as described above.     
Mouse luminal lipase activity
Luminal content collected from the small intestine was mixed with 19 volumes ice-cold PBS, vortexed 
vigorously and centrifuged at 15,000 g for 10 minutes at 4°C. Supernatants were collected and diluted 
1:100 in PBS for subsequent analysis. Lipase activity was measured using the Roar LPL activity assay kit 
(Roar Biomedical, Inc., New York, USA) according to the manufacturer’s protocol. The LPL activity kit 
employs a substrate that becomes fluorescent upon hydrolysis of an ester and can be used to assess the 
activity of other lipases too. Lipase activity was calculated as μmole per hour using a pre-hydrolyzed 
substrate and subsequently normalized for protein concentration of the fecal water as determined 
with BCA protein assay (Thermo Fisher Scientific, Landsmeer, The Netherlands). 
Human luminal lipase activity
Three otherwise healthy volunteers with a distal ileostomy volunteered to provide stoma output. 
Volunteers were aged 50-67 years and included one male and two females. Collected material was 
transported on ice and centrifuged at 5,000 g for 10 minutes at 4°C. Supernatants were collected and 
stored at -80°C until lipase activity assays. Samples were diluted 1:100 before determining lipase activity 
with the Roar LPL Activity Assay Kit. Recombinant mouse ANGPTL4 (R&D Systems, Abingdon 
United Kingdom) or Orlistat (Sigma-Aldrich, Schnelldorf, Germany) were allowed to preincubate with 
stoma output at 37°C for 45 minutes after which the fluorescent substrate was added. Fluorescence 
was measured after an additional incubation period of 45 minutes at 37°C. Fluorescent units were 
converted to μmol of hydrolyzed substrate per hour using the pre-hydrolyzed substrate, and normalized 
for protein content determined with a BCA protein assay.
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Pancreatic lipase activity
Recombinant PL (Sigma-Aldrich, Schnelldorf, Germany) at an amount of 250 units was added to the 
fluorescent substrate of the Roar LPL Activity Assay Kit. Recombinant mouse ANGPTL4 or Orlistat 
were included to address the inhibitory capacity of these compounds on PL mediated hydrolysis. 
Fluorescence was measured after incubation at 37°C for 45 minutes.
Statistical analysis
Unpaired two-tailed Student’s t-tests and analysis of variances with corresponding post-hoc tests were 
performed using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). The cutoff for significance 
level was set at P < 0.05.
Acknowledgements 
We thank Jvalini Dwarkasing for assistance with body composition analysis. This study was 
supported by the Netherlands Nutrigenomics Centre and the Netherlands Organization 
for Scientific Research (NWO) (TOP grant 40-00812-98-08030 to S.K.).
References
1.  Armand M. Lipases and lipolysis in the human digestive tract: where do we stand? Curr Opin Clin 
Nutr Metab Care. 2007;10(2):156-164.
2. Wilde PJ, Chu BS. Interfacial & colloidal aspects of lipid digestion. Adv Colloid Interface Sci. 
2011;165(1):14-22.
3. Carriere F, Barrowman JA, Verger R, Laugier R. Secretion and contribution to lipolysis of gastric and 
pancreatic lipases during a test meal in humans. Gastroenterology. 1993;105(3):876-888.
4. Whitcomb DC, Lowe ME. Human pancreatic digestive enzymes. Dig Dis Sci. 2007;52(1):1-17.
5. Brownlee IA, Forster DJ, Wilcox MD, Dettmar PW, Seal CJ, Pearson JP. Physiological parameters 
governing the action of pancreatic lipase. Nutr Res Rev. 2010;23(1):146-154.
6. Wang TY, Liu M, Portincasa P, Wang DQ. New insights into the molecular mechanism of intestinal 
fatty acid absorption. Eur J Clin Invest. 2013;43(11):1203-1223.
7. Demignot S, Beilstein F, Morel E. Triglyceride-rich lipoproteins and cytosolic lipid droplets in 
enterocytes: Key players in intestinal physiology and metabolic disorders. Biochimie. 2013.
8. Iqbal J, Hussain MM. Intestinal lipid absorption. Am J Physiol Endocrinol Metab. 2009;296(6):E1183-
1194.
9. Wang H, Eckel RH. Lipoprotein lipase: from gene to obesity. Am J Physiol Endocrinol Metab. 
2009;297(2):E271-288.
10. Beigneux AP, Davies BS, Gin P, Weinstein MM, Farber E, Qiao X, Peale F, Bunting S, Walzem RL, 
Wong JS, et al. Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 
plays a critical role in the lipolytic processing of chylomicrons. Cell Metab. 2007;5(4):279-291.
Chapter 4
100
11. Davies BS, Beigneux AP, Barnes RH, 2nd, Tu Y, Gin P, Weinstein MM, Nobumori C, Nyren R, Goldberg 
I, Olivecrona G, et al. GPIHBP1 is responsible for the entry of lipoprotein lipase into capillaries. Cell 
Metab. 2010;12(1):42-52.
12. Mattijssen F, Kersten S. Regulation of triglyceride metabolism by Angiopoietin-like proteins. Biochim 
Biophys Acta. 2012;1821(5):782-789.
13. Quagliarini F, Wang Y, Kozlitina J, Grishin NV, Hyde R, Boerwinkle E, Valenzuela DM, Murphy AJ, 
Cohen JC, Hobbs HH. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad 
Sci U S A. 2012;109(48):19751-19756.
14. Wang Y, Quagliarini F, Gusarova V, Gromada J, Valenzuela DM, Cohen JC, Hobbs HH. Mice lacking 
ANGPTL8 (Betatrophin) manifest disrupted triglyceride metabolism without impaired glucose 
homeostasis. Proc Natl Acad Sci U S A. 2013;110(40):16109-16114.
15. Zhang R. Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride 
levels. Biochem Biophys Res Commun. 2012;424(4):786-792.
16. Kaplan R, Zhang T, Hernandez M, Gan FX, Wright SD, Waters MG, Cai TQ. Regulation of the 
angiopoietin-like protein 3 gene by LXR. J Lipid Res. 2003;44(1):136-143.
17. Inaba T, Matsuda M, Shimamura M, Takei N, Terasaka N, Ando Y, Yasumo H, Koishi R, Makishima 
M, Shimomura I. Angiopoietin-like protein 3 mediates hypertriglyceridemia induced by the liver X 
receptor. J Biol Chem. 2003;278(24):21344-21351.
18. Mandard S, Zandbergen F, van Straten E, Wahli W, Kuipers F, Muller M, Kersten S. The fasting-
induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and 
governs plasma lipid levels and adiposity. J Biol Chem. 2006;281(2):934-944.
19. Lichtenstein L, Mattijssen F, de Wit NJ, Georgiadi A, Hooiveld GJ, van der Meer R, He Y, Qi L, Koster 
A, Tamsma JT, et al. Angptl4 protects against severe proinflammatory effects of saturated fat by 
inhibiting fatty acid uptake into mesenteric lymph node macrophages. Cell Metab. 2010;12(6):580-
592.
20. Georgiadi A, Lichtenstein L, Degenhardt T, Boekschoten MV, van Bilsen M, Desvergne B, Muller M, 
Kersten S. Induction of cardiac Angptl4 by dietary fatty acids is mediated by peroxisome proliferator-
activated receptor beta/delta and protects against fatty acid-induced oxidative stress. Circ Res. 
2010;106(11):1712-1721.
21. Yu X, Burgess SC, Ge H, Wong KK, Nassem RH, Garry DJ, Sherry AD, Malloy CR, Berger JP, Li C. 
Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart. 
Proc Natl Acad Sci U S A. 2005;102(5):1767-1772.
22. Kroupa O, Vorrsjo E, Stienstra R, Mattijssen F, Nilsson SK, Sukonina V, Kersten S, Olivecrona G, 
Olivecrona T. Linking nutritional regulation of Angptl4, Gpihbp1, and Lmf1 to lipoprotein lipase 
activity in rodent adipose tissue. BMC Physiol. 2012;12:13.
23. Sukonina V, Lookene A, Olivecrona T, Olivecrona G. Angiopoietin-like protein 4 converts lipoprotein 
lipase to inactive monomers and modulates lipase activity in adipose tissue. Proc Natl Acad Sci U S 
A. 2006;103(46):17450-17455.
24. Lafferty MJ, Bradford KC, Erie DA, Neher SB. Angiopoietin-like Protein 4 inhibition of lipoprotein 
lipase: evidence for reversible complex formation. J Biol Chem. 2013;288(40):28524-28534.
25. Kersten S, Lichtenstein L, Steenbergen E, Mudde K, Hendriks HF, Hesselink MK, Schrauwen P, 
Muller M. Caloric restriction and exercise increase plasma ANGPTL4 levels in humans via elevated 
free fatty acids. Arterioscler Thromb Vasc Biol. 2009;29(6):969-974.
26. Koliwad SK, Kuo T, Shipp LE, Gray NE, Backhed F, So AY, Farese RV, Jr., Wang JC. Angiopoietin-like 4 
(ANGPTL4, fasting-induced adipose factor) is a direct glucocorticoid receptor target and participates 
in glucocorticoid-regulated triglyceride metabolism. J Biol Chem. 2009;284(38):25593-25601.
101
ANGPTL4 is an inhibitor of intestinal lipid digestion
4
27. Staiger H, Haas C, Machann J, Werner R, Weisser M, Schick F, Machicao F, Stefan N, Fritsche A, 
Haring HU. Muscle-derived angiopoietin-like protein 4 is induced by fatty acids via peroxisome 
proliferator-activated receptor (PPAR)-delta and is of metabolic relevance in humans. Diabetes. 
2009;58(3):579-589.
28. Wong H, Schotz MC. The lipase gene family. J Lipid Res. 2002;43(7):993-999.
29. Alex S, Lange K, Amolo T, Grinstead JS, Haakonsson AK, Szalowska E, Koppen A, Mudde K, Haenen 
D, Al-Lahham S, et al. Short-chain fatty acids stimulate angiopoietin-like 4 synthesis in human colon 
adenocarcinoma cells by activating peroxisome proliferator-activated receptor gamma. Mol Cell Biol. 
2013;33(7):1303-1316.
30. Korecka A, de Wouters T, Cultrone A, Lapaque N, Pettersson S, Dore J, Blottiere HM, Arulampalam 
V. ANGPTL4 expression induced by butyrate and rosiglitazone in human intestinal epithelial cells 
utilizes independent pathways. Am J Physiol Gastrointest Liver Physiol. 2013;304(11):G1025-1037.
31. Lichtenstein L, Berbee JF, van Dijk SJ, van Dijk KW, Bensadoun A, Kema IP, Voshol PJ, Muller M, 
Rensen PC, Kersten S. Angptl4 upregulates cholesterol synthesis in liver via inhibition of LPL- and 
HL-dependent hepatic cholesterol uptake. Arterioscler Thromb Vasc Biol. 2007;27(11):2420-2427.
32. Yoshida K, Shimizugawa T, Ono M, Furukawa H. Angiopoietin-like protein 4 is a potent hyperlipidemia-
inducing factor in mice and inhibitor of lipoprotein lipase. J Lipid Res. 2002;43(11):1770-1772.
33. de la Garza AL, Milagro FI, Boque N, Campion J, Martinez JA. Natural inhibitors of pancreatic lipase 
as new players in obesity treatment. Planta Med. 2011;77(8):773-785.
34. Birari RB, Bhutani KK. Pancreatic lipase inhibitors from natural sources: unexplored potential. Drug 
Discov Today. 2007;12(19-20):879-889.
35. Marchbank T, Freeman TC, Playford RJ. Human pancreatic secretory trypsin inhibitor. Distribution, 
actions and possible role in mucosal integrity and repair. Digestion. 1998;59(3):167-174.
36. Laskowski M, Jr., Kato I. Protein inhibitors of proteinases. Annu Rev Biochem. 1980;49:593-626.
37. Bohe H, Bohe M, Lundberg E, Polling A, Ohlsson K. Production and secretion of pancreatic secretory 
trypsin inhibitor in normal human small intestine. J Gastroenterol. 1997;32(5):623-627.
38. Wang J, Ohmuraya M, Hirota M, Baba H, Zhao G, Takeya M, Araki K, Yamamura K. Expression 
pattern of serine protease inhibitor kazal type 3 (Spink3) during mouse embryonic development. 
Histochem Cell Biol. 2008;130(2):387-397.
39. Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. 
Nature. 2012;489(7415):242-249.
40. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut 
microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027-1031.
41. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. The 
gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 
2004;101(44):15718-15723.
42. Camp JG, Jazwa AL, Trent CM, Rawls JF. Intronic cis-regulatory modules mediate tissue-specific and 
microbial control of angptl4/fiaf transcription. PLoS Genet. 2012;8(3):e1002585.
43. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to 
diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007;104(3):979-984.
44. Santas J, Espadaler J, Cune J, Rafecas M. Partially hydrolyzed guar gums reduce dietary fatty acid and 
sterol absorption in guinea pigs independent of viscosity. Lipids. 2012;47(7):697-705.
45. Vahouny GV, Satchithanandam S, Chen I, Tepper SA, Kritchevsky D, Lightfoot FG, Cassidy MM. 
Dietary fiber and intestinal adaptation: effects on lipid absorption and lymphatic transport in the 
rat. Am J Clin Nutr. 1988;47(2):201-206.
Chapter 4
102
46. Alex S, Lichtenstein L, Dijk W, Mensink RP, Tan NS, Kersten S. ANGPTL4 is produced by entero-
endocrine cells in the human intestinal tract. Histochem Cell Biol. 2013.
47. Kim HK, Youn BS, Shin MS, Namkoong C, Park KH, Baik JH, Kim JB, Park JY, Lee KU, Kim YB, 
et al. Hypothalamic Angptl4/Fiaf is a novel regulator of food intake and body weight. Diabetes. 
2010;59(11):2772-2780.
48. Koster A, Chao YB, Mosior M, Ford A, Gonzalez-DeWhitt PA, Hale JE, Li D, Qiu Y, Fraser CC, Yang 
DD, et al. Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 
and angptl3: regulation of triglyceride metabolism. Endocrinology. 2005;146(11):4943-4950.
49. Hoevenaars FP, Keijer J, Swarts HJ, Snaas-Alders S, Bekkenkamp-Grovenstein M, van Schothorst EM. 
Effects of dietary history on energy metabolism and physiological parameters in C57BL/6J mice. Exp 
Physiol. 2013;98(5):1053-1062.
50. Govers MJ, Van der Meet R. Effects of dietary calcium and phosphate on the intestinal interactions 
between calcium, phosphate, fatty acids, and bile acids. Gut. 1993;34(3):365-370.
51. Goudriaan JR, Dahlmans VE, Febbraio M, Teusink B, Romijn JA, Havekes LM, Voshol PJ. Intestinal 
lipid absorption is not affected in CD36 deficient mice. Mol Cell Biochem. 2002;239(1-2):199-202.
52. Plosch T, Kok T, Bloks VW, Smit MJ, Havinga R, Chimini G, Groen AK, Kuipers F. Increased 
hepatobiliary and fecal cholesterol excretion upon activation of the liver X receptor is independent 
of ABCA1. J Biol Chem. 2002;277(37):33870-33877.
53. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry 
J, et al. Bioconductor: open software development for computational biology and bioinformatics. 
Genome Biol. 2004;5(10):R80.
54. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, 
normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 
2003;4(2):249-264.
55. Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil 
H, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. 
Nucleic Acids Res. 2005;33(20):e175.
56. Bunger M, van den Bosch HM, van der Meijde J, Kersten S, Hooiveld GJ, Muller M. Genome-wide 
analysis of PPARalpha activation in murine small intestine. Physiol Genomics. 2007;30(2):192-204.
103
ANGPTL4 is an inhibitor of intestinal lipid digestion
4Supplemental Figure 1. Tissue weights of wild-type and Angptl4
–/– animals
(A-E) Liver (A), heart (B), gastrocnemius (C), soleus (D), and tibialis weight of wild-type and Angptl4–/– mice 
fed a standard chow diet (n = 10-11 per group). 
Data are mean ± SEM.
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Abstract
Peroxisome proliferator-activated receptors (PPARs) play major roles in the regulation 
of hepatic lipid metabolism through the control of numerous genes involved in processes 
such as lipid uptake and fatty acid oxidation. Here we identify hypoxia inducible 
lipid droplet associated (Hilpda) as a novel PPAR target gene involved in hepatic 
lipid metabolism. Microarray and qPCR analysis showed that Hilpda expression is 
markedly induced by the PPARα agonist Wy14643 in mouse liver slices. Induction of 
Hilpda mRNA by Wy14643 was confirmed in mouse and human hepatocytes. Oral 
dosing with Wy14643 similarly induced Hilpda mRNA levels in livers of wild-type mice 
but not Ppara–/– mice. Transactivation studies and chromatin immunoprecipitation 
showed that Hilpda is a direct PPARα target gene via a conserved PPAR response 
element (PPRE) located 1200 base pair upstream of the transcription start site. Hepatic 
overexpression of HILPDA in mice via adeno-associated virus led to a 4-fold increase 
in liver triglyceride storage, without any changes in key genes involved in de-novo 
lipogenesis, β-oxidation, or lipolysis. Moreover, HILPDA did not affect intracellular 
lipase activity. Strikingly, HILPDA overexpression significantly impaired hepatic 
triglyceride secretion. Taken together, our data uncover HILPDA as a novel PPAR 
target that raises hepatic triglyceride storage via regulation of triglyceride secretion.
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Introduction
The liver is a key organ in the control of carbohydrate and lipid metabolism. During the 
postprandial phase the liver is exposed to high concentrations of glucose and chylomicron 
remnants, which are taken up, processed, and subsequently stored as glycogen and 
triglycerides, respectively. In the fasted state, the liver assures the maintenance of stable 
plasma glucose and lipid levels to provide peripheral organs with the necessary nutrients. 
Indeed, gluconeogenesis, VLDL production, and ketogenesis are important metabolic 
processes in the liver aimed at maintaining energy homeostasis in times of food deprivation 
(1-4). Many genes involved in these processes are regulated by nuclear receptors (5-7).
Nuclear receptors comprise a family of transcription factors that bind to specific response 
elements across the genome and regulate the expression of a large network of genes (8). 
As a group they are activated by a variety of steroid hormones and other lipid-derived 
compounds, including fat-soluble vitamins, cholesterol, and fatty acids (9). Binding of 
ligand to nuclear receptors promotes the recruitment and release of coactivators and 
corepressors, respectively, to form multiprotein complexes that induce transcription of 
target genes (10-14). A group of nuclear receptors that has been extensively studied and 
that plays a central role in the regulation of nutrient homeostasis in liver and other organs 
are the peroxisome proliferator activated receptors (PPARs) (15-17). PPARs are ligand-
activated transcription factors that bind a variety of (dietary) fatty acids and fatty-acid 
derived compounds, including various eicosanoids (18, 19). Furthermore, PPARs are the 
molecular target of the thiazolidinedione and fibrate classes of drugs used in the treatment 
of diabetes and dyslipidemia, respectively (20-23). 
PPARs share a common structure with other nuclear receptors consisting of several 
distinct domains: a DNA-binding domain (DBD) containing two zinc-fingers, a ligand 
binding domain (LBD), and two transcriptional activation functions located in the 
N-terminal domain (AF1) or the LBD (AF2) (24). All domains can contribute to PPAR 
activation via ligand dependent and independent mechanisms. 
Induction of gene transcription by PPARs requires the cooperative binding to retinoid 
X receptors (RXR), a nuclear receptor that is ligand-activated by 9-cis retinoic acid, to 
form an active heterodimer (25). The PPAR-RXR heterodimer binds to so called PPAR 
response elements (PPRE) composed of the consensus sequence AGGTCAnAGGTCA 
located in proximal promoters, introns, and more distant regions of target genes (26, 27).
Three different PPARs can be distinguished: PPARα (Nr1c1), PPARβ/δ (Nr1c2), and 
PPARγ (Nr1c3) (24, 28, 29). PPARγ is highly expressed in adipose tissue where it regulates 
genes involved in fat cell development, lipid deposition, insulin signaling, and inflammation 
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(30). PPARβ/δ is found at high levels in many tissues and compelling evidence indicates 
that it stimulates fatty acid oxidation, at least in skeletal muscle and adipose tissue (31). 
Expression of PPARα is highest in tissues that oxidize fatty acids at a rapid rate, including 
liver, brown adipose tissue, heart and kidney (32).
Activation of PPARα leads to induction of a large set of target genes involved in various 
pathways of lipid metabolism, including fatty acid transport, activation, storage, and 
oxidation (33, 34). Indeed, PPARα can be considered as the master regulator of hepatic 
lipid metabolism. As a consequence, mice lacking PPARα suffer from hepatic steatosis, 
hypoglycemia, hypoketonemia, and elevated plasma free fatty acids, all of which are 
aggravated during fasting (35). Inasmuch as most of our knowledge about the biological 
function of PPARα is directly coupled to the function of its target genes, the identification 
of genes regulated by PPARα may help in further deciphering the role of PPARα in vivo. 
In this study we set out to identify novel PPARα targets using mouse liver slices. We 
identify Hilpda as a PPAR target in mouse and human hepatocytes and show it plays an 
important role in hepatic triglyceride storage and secretion.
Results
Hildpa is regulated by PPARα in liver slices and hepatocytes
To identify potential novel target genes of PPARα, mouse liver slices were treated with the 
PPARα ligand Wy14643. Whole genome microarray analysis using Affymetrix GeneChips 
revealed increased expression of numerous classical PPARα target with roles in β-oxidation 
(e.g. Ehhadh, Slc22a5, Pdk4, Abcd2, Cpt1b) and other lipid metabolic pathways (e.g. Acot2, 
Creb3l3, Fabp4, Mgll, Cidec) (Figure 1A). However, several genes in the top 40 of most 
highly induced genes by Wy14643 have not or have only been very poorly characterized. 
Among those genes 2310016C08Rik, later annotated as Hilpda, was of particular interest as 
it has recently been identified as a putative lipid droplet associated protein that is regulated 
via a hypoxia-dependent mechanism involving HIF1 (36). Induction of Hildpa expression 
by Wy14643 was confirmed by qPCR analysis, which revealed a ~3 fold increase of Hilpda 
mRNA (Figure 1B). The Hilpda gene contains one intron and two exons and encodes a 
highly conserved protein of 63 and 64 amino acids in human and mouse, respectively 
(Figure 1C). In mice, an isoform of 95 amino acids has been suggested to be translated 
from an alternative start codon in the first exon. In silico analysis revealed neither a signal 
peptide nor other putative conserved sequences. In addition, no homologous proteins 
were identified. 
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Figure 1. Wy14643 increases Hilpda expression in liver slices and hepatocytes
(A) Top 40 of most highly induced genes in mouse liver slices exposed to 20 μM Wy14643 for 24 hours. 
Values are expressed as fold changes over DMSO treated slices from the same animal (n = 4). 
(B) Hilpda mRNA determined by qPCR in mouse liver slices exposed to 20 μM Wy14643 for 6 hours. 
Samples include the 4 described in A plus two additional animals (n = 6).
(C) Amino acid sequence of mouse and human HILPDA. 
(D and E) Hilpda mRNA levels in mouse (D, n = 6 animals from different strains) and human (E, n = 6) 
hepatocytes after exposure to Wy14643 for 6 hours.
Data are mean ± SEM. Asterisks indicate significant differences according to Student’s t-test; *P < 0.05, 
**P < 0.01.
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To substantiate our findings in mouse liver slices we analyzed Hilpda expression in 
isolated mouse and human hepatocytes exposed to DMSO or Wy14643 for 6 hours. In 
congruence with the data from liver slices, we found a significant increase in Hilpda 
mRNA levels following Wy14643 treatment in mouse and human hepatocytes (Figures 
1D and 1E). Together these data indicate that expression of Hilpda is positively regulated 
by PPARα in mouse and human hepatocytes, suggesting that Hilpda may represent a novel 
putative PPARα target.
Hepatic Hilpda expression is regulated by PPARs in vivo
We next sought to explore the PPARα dependent regulation of Hilpda in vivo by employing 
wild-type and Ppara–/– animals which were fed either a control diet or the same diet 
supplemented with aforementioned Wy14643. Five days after switching the mice to the 
diet containing Wy14643 their livers were excised and analyzed for Hilpda expression. 
Interestingly, Hilpda mRNA levels were significantly increased in wild-type mice fed 
Wy14643, whereas the response was absent in Ppara–/– animals, suggesting a PPARα 
mediated regulation of Hilpda (Figure 2A). Moreover, increased Hilpda mRNA levels were 
associated with a marked induction of HILPDA protein levels (Figure 2B). 
PPARα is an important regulator in the metabolic response to fasting and the expression 
of many PPARα regulated genes increases upon fasting (35). However, we found a much 
less pronounced increase in Hilpda mRNA and protein in livers of fasted wild-type mice 
compared to Ppara–/– mice. Indeed, Hilpda mRNA was increased 1.4-fold and 9.2-fold by 
fasting in wild-type and Ppara–/– mice, respectively (Figure 2C), which was confirmed by 
Western blot (Figure 2D). It has been observed that PPARγ is able to partially compensate 
for PPARα deletion during high-fat diet feeding or fasting (37, 38). Indeed, Pparg 
expression was increased in livers of Ppara–/– animals (Figure 2E). Moreover, we found 
markedly increased Hilpda mRNA expression upon adenoviral-mediated hepatic Pparg1 
overexpression (Figure 2E). Together, these data suggest that Hilpda expression in liver is 
regulated by both PPARα and PPARγ.
Hilpda is a direct PPAR target
In silico screening revealed the presence of a potential PPRE around 1200 base pair (bp) 
upstream of the transcription start site (TSS) of Hilpda that is highly conserved between 
mouse and human. To determine whether this PPRE is indeed contributing to PPAR 
dependent regulation of Hilpda, we generated luciferase reporter vectors containing a 
~200 bp genomic fragment flanking the mouse or human PPRE (Figure 3A). Notably, all 
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Figure 2. PPAR dependent regulation of Hilpda expression in vivo
(A and B) Hilpda gene expression (A, n = 4-5 per group) and Western blot (B) analysis of livers from 
wild-type and Ppara–/– mice fed a control diet or similar diet supplemented with Wy14643 for 5 days.
(C and D) Hilpda gene expression (C, n = 4-5 per group) and Western blot (D) analysis of livers from 
wild-type and Ppara–/– mice after 24 hours fasting. 
(E) Analysis of Pparg mRNA levels in same samples as in C (n = 4-5 per group).
(F) Hilpda mRNA levels in livers from Ppara–/– mice intravenously injected with adenovirus encoding 
LacZ or Pparg1 (n = 4 per group). 
Data are mean ± SEM. Two-way ANOVA with Bonferroni post-hoc test (A, C, and E) or Student’s t-test (F) 
were performed; *P < 0.05, **P < 0.01, ##P < 0.01. *, difference between WT and Ppara–/– (A, C, and E); #, 
difference between Ctrl/Wy14643 (A) or Fed/Fasted (C and E).
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Figure 3. PPAR mediated regulation of Hilpda expres-
sion is mediated by a PPRE 1200 bp upstream of the 
transcription start site
(A) Sequence of the human and mouse PPRE located 1200 bp 
upstream of the TSS of Hilpda. Three adenine residues were 
mutated to cytosine to serve as negative controls.
(B-G) HepG2 cells were transfected with luciferase reporter 
constructs containing wild-type or mutant mouse (B-D) or 
human (E-G) PPRE together with empty vector or PPAR/RXRα 
expression vectors as indicated. All conditions contain equal 
amounts of DNA and β-galactosidase was co-transfected for 
normalization. Transfected cells were subsequently exposed to DMSO, 50 μM Wy14643, 5 μM GW501516, 
or 5 μM rosiglitazone for 24 hours. Luciferase readings in cell lysates were normalized against 
β-galactosidase activity (n = 3).
(H) Chromatin was extracted from wild-type and Ppara–/– primary hepatocytes and ChIP assay was 
performed using antibodies specific for PPARα or IgG. PCR was performed using primers flanking the 
conserved PPRE 1200 bp upstream of the Hilpda TSS or negative control primers to amplify an intergenic 
region 100 kb upstream of Pdk4 (n = 3).
Data are mean ± SEM. Asterisk indicates significant difference according to Student’s t-test; *P < 0.01.
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PPARs were able to stimulate luciferase activity driven by the mouse and human wild-type 
PPRE (Figures 3B-G). By contrast, mutating the indicated adenine residues (Figure 3A) 
completely abolished the PPAR dependent increase in luciferase activity (Figures 3B-G). 
To explore if the characterized PPRE is occupied by PPARα in liver, we performed 
chromatin immunoprecipitation experiments using primary hepatocytes from wild-type 
and Ppara–/– mice. Consistent with direct PPAR binding, we efficiently recovered a 125-bp 
region surrounding the conserved PPRE from PPARα immunoprecipitates in wild-type 
hepatocytes compared with Ppara–/– hepatocytes (Figure 3H). Taken together, these data 
demonstrate the presence of a functional PPRE 1200 bp upstream of the TSS of Hilpda, 
suggesting that Hilpda is a novel PPAR target gene.
Hepatic overexpression of HILPDA results in a fatty liver
To address the functional role of HILPDA in liver we employed adeno-associated 
viruses expressing GFP (AAV-GFP) or HILPDA (AAV-HILPDA) under the control of 
a modified albumin promoter. Intravenous injection of a dose as low as 1x1011 genomic 
copies (GC) caused a marked increase in HILPDA expression 4 weeks after injection 
(Supplemental Figure 1A). Consistent with the absence of a signal peptide as observed by 
in silico analysis, we were unable to detect Hilpda in the circulation, even after injecting 
higher doses (Supplemental Figure 1B). We subsequently injected 2.5x1011 GC for further 
characterization of hepatic HILPDA. Fluorescent microscopy of AAV-GFP injected animals 
indicated that almost all cells were infected at the dosage used (Figure 4A). Injecting 
equal amounts of AAV-HILPDA markedly increased HILPDA protein levels (Figure 4B). 
Importantly, HILPDA protein expressed by the AAV had the same molecular weight as 
the endogenous protein (Figure 4C). No differences were found in body weight between 
AAV-GFP and AAV-HILPDA mice 4 weeks post-injection (Figure 4D). Similarly, we did 
not observe any change in the weight of livers, epididymal fat pads (eWAT) or brown 
adipose tissue (BAT) (Figures 4E-G) between the two sets of mice. Furthermore, EchoMRI 
analysis did not show any difference in lean mass or fat mass (Supplemental Figure 1C). 
However, during dissections we noticed that livers from AAV-HILPDA animals showed 
a different, slightly more yellowish color compared to AAV-GFP animals (Figure 5A), 
which is often indicative of increased liver fat deposition. Hematoxylin and eosin staining 
of livers from AAV-GFP and AAV-HILPDA animals indicated no major histological 
perturbations associated with HILPDA overexpression (Figure 5B). However, qualitative 
and quantitative analysis revealed a significant increase in hepatic triglyceride (TG) 
deposition upon Hilpda overexpression (Figures 5C and 5D), whereas there was no effect 
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Figure 4. Hepatic overexpression of HILPDA does not impact body weight
(A) Fluorescent microscopy of liver sections from AAV-GFP and AAV-HILPDA mice 4 weeks post-injection 
of according AAVs.
(B) HILPDA protein expression in livers from AAV-GFP and AAV-HILPDA animals. HSP90 serves as loading 
control.
(C) Western blot analysis of endogenous and overexpressed HILPDA. For endogenous protein an aliquot 
of a sample used in Figure 2B (wild-type animal fed diet supplemented with Wy14643) was loaded. 
(D) Body weight of AAV-GFP and AAV-HILPDA animals 4 weeks after injection of corresponding AAVs 
(n = 10-13 animals per group).
(E-G) Liver (E), eWAT (F), and BAT (G) weight of AAV-GFP and AAV-HILPDA animals (n = 8 animals per group).
Data are mean ± SEM.
?
??
???
???
???
???
???
???
??????? ??????????
?
???
???
???
???
???
??????? ??????????
?
?
??
??
??
??
??
??????? ??????????
?
??
??
??
?
?
??
?
??
??
??
??
?
?
??????
??????????????????????
??????
??????
??????
?????
?
??????????? ????????????????? ?????????
??????
?
?
?
??
??
?
??
??
???
??
??
??
???
??
??
???
??
?
??
??
??
??
??
???
?
??
??
??
??
??
??
???
?
??
?
??
??
??
??
??
??
??????? ??????????
? ?
? ?? ? ?? ? ?? ? ?????? ? ??? ???? ? ??? ???? ? ??? ???? ? ???
on hepatic glycogen content (Figure 5E). Analysis of multiple plasma parameters including 
TG, NEFAs, glycerol, ketone bodies, and cholesterol revealed no significant differences 
between AAV-GFP and AAV-HILPDA mice (Figures 5F-K). Thus, HILPDA is involved 
in the regulation of hepatic TG metabolism, but has no effect on plasma lipid levels.
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Figure 5. AAV mediated HILPDA overexpression induces hepatic steatosis
(A) Gross morphology of livers from AAV-GFP and AAV-HILPDA animals 4 weeks after injection of viruses. 
Animals were sacrificed under fed conditions.
(B) Representative H&E staining of livers from AAV-GFP and AAV-HILPDA animals.
(C) Oil Red O staining of liver sections from AAV-GFP and AAV-HILPDA animals.
(D) Hepatic TG content determined 4 weeks post-injection of AAVs (n = 8 animals per group).
(E) Hepatic glycogen levels in AAV-GFP and AAV-HILPDA animals (n = 8 animals per group).
(F-K) Plasma TG (F), NEFAs (G), glycerol (H), cholesterol (I), glucose (J), ketone bodies (K) levels in AAV-GFP 
and AAV-HILPDA animals 4 weeks post-injection of respective viruses (n = 7-8 animals per group). 
Data are mean ± SEM. Asterisks indicate significant difference according to Student’s t-test; **P < 0.01.
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HILPDA does not aff ect neutral lipase activity
Hepatic TG storage is the net result of several processes, including fatty acid β-oxidation, de-
novo lipogenesis, fatty acid uptake, TG hydrolysis, and TG secretion as VLDL. To identify 
the mechanism underlying the increased lipid deposition in livers of AAV-HILPDA mice, 
we analyzed the expression of a selection of genes involved in abovementioned metabolic 
pathways. However, no differences were found in the expression of relevant genes (Figure 6).
Gene expression profiling by microarray identified only 139 genes to be significantly altered 
upon HILPDA overexpression (P value < 0.01), with more than 75% of these genes altered less 
than 1.5-fold. Gadd45g, a PPARγ target, was the most highly induced gene showing a 2.5-fold 
increase in expression. Together, these data suggest that increased HILPDA expression does 
not induce major changes in the expression of genes involved in hepatic lipid metabolism. 
Previously we identified G0s2 as a novel PPAR target in liver (39). Similar to HILPDA, 
G0S2 is a small protein (103 amino acids) with no conserved sequences or homology 
to other proteins. Recently, G0S2 was characterized as a critical regulation of adipose 
tissue triglyceride lipase (ATGL/PNPLA2) (40). In liver, similar to our data for HILPDA, 
overexpression of G0S2 increases TG storage, whereas G0S2 knock-down decreases TG 
levels associated with decreased or increased TG hydrolase activity, respectively (41, 42). 
To explore a possible effect of HILPDA overexpression on intracellular lipase activity we 
performed a TG hydrolase activity assay. No difference in total TG hydrolase activity was 
observed between AAV-GFP and AAV-HILPDA livers (Figure 7A). HILPDA also did 
not affect the activity of ATGL and HSL in vitro (Figure 7B). Thus, the development of 
a fatty liver upon HILPDA overexpression seems independent of neutral lipase activity. 
Figure 6. Hepatic overexpression of HILPDA does not affect the expression of key genes 
involved in β-oxidation or de-novo lipogenesis
qPCR analysis of important genes related to β-oxidation, lipogenesis, hepatic lipid uptake, and VLDL 
production in livers of AAV-GFP and AAV-HILPDA animals (n = 7-8 animals per group). 
Data are mean ± SEM. 
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Figure 7. AAV-HILPDA animals secrete less triglyceride 
(A) Total TG hydrolyase activity in liver samples from AAV-GFP and AAV-HILPDA animals (n= 8 animals 
per group). 
(B) Mouse ATGL or HSL was overexpressed in COS-7 cells and lysates were assayed for hydrolase activity 
in the presence of COS-7 lysates from cells transfected with expression vectors for LacZ or HILPDA (n = 2). 
(C) Plasma TG levels after intravenous administration of tyloxapol to determine hepatic TG secretion in 
16-hour fasted AAV-GFP and AAV-HILPDA animals (n = 7 animals per group).
(D and E) Lipoprotein-associated TG (D) and cholesterol (E) levels in HPLC fractions of pooled plasma 
samples from AAV-GFP and AAV-HILPDA animals.
(F-H) Hilpda mRNA (F) and protein levels (G) in wild-type animals after a 16-week HFD intervention 
resulting in the development of hepatic steatosis (H) (n = 8-10 animals per group).
Data are mean ± SEM. Asterisks indicate significant differences according to Student’s t-test; **P < 0.01.
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Hepatic TG secretion is decreased with HILPDA overexpression
To determine if HILPDA might impact TG secretion, we performed a VLDL production 
test in AAV-GFP and AAV-HILPDA mice using the lipase inhibitor tyloxapol. Remarkably, 
we noticed a robust reduction in hepatic TG secretion with HILPDA overexpression that 
was already apparent 1 hour after administration of tyloxapol (Figure 7C). Despite the 
inhibitory effect of HILPDA on hepatic TG secretion, we were unable to find significant 
changes in plasma total TG levels after 16 hours fasting (Figure 7C, time point 0) or in 
the fed state (Figure 5F). To investigate if HILPDA overexpression is associated with 
a difference in VLDL particle size or VLDL-TG content we performed lipoprotein 
profiling using gel-filtration high-performance liquid chromatography (HPLC). However, 
chylomicron and VLDL particle size and TG content, as well as LDL and HDL size and 
cholesterol content were unchanged between the two sets of mice (Table 1, Figures 7D and 
7E). Finally, we explored the potential role of HILPDA in high fat diet-induced fatty liver. 
Interestingly, feeding wild-type mice a high-fat diet for 16 weeks did not elicit a change in 
liver HILPDA expression (Figures 7F and 7G), despite the development of severe hepatic 
steatosis (Figure 7H).
Discussion
PPARα plays important roles in hepatic lipid metabolism by regulating the transcription of 
numerous genes involved in lipid metabolic pathways (33, 43). Here we provide evidence 
that Hilpda is a novel PPARα target gene that promotes hepatic TG deposition by reducing 
TG secretion.  
One of our main findings is the inhibition of VLDL-TG secretion by hepatic 
HILPDA overexpression (Figure 7C). VLDL assembly and secretion have been studied 
extensively over the last decades (44). Central to the synthesis of VLDL is the lipidation of 
Table 1. VLDL, LDL, and HDL particle size in AAV-GFP and AAV-HILPDA animals
AAV-GFP AAV-HILPDA
Chylomicron (nm) >100 >100
VLDL (nm) 46.46 46.99
LDL (nm) 24.67 24.78
HDL (nm) 11.08 11.15
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apolipoprotein B100 (APOB100) in the endoplasmic reticulum (ER) by the microsomal 
triglyceride transfer protein (MTTP) to generate pre-VLDL (45-48). Next, large amount 
of lipids are transferred to pre-VLDL to yield mature VLDL, though it is not exactly clear 
whether this lipidation takes place solely in the ER or whether the Golgi-apparatus is 
involved as well (49-52). Indeed, many details regarding VLDL synthesis, ER to Golgi 
transport, and VLDL exocytosis remain unknown. Recently, additional players have 
been implicated in the lipidation and secretion of VLDL, including other apolipoproteins 
(APOC3), lipid droplet associated proteins (CIDEB), and sorting receptors (SORT1) (53-
58). In vitro studies have previously identified HILPDA as a lipid droplet associated protein 
(36) and it is therefore of particular interest that the lipid droplet associated protein PLIN2 
has been shown to inhibit VLDL synthesis due to increased shunting of triglycerides to 
cytosolic lipid droplets (55, 59). Future studies will have to determine the precise molecular 
mechanism underlying regulation of hepatic TG levels and secretion by HILPDA, as well 
as the molecular details of its association with lipids droplets. 
Reduced hepatic VLDL-TG secretion might be expected to lead to a decrease in 
plasma TG levels. However, we did not observe a change in plasma TG levels when 
comparing AAV-GFP and AAV-HILPDA animals under either random fed conditions 
or after an overnight fast. A possible explanation is that VLDL produced in livers of mice 
overexpressing HILPDA is cleared from the circulation less efficiently, potentially due to 
an altered apolipoprotein make up decorating the VLDL. 
The limited data available on HILPDA suggest that it may represent a lipid droplet 
associated protein that is induced by hypoxia (36, 60). Hypoxia is known to elicit numerous 
metabolic changes driven by the HIF transcription factors, including upregulation of many 
glycolytic genes (61-63). The specific regulatory effect of hypoxia/HIF1 on lipid metabolism 
is less well characterized, yet it is well known that hypoxia raises intracellular lipids (64-
66). The rationale for hypoxia-induced lipid accumulation is not well characterized but it 
may be part of a general mechanism aimed at directing non-oxidized fatty acids towards 
storage, and thus shifting them away from potential lipotoxic effects. Taking into account 
the ability of HILPDA to promote intracellular lipid storage, it can be hypothesized that 
HILPDA may play a role in hypoxia-induced lipid accumulation.  
The far majority of PPARα target genes identified so far are induced by fasting and by 
synthetic PPARα agonists in wild-type mice but not Ppara–/– mice, including Fgf21, Cpt1a, 
Ehhadh, Hmcgcs2 and many others (67). In contrast, HILPDA expression was induced 
by fasting specifically in Ppara–/– mice but much less in wild-type mice, resembling the 
expression pattern of a small set of PPARα targets that include Lpin2. A number of genes 
with similar expression pattern were found to be regulated by PPARβ/δ, which may also 
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be true for Hilpda (67). Alternatively, upregulation of HILPDA in fasted Ppara–/– mice 
may be mediated by PPARγ, expression of which is elevated in livers of Ppara–/– mice and 
which potently induces Hilpda expression in liver, as shown by adenoviral overexpression of 
PPARγ. Transactivation experiments indicated that all three PPARs were able to activate a 
reporter construct driven by a portion of the Hilpda promoter, suggesting that Hilpda likely 
represents a pan-PPAR target gene. Accordingly, it can be hypothesized that depending 
on the specific stimulus, Hilpda can be regulated by either PPARα, PPARβ/δ, or PPARγ. 
Synthetic PPARα agonists in the form of fibrates are used clinically for their ability to 
raise plasma HDL and reduce plasma TG levels (68). The plasma TG-lowering action of 
fibrates is primarily achieved via augmentation of plasma TG clearance, although there 
is in vivo and in vitro evidence that PPARα agonists also lower VLDL-TG production, 
potentially due to induction of PLIN2 and FABP1 and subsequent storage of TGs in 
cytosolic lipid droplets (69-72). Conversely, deletion of PPARα leads to elevated VLDL-TG 
production (73, 74). Conceivably, HILPDA may be involved in mediating the suppressive 
effect of synthetic PPARα agonists on TG secretion by the liver. Overall, it is evident that 
the role of PPARs in regulation of hepatic lipid homeostasis goes beyond the induction of 
genes involved in β-oxidation and ketogenesis. The direct effect of HILPDA on β-oxidation, 
lipid uptake, and lipogenesis has not been tested; nevertheless, we did not observe any 
difference in mRNA levels of key genes involved in these processes between AAV-GFP 
and AAV-HILPDA animals.
In conclusion, we identify Hilpda as a novel PPAR regulated gene involved in the 
regulation of hepatic TG metabolism. Increased HILPDA expression decreases the 
production of VLDL-TG resulting in the development of a fatty liver. Future experiments 
aim to elucidate the mechanism underlying the decrease in VLDL production.
Methods
Recombinant adeno-associated viruses (AAVs)
AAVs were made by Vector Biolabs (Philadelphia, PA, USA). In short, mouse Hilpda cDNA was 
inserted in pAAV-ALBp-3’iALB, a vector containing a modified albumin promoter flanked by two 
AAV2 derived Inverted Terminal Repeats (ITRs). To produce viruses, the above construct was packaged 
into AAV8 capsid in HEK293 cells by transfecting pAAV-ALBp-3’iALB, AAV2/AAV8 rep/cap vector, 
and Ad helper vector. Viral particles were purified by two sequential CsCl2 gradients and titrated by 
qPCR to determine viral genomes. The same amount of AAV2/AAV8 hybrid virus expressing GFP 
was injected to serve as control. 
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Animal studies
Wild-type and Ppara–/– mice on a Sv129 background were obtained from The Jackson Laboratory 
(Bar Harbor, ME, USA). Five-months-old wild-type and Ppara–/– mice were fed a diet containing 
Wy14643 at a concentration of 0.1% for 5 days after which the livers were excised and snap-frozen. 
Five-months-old wild-type and Ppara–/– mice were fasted for 24 hours and their livers were collected 
for analysis of HILPDA mRNA and protein levels.
Male 8-week-old C57BL/6J mice were purchased from Charles River Laboratories (Sulzfeld, 
Germany) and maintained on a 12-hour light-dark cycle with ad libitum access to chow and water. 
Adeno-associated viruses were administrated in a volume of 100 μl via the tail vein. Ten animals were 
injected with different amounts of AAV ranging from 1x1011 – 5x1011 genomic copies to determine 
the dose required for a significant increase in hepatic HILPDA expression. Subsequent experiments 
were performed after injection of 2.5x1011 GC. Body composition analysis of AAV-GFP and AAV-
HILPDA animals 4 weeks post-injection was performed using EchoMRI (Echo Medical Systems, 
Houston, TX, USA). 
Wild-type C57BL/6 animals (9-12 weeks old) were fed a low-fat or high-fat diet containing 10 
or 45en% fat, respectively (D12450B/D12451, Research Diets Services, Wijk bij Duurstede, The 
Netherlands). After 16 weeks the livers where analyzed for triglyceride content and HILPDA expression. 
All animal experiments were approved by the local animal welfare committees of Wageningen 
University or the German Cancer Research Center (DKFZ, Heidelberg, Germany), respectively.
VLDL production test
AAV-GFP and AAV-HILPDA animals were fasted for 16 hours and subsequently anesthetized via 
intra-peritoneal injection of a mixture of Dormicum (midazolam, Roche, Woerden, The Netherlands) 
and Hypnorm (fentanyl/fluanisone, VetaPharma, Leeds, United Kingdom) prepared in saline at 7 and 
14/0.5 mg/kg, respectively. Then, a blood sample was drawn and the animals were injected intravenously 
with 500 mg/kg bodyweight tyloxapol (Sigma-Aldrich, Schnelldorf, Germany) diluted in saline to a 
10% w/v solution. Every 30 minutes thereafter blood was collected via the tail vein over the course of 2 
hours. Serum samples were assayed for triglycerides using a Triglycerides liquicolormono kit (HUMAN, 
Wiesbaden, Germany).
Hepatic Pparγ1 overexpression
Ppara–/– mice were injected with adenovirus encoding LacZ or Pparγ1 via the tail vein and sacrificed 
6 days later (75).
Liver slices
Livers from C57BL/6 mice were briefly perfused with saline, excised and submerged in ice-cold Krebs-
Henseleit Buffer (KHB) supplemented with 11 mM glucose, 25 mM sodium bicarbonate, 10 mM 
HEPES, and penicillin/streptomycin. Next, 5 mm cylindrical liver cores were prepared with a surgical 
biopsy punch and sectioned to 200 μm slices using a Krumedieck tissue slicer (Alabama Research and 
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Development, Munford, AL, USA) filled with carbonated KHB. Liver slices were incubated in William’s 
E Medium (Lonza, Verviers, Belgium) in 6-well plates at 37°C/5% CO2 under continuous agitation. 
After 1 hour the media were replaced with fresh William’s E Medium containing 0.1% DMSO or 20 
μM Wy14643 and the slices were incubated for 6 or 24 hours. 
Transactivation assays
A fragment of 645 bp and 519 bp containing the PPRE localized 1200 bp upstream of the TSS was 
amplified from human and mouse genomic DNA, respectively, using the primers: human Fwd1 
5’-GCCTTCACCTGGCAAAGTAG-3’, human Rev1 5’-AAGAGCCAGGAGGTCACAGA-3’, mouse 
Fwd1 5’-GGATGACTCCCAGAAGTGGA-3’, mouse Rev1 5’-GACCTGCCTTACCAGTCACC-3’. 
The resulting fragments were gel-purified using a QIAquick Gel Extraction Kit (Qiagen, Venlo, 
The Netherlands) and employed in a second PCR to introduce KpnI and BglII restriction sites to 
the resulting 278 bp and 219 bp fragments containing the human and mouse PPRE, respectively. 
Primers used for this PCR were: human Fwd2 5’-aaggtaccAGTTGGCTCCAAATGTCTGC-3’, 
human Re v2  5 ’ -cgaaagatc tTGGTGGCT T TAGAACTGGC G-3 ’,  mous e  Fwd2 5 ’ - 
aaggtaccATTTCCACCTCCTGTGCTTG-3’, mouse Rev2 5’-cgacagatctTGCGTTCTCATGACTTCCAG-3’. 
To introduce mutations in both the human and mouse PPRE an overlap PCR strategy was carried out. First, 
to generate partially overlapping fragments, the human Fwd2 primer was used together with reverse primer 
5’-TCCCCACTGCGACCGGGCCCCTCCTTTCCT-3’, and human Rev2 primer with forward primer 
5’-AGGAAAGGAGGGGCCCGGTCGCAGTGGGGA-3’ using wild-type insert as template. The resulting 
fragments were gel-purified and used in a second PCR with human Fwd2 and Rev2 primers. For mouse: 
Fwd2 primer was combined with reverse primer 5’-CTTCCGCTGTGACCGGGCCCCTACTTTTCA-3’, 
and Rev2 primer with forward primer 5’-TGAAAAGTAGGGGCCCGGTCACAGCGGAAG-3’. For the 
final PCR, purified fragments were combined in a PCR to generate mutant insert using mouse Fwd2 and 
Rev2 primers. Resulting fragments were cloned in the KpnI and BglII sites of the pGL3-Promoter vector 
(Promega, Leiden, The Netherlands). The presence of the correct insert was confirmed with sequencing (EZ-
Seq, Macrogen, Amsterdam, The Netherlands) using RV3primer: 5’-CTAGCAAAATAGGCTGTCCC-3’ 
(Promega). Reporter vectors were transfected into the human hepatocellular cell line HepG2 (ATCC, 
Manassas, VA, USA) in the presence or absence of pSG5 vector expressing either PPARα, PPARβ/δ, 
PPARγ, or pSG5 empty vector. pSG5 expression vector encoding RXR was co-transfected with PPAR 
expression vectors. A β-galactosidase expression vector was co-transfected in all cases for determination 
of transfection efficiency. All transfections were performed using polyethylenimine (PEI). Sixteen hours 
post-transfection the cells were incubated with Wy14643 (50 μM), GW510516 (5 μM), Rosiglitazone (5 μM), 
or DMSO, respectively. Reporter activity was measured 24 hours after adding the corresponding ligands 
using the Promega luciferase assay kit (Promega) on a Fluoroskan Ascent apparatus (Thermo Scientific). 
β-Galactosidase activity in cell lysates was determined using 2-Nitrophenyl β-D-galactopyranoside (ONPG) 
as a substrate, and absorbance values were used to normalize the luciferase measurements. Data presented 
are based on 3 individual experiments.
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ChIP 
Primary hepatocytes were isolated from 10- to 12-week-old wild-type or Ppara–/– animals on a C57BL/6 
background according to published methods (76). Hepatocytes were plated on 15 cm dished coated 
with rat-tail collagen at a density of 1x105 cells per cm2. To cross-link proteins to DNA, the cells were 
incubated with 1% formaldehyde for 10 minutes after which glycine was added to a final concentration 
of 0.125 M to stop the cross-linking reaction. Cells were collected in ice-cold PBS, washed twice and 
snap-frozen in liquid nitrogen. Cell pellets were lysed in 500 μl lysis buffer containing 0.1% SDS, 1% 
Triton X-100, 0.15 M NaCl, 1 mM EDTA, 20 mM Tris pH 8, and protease inhibitor cocktail (Pierce). 
Following 30 cycles of sonication (30 seconds on, 30 seconds off, high intensity) at 4°C, the samples 
were centrifuged at 20,000 g for 30 minutes. Next, 100 μl of the supernatant was diluted 4 times with 
incubation buffer (0.15% SDS, 1% Triton X-100, 0.15 M NaCl, 1 mM EDTA, 20 mM HEPES) and 
subsequently mixed with antibodies (anti-PPARα (Santa-Cruz, H-98) or IgG (Santa Cruz, sc2027)) for 
2 hours at 4°C on a rotating wheel. To reduce non-specific binding, Protein A Sepharose beads (GE 
Healthcare Life Sciences) were washed twice and pre-incubated with incubation buffer supplemented 
with 1 μg/μl BSA for 2 hours at 4°C on a rotating wheel. Then, blocked Protein A Sepharose mixture 
was combined with chromatin/antibody mixtures and incubated overnight at 4°C on a rotating 
wheel. The beads were subsequently washed in a series of buffers: twice in buffer 1 (0.1% SDS, 0.1% 
NaDOC, 1% Triton X-100, 0.15 M NaCl, 1 mM EDTA, 20 mM HEPES), once in buffer 2 (0.1% SDS, 
0.1% NaDOC, 1% Triton X-100, 0.5 M NaCl, 1 mM EDTA, 20 mM HEPES), once in buffer 3 (0.25 
M LiCl, 0.5% NaDOC, 0.5% NP-40, 1 mM EDTA, 20 mM HEPES) and twice in buffer 4 (1 mM 
EDTA, 20 mM HEPES). Protein-DNA complexes were eluted in 200 μl elution buffer (1% SDS + 0.1 
M NaHCO3). To disrupt the cross-links between protein-DNA, eluted samples were supplemented 
with 8 μl of 5 M NaCl, 8 μl of RNAse A (0.5 mg/ml), and 10 μl of Proteinase K (20 mg/ml, Qiagen) 
and incubated overnight at 65°C. DNA was purified using a QiAQuick PCR purification kit (Qiagen) 
according to the manufacturer’s protocol and analyzed by real-time PCR using primers directed 
against a 125 bp fragment encompassing the PPRE located 1200 base pair upstream of the TSS of 
Hilpda. Sequences of the primers that were used: Hilpda Fwd 5’-GCACGTCTCTCTTCTTCTAGGT-3’, 
Hilpda Rev 5’ TCGCCTCTAAACTAAACGGAA-3’. Primers against an intergenic region 
100 kb upstream of Pdk4 served as control: Fwd 5’-TTGGCTTGCCAAGCTTCTTC-3’, Rev 
5’-AGGGAACGCATTTCCATCAC-3’.
Plasma analysis
Non-esterified fatty acids were measured using a NEFA-HR(2) kit and ketone bodies using a Autokit 
Total Ketone Bodies assay (Wako Chemicals GmbH, Neuss, Germany). Triglycerides were determined 
with a Triglycerides liquicolormono kit (HUMAN). Glucose, glycerol, and cholesterol were measured 
using kits from DiaSys (DiaSys Diagnostic Systems, Holzheim, Germany).
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Plasma lipoprotein analysis
Pooled plasma samples from AAV-GFP and AAV-HILPDA animals were fractionated using gel-
filtration high-performance liquid chromatography (HPLC) offered by LipoSEARCH (Skylight Biotech, 
Inc., Akita, Japan). Effluent was subsequently analyzed for triglycerides and cholesterol content. 
Histology
For GFP fluorescence microscopy, samples were fixed in 4% formaldehyde (Sigma-Aldrich) overnight, 
soaked in PBS containing 15% w/v sucrose for 12 hours then incubated in PBS containing 30% w/v 
sucrose overnight. Tissues were subsequently frozen in Tissue-Tek® O.C.T.™ (Sakura Finetek Holland 
B.V., Alphen aan de Rijn, The Netherlands) and sectioned to 5 μm and mounted on Superfrost 
microscopy slides. GFP fluorescence was determined using an Olympus CKX31 fluorescent microscope 
(Olympus Nederland B.V, Zoeterwoude, The Netherlands). 
For hematoxylin and eosin staining liver pieces were fixed in 4% formaldehyde for 24 hours and 
subsequently embedded in paraffin. Samples were sectioned to 5 μM and stained in hematoxylin for 
8 minutes and eosin for 30 seconds. Following dehydration in 95% ethanol and 2 xylene changes, the 
sections were mounted using a xylene based mounting medium.
To visualize neutral lipids, liver samples were frozen in Tissue-Tek® O.C.T.™, sectioned to 5 μm 
using a cryostat and mounted on Superfrost microscopy slides. After drying at room temperature 
for 30 minutes, the tissue sections were fixed in 4% formaldehyde (Sigma-Aldrich) for 10 minutes. 
Following 3 washes with ddH2O the slides were incubated in Oil Red O (Sigma-Aldrich) solution 
(30 mg/ml in 60% isopropanol) for 10 minutes. Finally, the slides were rinsed with ddH2O twice 
and mounted using an aqueous mounting medium. 
Hepatic triglycerides
Liver pieces of ~50 mg were homogenized to a 5% lysate (m/v) using 10 mM Tris, 2 mM EDTA, 0.25 
M sucrose, pH 7.5. Lysates were assayed for TGs using a Triglycerides liquicolormono kit (HUMAN). 
TG levels were normalized against liver weight. 
Hepatic glycogen
Tissues (~50 mg) were homogenized in 0.5 ml 30% KOH, incubated at 95°C for 30 minutes. And 
centrifuged at 15,000 g to pellet undigested material. Glycogen was precipitated from the supernatants 
by adding 0.75 ml 95% ethanol and subsequent centrifugation at 3,000 g for 20 minutes. Glycogen 
pellets were washed with fresh 95% ethanol, centrifuged, and air-dried. Pellets were dissolved in 0.25 
ml ddH2O and incubated at 37°C for 30 minutes. To digest the glycogen, 5 mg of amyloglucosidase 
(#A7420, Sigma-Aldrich) was dissolved in 15 ml 0.2 M sodium acetate pH 4.8, and 450 μl of the 
resulting enzyme solution was mixed with 50 μl glycogen solution. After incubation at 40°C for 2 hours 
the samples were neutralized using 10 μl 30% KOH. Glucose concentrations were determined with 
a kit from DiaSys, protein concentrations were measured with a Pierce BCA kit (Thermo Scientific, 
Landsmeer, The Netherlands).
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Western blot
Liver samples were homogenized in 50 mM Tris, pH 8.0, 150 mM NaCl, 1% v/v NP-40, 0.5% v/v 
sodium deoxycholate, 0.1% SDS, supplemented with Complete EDTA-free protease inhibitor cocktail 
with a Qiagen TissueLyser II. Samples were incubated on a rotating wheel for 30 minutes at 4ºC and 
subsequently centrifuged at 15,000 g for 15 minutes at 4°C. Protein concentration was determined 
using a Pierce BCA kit (Thermo Scientific) and equal amounts of protein were diluted with 2x Laemmli 
sample buffer. After boiling, the samples were separated on 4-20% or 8-16% gradient Criterion gels. 
For plasma analysis, 1 μl plasma from AAV-GFP or AAV-HILPDA animals was loaded on an 8-16% 
Criterion gel. Proteins were transferred to PVDF membrane using the Transblot turbo system (Bio-
Rad, Veenendaal, The Netherlands). Antibodies against HILPDA (1:1000, Santa Cruz Biotechnology, 
Inc, #sc-137518), ACTIN (1:2000, Sigma-Aldrich #A2066), HSP90 (1:4000, Cell Signaling Technology, 
Inc, #4874), and goat anti-rabbit (1:5000, Jackson ImmunoResearch, #111-035-003) were diluted in 
5% w/v skimmed milk powder in PBS-T. Primary antibodies were applied overnight at 4ºC, secondary 
antibody for 1 hour at room temperature. Bands were visualized using Pierce ECL Plus (Thermo 
Scientific) and a ChemiDoc MP (Bio-Rad). The presence of plasma proteins on the PVDF membrane 
was confirmed using Ponceau S solution (Sigma-Aldrich).
Gene expression analysis including microarrays
Mouse liver slices and tissues were homogenized in TRIzol® (Life Technologies Europe BV, Bleiswijk, 
The Netherlands) using the Qiagen TissueLyser II and stainless steel beads. One microgram of RNA 
was subsequently employed for cDNA synthesis using the First Strand cDNA synthesis kit (Thermo 
Scientific). RNA from a selection of slices and tissues was purified with RNeasy Minikit columns 
(Qiagen) and analyzed for quality with RNA 6000 Nano chips on the Agilent 2100 Bioanalyzer (Agilent 
Technologies, Amsterdam, the Netherlands). Purified RNA (100 ng) was labeled with the Ambion 
WT expression kit (Life Technologies, Bleiswijk, The Netherlands kit and hybridized to Affymetrix 
Mouse Gene 1.1 ST array plate (Affymetrix, Santa Clara, CA). Hybridization, washing, and scanning 
was carried out on an Affymetrix GeneTitan platform, and readouts were processed and analyzed 
according to published methods (77). qPCRs were performed using SensiMix (Bioline, GC biotech, 
Alphen aan den Rijn, The Netherlands) and a CFX384 Real-Time PCR Detection System (Bio-
Rad). Primer sequences were derived from the Harvard PrimerBank and synthesized by Eurogentec 
(Eurogentec S.A., Seraing, Belgium). Primer sequences are listed in Table 2. Normalization was 
performed using the expression of 36b4. qPCR analysis of mouse and human hepatocytes exposed to 
DMSO or Wy14643 for 6 hours was performed as described above using RNA from hepatocytes of 6 
different mouse strains and 6 human hepatocyte sample sets as described (78). 
ATGL and HSL activity assay
COS-7 cells were grown in DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf serum 
(Sigma-Aldrich) and 100 IU/ml penicillin / 100 μg/ml streptomycin (Invitrogen). cDNAs encoding 
ATGL/PNPLA2, HSL, HILPDA, and LacZ were cloned in the pcDNA4/His Max vector (Invitrogen) 
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and transfected into COS-7 cells using Metafectene (Biontex GmbH, München, Germany). 50 μg of 
either ATGL or HSL recombinant lysate was combined with 50 μg LacZ or HILPDA lysate. Radioactive 
emulsion was prepared by sonication of 0.3 mM triolein, phosphatidylcholine/phosphatidylinositol, 
and 9,10-[3H] triolein (PerkinElmer Life Sciences) in 100 mM potassium phosphate buffer (pH 
7) supplemented with 2% BSA (essentially fatty acid free, Sigma). Protein lysates and radioactive 
emulsion were incubated for 60 minutes at 37°C. Next, the reactions were stopped by adding 3.25 ml 
of methanol/chloroform/heptane (10:9:7) and 1 ml of 0.1 M potassium carbonate/boric acid buffer 
(pH 10.5). Samples were centrifuged at 800 g for 20 minutes and radioactivity was determined in 1 
ml of the supernatant using a scintillation counter (Beckman Coulter, Fullerton, CA)
Total TG hydrolase activity assay
Liver TG hydrolase activity was measured using published methods (79, 80). In short, samples from 
AAV-GFP and AAV-HILPDA animals were homogenized in lysis buffer (0.25 M sucrose, 1 mM EDTA, 
protease inhibitor cocktail, pH 7.0) and centrifuged at 20,000 g for 30 minutes at 4°C to collect the 
soluble infranatant fraction. Triolein and 9,10-[3H]triolein (PerkinElmer Life Sciences) were sonicated 
with phosphatidylcholine and phosphatidylinositol in 100mM potassium phosphate buffer (pH 7.0) to 
a final concentration of 1.67 mM triolein. 200 μg of infranatant from each liver sample was incubated 
with 0.1 ml radioactive substrate at 37°C for 60 minutes. The reaction was terminated by adding 3.25 
ml of methanol/chloroform/heptane (10:9:7) and 1 ml of 0.1 M potassium carbonate/boric acid buffer 
(pH 10.5). Following centrifugation at 800 g for 20 minutes, radioactivity was determined in 1 ml of 
the upper phase using a LS 6500 Multi-Purpose Scintillation Counter (Beckman Coulter).
Statistical analysis
Student’s t-tests or two-way ANOVA with Bonferroni post-hoc tests where appropriate were calculated 
using GraphPad Prism (GraphPad Software, Inc., La Jolla, CA). Results were considered significant 
at P < 0.05.
Table 2. Primers sequences of forward and reverse primers used in qPCR analysis
Gene Forward (5’-3’) Reverse (5’-3’)
36b4 ATGGGTACAAGCGCGTCCTG GCCTTGACCTTTTCAGTAAG
Hilpda TGCTGGGCATCATGTTGACC TGACCCCTCGTGATCCAGG
Pparg
Cpt1a
CACAATGCCATCAGGTTTGG
CTCAGTGGGAGCGACTCTTCA
GCTGGT CGATATCACTGGAGATC
GGCCTCTGTGGTACACGACAA
Cyp4a10 ACCACAATGTGCATCAAGGAGGCC AGGAATGAGTGGCTGTGTCGGGGAGAG
Pdk4 TCTACAAACTCTGACAGGGCTTT CCGCTTAGTGAACACTCCTTC
Srebp1c GGAGCCATGGATTGCACATT CCTGTCTCACCCCCAGCATA
Fasn TCCTGGGAGGAATGTAAACAGC CACAAATTCATTCACTGCAGCC
Ldlr GCATCAGCTTGGACAAGGTGT GGGAACAGCCACCATTGTTG
Mttp ATACAAGCTCACGTACTCCACT TCCACAGTAACACAACGTCCA
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Supplemental  Figure 1.
(A) Western blot analysis of hepatic HILPDA expression after administration of 1, 2.5, and 5x1011 genomic 
copies of AAV-HILPDA. Livers were dissected 4 weeks after injection of respective viruses. 
(B) HILPDA Western blot on plasma samples of the same animals as in A. An aliquot of diluted liver lysate 
from an animal injected with 2.5x1011 GC AAV-HILPDA virus was used as positive control. Ponceau S 
staining is shown to illustrate the presence of plasma proteins.
(C) Fat mass and lean mass in AAV-GFP and AAV-HILPDA animals determined using EchoMRI (n = 10-13 
animals per group).
Data are mean ± SEM.
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Hypoxia inducible lipid droplet 
associated (HILPDA) is a PPARγ and 
β-adrenergic receptor target gene 
involved in adipose tissue lipolysis
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Abstract
Peroxisomal-proliferator activator receptor gamma (PPARγ) is a ligand-activated 
transcription factor of eminent importance in the development and maintenance of 
adipose tissue. Hypoxia inducible lipid droplet associated protein (HILPDA) is a newly 
recognized PPAR target gene involved in the regulation of hepatic VLDL secretion. 
Here we study the regulation of and function of HILPDA in adipose tissue. HILPDA 
expression increased upon fasting whereas high-fat feeding induced the opposite effect. 
In congruence with PPARγ binding as determined by ChIP-seq, we revealed Hilpda to 
be regulated by PPARγ in a number of mouse and human adipocyte models. Moreover, 
HILPDA was potently induced upon β-adrenergic receptor stimulation. Manipulation 
of HILPDA expression in vitro did not affect the adipogenic capacity of 3T3-L1 cells. 
Adipose tissue-specific Hilpda knockout mice showed no major metabolic perturbations 
when fasted. However, overexpression of HILPDA in adipocytes was found to reduce 
the amount of NEFAs released upon β-adrenergic receptor activation. Thus, HILPDA 
is regulated by PPARγ and β-adrenergic receptor and is potentially part of a feedback 
mechanism to regulate adipocyte lipolysis.
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Introduction
The peroxisomal-proliferator activator receptor gamma (PPARγ, NR1C3) is a ligand 
activated transcription factor that is part of the PPAR family of nuclear receptors (1). 
Whereas the other two family members, PPARα and PPARβ/δ, are expressed ubiquitously, 
PPARγ expression is predominant in adipose tissue (2-4). PPARs have a classical structure 
observed in many nuclear receptors that includes an N-terminal activation function (AF1), 
a DNA-binding domain, and a ligand binding domain that contains a ligand-dependent 
activation function (AF2) (5). All three PPARs function in conjunction with their obligatory 
binding partner, the retinoid x receptor (RXR). Ligand activation of PPARs initiates the 
recruitment of coactivators including CBP, SRC-1, and TBL1/TBLR1 (6-10) and at the 
same time the dismissal of corepressors such as NCoR/SMRT (11, 12), although many 
mechanistic aspects regarding cofactor recruitment and dismissal remain elusive (13). 
PPARs bind to specific loci in the DNA, called PPAR response elements (PPRE) that are 
localized across the genome in promoter regions but also in intronic or intergenic regions. 
Shortly after the initial cloning of PPARs (14, 15), PPARγ was found to drive adipocyte 
differentiation (1). Subsequent studies using in vivo gene targeting have shown that PPARγ 
is indispensable for normal development of adipose tissue (16, 17). There are two variants 
of PPARγ, PPARγ1 and PPARγ2, due to alternative promoter usage and alternative splicing 
(4). PPARγ2 contains 30 additional amino acids at its N-terminus and is exclusively 
expressed in adipose tissue, whereas PPARγ1 is expressed in several tissues including 
colon and liver (18). Both isoforms are capable of inducing adipogenesis, with PPARγ2 
being the most potent (4). Target genes of PPARγ include genes related to adipogenesis 
(Cebpa), lipid uptake and transport (Lpl, Cd36, Fabp4), uncoupling (Ucp1), lipid droplets 
associated proteins (Plin1, Plin2, Cidea, Cidec) and glucose metabolism (Adipoq, Pck1, 
Slc2a4) (4, 19-26).
The complete set of endogenous ligands for PPARγ has not been well characterized, 
though the general consensus is that fatty acids and mainly their derivatives such as 
prostaglandins can serve as PPARγ activators (27, 28). The most well-known PPARγ 
ligands are the insulin-sensitizing thiazolidinedione (TZD) class of drugs utilized in the 
treatment of type 2 diabetes (18). The PPARγ mediated insulin-sensitizing effects are 
not completely understood but include the redirection of fatty acids away from ectopic 
storage to adipose tissue depots, production and section of adiponectin, and inhibition 
of inflammatory signaling in macrophages (4).
Recently, we identified hypoxia inducible lipid droplet associated (HILPDA) as a novel 
PPAR regulated gene involved in hepatic VLDL-TG secretion (Chapter 5). HILPDA is a 
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relatively small protein of 63 and 64 amino acids in human and mouse, respectively, with 
no homologous proteins. HILPDA expression is highly induced upon hypoxia and several 
studies have identified HILPDA to be expressed in a variety of carcinomas where it might 
contribute to tumor growth via inhibition of apoptosis (29-33). Recently, HILPDA was 
found to localize to lipid droplets and to be involved in lipid storage (34). 
In chapter 5 we showed that HILPDA can be transactivated by PPARα, PPARδ, and 
PPARγ. Furthermore, PPARγ overexpression in liver markedly induced Hilpda expression. 
Given the regulation of HILPDA by PPARs and its potential localization to lipid droplets 
we set out to study the role of HILPDA in other organs. In this study we identify Hilpda 
as a PPARγ- and β-adrenergic receptor-regulated gene involved in adipose tissue lipolysis.
Results
Hildpa is expressed in adipocytes
We first determined the distribution of HILPDA mRNA across various human and mouse 
tissues. Highest expression of HILPDA expression was found in white adipose tissue (WAT), 
with lower levels in muscle, intestine, liver, and kidney (Figures 1A and 1B). Considering 
the abundance of HILPDA mRNA in adipose tissue and its reported localization to lipid 
droplets we decided to focus on the potential role and regulation of HILPDA in adipose 
tissue. Separation of adipose tissue into adipocytes and stromal vascular fraction (SVF), 
which contains adipocyte progenitor cells and various immune cells, indicated that Hilpda 
expression was highly enriched in the adipocyte fraction (Figure 1C). Successful separation 
of adipose tissue was confirmed by the adipocyte- and SVF-specific expression of Adipoq 
and Cd68 (Figure 1C). Human subcutaneous- and visceral adipose tissue separated into 
adipocytes and SVF similarly revealed enrichment of HILPDA mRNA in adipocytes (Figure 
1D). Thus, HILPDA is highly expressed in adipose tissue where it is mainly confined to 
adipocytes.
We next determined whether HILPDA expression is influenced by diet-induced obesity 
and associated adipocyte hypertrophy. Intriguingly, high fat feeding, which caused a marked 
increase in bodyweight and expansion of adipose tissue mass (Figures 2A and 2B), led to 
a significant reduction in Hilpda mRNA in the adipocyte fraction (Figure 2C). Increased 
macrophage abundance, as illustrated by increased Cd68 mRNA levels, did not associate 
with altered Hilpda expression in the SVF (Figure 2C). Another stimulus that causes major 
remodeling of the adipose tissue is fasting. Interestingly, fasting markedly increased Hilpda 
mRNA as well as protein levels in epididymal WAT (Figures 2D and 2E).
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Figure 1. HILPDA is expressed in adipocytes
(A and B) HILPDA mRNA levels in various human (A, n =1) and mouse (B, n = 2) tissues. 
(C) Hilpda, Adipoq, and Cd68 expression in eWAT adipocytes and SVF of C57BL6 mice (n = 3).
(D) HILPDA, ADIPOQ, and CD45 expression in adipocytes and SVF derived from human subcutaneous 
and visceral adipose tissue (n = 7). 
Data are mean ± SEM. Asterisks indicate significant differences according to Student’s t-test; *P < 0.05, 
**P < 0.01.
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HILPDA does not aff ect adipogenesis 
To gain insight into the expression of Hilpda during adipocyte differentiation, we employed 
the 3T3-L1 adipogenesis model. Hilpda mRNA levels increased 4-fold during 3T3-L1 
adipogenesis (Figures 3A), which was copied at the protein level (Figure 3B). Similarly, 
Hilpda mRNA went up upon differentiation of mouse SVF cells into adipocytes, concurrent 
with established markers of adipogenesis (Figure 3C), as well as during SGBS (Simpson-
Golabi-Behmel syndrome) pre-adipocyte differentiation (Figure 3D). Next, we explored 
the potential role of HILPDA in 3T3-L1 adipocyte differentiation by employing siRNA 
mediated knockdown of Hilpda. Although treatment of cells with siRNA against HILPDA 
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Figure 2. HILPDA expression during high-fat diet and fasting
(A and B) Increase in body weight (A) and eWAT weight of C57BL6 animals after 7 days of HFD (n = 3-4 
animals per group).
(C) mRNA levels of Hilpda, Adiponectin, and Cd68 in adipocytes and SVF of C57BL6 mice fed HFD for 7 
days (n = 3-4 animals per group).
(D and E) Expression of Hilpda mRNA (D, n = 6 animals per group) and protein (E) in 18-hour fasted 
wild-type mice. ACTIN was used as loading control. 
Data are mean ± SEM. Asterisks indicate significant differences according to Student’s t-test or two-way 
ANOVA with Bonferroni post-hoc test (C); *P < 0.05, **P < 0.01, ##P < 0.01. In (C): *, difference between 
adipocyte and SVF; #, difference between chow and HFD.
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Figure 3. Hilpda expression during adipogenesis
(A and B) Hilpda mRNA (A, n = 3) and protein level (B) during 3T3-L1 adipogenesis.
(C) Hilpda mRNA during primary SVF differentiation into adipocytes. Fabp1 and Plin1 were measured to 
confirm successful differentiation. Adipose tissue from 3 C57BL6 animals was dissected, pooled, digested 
with collagenase and resulting SVF cells differentiated. 
(D) SGBS cells were differentiated and Hilpda mRNA was measured at the indicated days (n =1).
Data are mean ± SEM. Asterisks indicate significant differences according to one-way ANOVA with Tukey’s 
post-hoc test (A) or Student’s t-test (C); *P < 0.05, **P < 0.01.
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effectively reduced Hilpda mRNA and protein levels (Figures 4A and 4B), we observed 
no difference in adipogenic potential compared to cells treated with control siRNA, as 
illustrated by the lack of change in expression of adipogenic markers and the lack of change 
in Oil Red O staining (Figures 4C-4E). In congruence, adenovirus mediated overexpression 
of Hilpda also did not influence 3T3-L1 adipogenesis (Figures 5A and 5B).
Adipocyte HILPDA is regulated by PPARγ
HILPDA was recently identified as target of PPARs in liver, including PPARγ (Chapter 5). 
To explore the potential effect of PPARγ on Hilpda expression in adipocytes we treated 
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Figure 4. siRNA mediated HILPDA knockdown does not affect adipogenesis
(A and B) Hilpda mRNA (A) and protein (B) levels during 3T3-L1 adipogenesis. siRNAs were added two days 
before initiation of adipogenesis, at the start of differentiation and on day 3 and 6 of differentiation (n = 3). 
(C and D) Fabp4 (C) and G0s2 (D) expression in siCtrl and siHilpda cells (n = 3).
(E) Oil Red O staining of siCtrl and siHilpda cells at indicated days during the process of differentiation.
Data are mean ± SEM. Asterisks indicate significant differences according to Student’s t-test; **P < 0.01.
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Figure 5. Adenovirus mediated overexpression of Hilpda does not affect adipogenesis
(A) Recombinant viruses expressing GFP of HILPDA were added at an MOI of 500 two days before initiation 
of differentiation and Hilpda mRNA was determined on the indicated days (n = 3).
(B) Oil Red O staining of parallel samples described in A.
Data are mean ± SEM. Asterisks indicate significant differences according to Student’s t-test; **P < 0.01.
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3T3-L1 adipocytes with the PPARγ agonist rosiglitazone. Rosiglitazone significantly 
induced Hilpda mRNA and protein in mature 3T3-L1 adipocytes but not undifferentiated 
3T3-L1 fibroblasts (Figures 6A-6C). Consistent with PPARγ-dependent regulation, Hilpda 
expression in 3T3-L1 adipocytes was markedly decreased upon knockdown of Pparg 
(Figure 6D). 
In chapter 5 we identified a functional PPAR response element (PPRE) around 1200 
base pair upstream of the transcriptional start site (TSS) of the HILPDA gene. To examine 
whether PPARγ binds to this PPRE in adipocytes we performed ChIP-seq experiments in 
3T3-L1 adipocytes. It was found that PPARγ binds to three loci upstream of the TSS (Figure 
6E). The PPARγ binding site nearest to the TSS is identical to the binding site that binds 
PPARα (Chapter 5) and harbors a conserved and functional PPRE. Interestingly, PPARγ 
exclusively occupied the binding sites in 3T3-L1 adipocytes and not in fibroblasts (Figure 
6E), which is consistent with exclusive induction of HILPDA by rosiglitazone in 3T3-L1 
adipocytes and not fibroblasts (Figure 6B and 6C). Finally, despite the modest induction 
of Hilpda mRNA during 3T3-L1 adipocyte differentiation, binding of RNA polymerase II 
to the Hilpda promoter remained relatively stable during 3T3-L1 adipogenesis (Figure 6E).
Confirming regulation of HILPDA by PPARγ in human adipocytes, HILPDA was in 
the top 25 of most highly induced genes by rosiglitazone in differentiated human SGBS 
and MADs (multipotent adipose-derived stem cell) adipocytes, together with well-known 
PPARγ targets such as PCK1 and PDK4, as assessed by microarray (Figure 7A and 7B). 
Again, consistent with PPARγ-dependent regulation, HILPDA expression in human SGBS 
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adipocytes was markedly decreased upon knockdown of PPARG (Figure 7C). Finally, 
ChIP-seq experiments indicated markedly enhanced binding of PPARγ to multiple binding 
sites in differentiated hMADs adipocytes, including the conserved binding site nearest to 
the TSS referred to above (Figure 7D). Binding of PPARγ upon differentiation of hMADs 
cells was accompanied by increased RNA polymerase II binding to the HILPDA promoter 
(Figure 7D). Together, these data suggest that HILPDA is regulated by PPARγ in human 
and mouse adipocytes via at least one functional PPRE.
Figure 6. PPARγ binds to a conserved PPRE at the Hilpda loci in 3T3-L1 adipocytes
(A and B) Mature 3T3-L1 adipocytes (A) or 3T3-L1 fibroblasts (B) were exposed to 10 μM rosiglitazone 
for 24 hours and subsequently analyzed for Hilpda mRNA (n = 3). 
(C) Western blot analysis on a subset of samples described in A and B.
(D) 3T3-L1 adipocytes were incubated with siRNA against PPARγ and three days later analyzed for 
expression of Pparg and Hilpda (n = 3).
(E) ChIP-seq profiles of RXR, PPARγ, and RNA polymerase II in 3T3-L1 fibroblasts and adipocytes at the 
Hilpda loci. Sequences indicate a conserved PPRE located 1200 base pair upstream of the TSS.
Data are mean ± SEM. Asterisks indicate significant differences according to Student’s t-test; **P < 0.01.
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Figure 7. HILPDA is regulated by PPARγ in human adipocytes
(A and B) Gene expression profiling identified HILPDA to be in the top 25 of most highly induced genes 
upon rosiglitazone treatment of hMADs adipocytes (A) and SGBS (B) adipocytes.
(C) PPARG was knocked-down in SGSB cells and mRNA levels of PPARG and HILPDA were analyzed with 
qPCR (n = 3).
(D) ChIP-seq profiles of PPARγ and RNA polymerase II at the human HILPDA loci. hMADs fibroblasts and 
adipocytes were used for IP. Sequences show the location of the conserved PPRE.
Data are mean ± SEM. Asterisks indicate significant differences according to Student’s t-test; **P < 0.01.
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β-adrenergic receptor agonists induce Hilpda expression 
To identify additional regulators of HILPDA expression we exposed 3T3-L1 adipocytes to a 
variety of compounds including insulin and dexamethasone. None of these metabolic cues 
affected HILPDA expression (data not shown). However, we noticed marked induction of 
Hilpda expression when 3T3-L1 adipocytes were exposed to β-adrenergic receptor agonists 
or forskolin, suggesting that HILPDA is responsive to cAMP levels (Figure 8A). Hilpda 
mRNA levels peaked after 3 hours of exposure to isoproterenol or forskolin (Figure 8B), 
which translated into increased protein levels (Figure 8C). Similarly, we found significant 
induction of Hilpda expression in primary mouse epididymal and inguinal adipocytes 
exposed to isoproterenol (Figure 8D). Moreover, the induction of Hilpda by isoproterenol 
was apparent at low concentrations and saturated at 1 μM (Figures 8E and 8F). Interestingly, 
the effect of isoproterenol was specific for mature adipocytes as we failed to observe 
induction of Hilpda expression in 3T3-L1 fibroblasts and non-differentiated SVF cells 
(Figures 8G and 8H). Adding to a β-AR mediated regulation of HILPDA we observed 
a robust increase in Hilpda expression in mice injected with the β3-adrenergic receptor 
agonist CL316,243, suggesting in vivo relevance (Figure 8I). Thus, adipocyte HILPDA 
is under strong positive control of β-adrenergic receptor signaling in vitro and in vivo.
To examine the induction of HILPDA by β-adrenergic receptor agonists in more detail 
we pretreated mature adipocytes with inhibitors for RNA polymerase II or translation, 
followed by exposure to isoproterenol or forskolin. Blocking RNA polymerase II partially 
reduced Hilpda mRNA levels whereas interfering with translation induced the expression 
of Hilpda (Figure 9A). Immunoblot analysis indicated partially reduced HILPDA protein 
levels upon RNA polymerase II inhibition while blocking protein synthesis completely 
abolished the isoproterenol- and forskolin-induced increase in HILPDA protein 
expression (Figure 9B). Many proteins involved in the regulation of lipolysis undergo 
phosphorylation. Nonetheless, we found no evidence for HILPDA being phosphorylated 
in 3T3-L1 adipocytes exposed to β-adrenergic receptor agonists (Figure 9C). These data 
suggest that isoproterenol and forskolin increase HILPDA protein via transcriptional and 
translational mechanisms but do not induce phosphorylation. 
Adipose tissue-specifi c Hilpda–/– animals show no major metabolic perturbations 
To explore the functional role of HILPDA in adipose tissue we generated adipose tissue-
specific null mice by crossing floxed Hildpa mice with Adiponectin-Cre mice, resulting in 
WAT- and BAT-specific deletion of Hilpda (ATHilpda–/–) and concomitant transcription 
of human placental alkaline phosphatase (ALPP) reporter gene (Figures 10A and 10B). 
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Figure 8. HILPDA is highly responsive to β-adrenergic receptor stimulation
(A) Hilpda mRNA levels in 3T3-L1 cells exposed to β-adrenergic receptor agonists and forskolin, an 
activator of adenylate cyclase, for 3 hours. Isoproterenol is a general β-adrenergic agonist. CL316,243 
is specific for β3 receptors, procaterol for β2, and norepinephrine acts as a general adrenergic receptor 
agonist (n = 3).  
(B) Time course of Hilpda expression upon exposure to 10 μM isoproterenol or 5 μM forskolin (n = 3).
(C) HILPDA protein expression in samples described in B.
(D) Primary adipocytes differentiated from epididymal and inguinal SVF were exposed to 10 μM 
isoproterenol for 3 hours and subsequently analyzed for Hilpda mRNA levels (n = 3).
(E and F) 3T3-L1 adipocytes were exposed to different concentrations isoproterenol for 6 hours after 
which the cells were analyzed for Hilpda mRNA (E, n = 3) and HILPDA protein.
(G) 3T3-L1 fibroblasts were treated as described for E and F (n = 3). 
(H) SVF from eWAT was plated, exposed to 10 μM isoproterenol for 6 hours and subsequently analyzed 
for Hilpda expression (n = 3).
(I) Female NMRI mice were injected intraperitoneally with 1 mg/kg CL316,24 and eWAT was collected 
4 hours later (n = 5 animals per group).
Data are mean ± SEM. Asterisks indicate significant differences according to Student’s t-test or one-way 
ANOVA with Tukey’s post-hoc test (A and E); *P < 0.05, **P < 0.01.
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Figure 9. HILPDA is translated upon exposure to isoproterenol and forskolin
(A) Mature 3T3-L1 adipocytes were preincubated with 10 μg/ml alpha-amanitin or cycloheximide for 
45 minutes followed by exposure to isoproterenol or forskolin for 3 hours. Following RNA isolation and 
cDNA synthesis, Hilpda mRNA levels were determined by qPCR (n = 3).
(B) Western blot analysis of samples used in described in A.
(C) 3T3-L1 adipocytes were exposed to isoproterenol (10 μM), forskolin (10 μM), CL316,243 (10 μM), 
procaterol (5 μM), and norepinephrine (1 μM) for 3 hours and analyzed for potential phosphorylation 
with Phos-tag gel. ns = non-specific immunodetection.
Data are mean ± SEM. Asterisks and number signs indicate significant differences according to two-way 
ANOVA with Bonferroni post-hoc test; *P < 0.05, **P < 0.01, ##P < 0.01. *, difference between DMSO, 
AAM or CHX; #, difference between control, isoproterenol or forskolin.
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ATHilpda–/– mice developed normally over time. However, a small increase in body weight 
was detected in female ATHilpda–/– mice compared to wild-type mice (Figure 10C).  
Since we observed a prominent increase in Hilpda expression in epididymal white adipose 
tissue (eWAT) upon fasting, we characterized wild-type and ATHilpda–/– mice after an 
overnight fast. Weight loss was similar between the two sets of mice (Figure 10D). Moreover, 
149
HILPDA regulates adipose tissue lipolysis
6
no differences were observed between the weights of several tissues from wild-type and 
ATHilpda–/– animals (Figures 10E-10H). Heamatoxylin and eiosin staining revealed no major 
differences in eWAT or BAT histology between the two sets of mice (Figures 10I and 10J). 
To gain insight in the potential function of adipose tissue HILPDA, we assayed several 
serum parameters. No changes were observed in serum triglycerides, non-esterified fatty 
acids (NEFAs), glucose, ketone bodies, or glycerol, though a minor reduction in serum 
cholesterol was apparent in the male ATHilpda–/– animals (Figure 11A-11F). Likewise, 
serum adiponectin and insulin levels were similar between wild-type and ATHilpda–/–
animals (Figures 11G and 11H). Thus, deletion of adipose Hilpda does not seem to alter 
the metabolic response to fasting. 
Hilpda reduces isoproterenol induced NEFA release
We observed a striking induction of HILPDA expression with β-adrenergic receptor 
agonists (Figures 8A-8F). β-adrenergic activation leads to stimulation of intracellular 
lipolysis in adipose tissue. To explore a potential role for HILPDA in β-adrenergic receptor-
mediated lipolysis, we exposed eWAT explants from wild-type and ATHilpda–/– mice to 
isoproterenol. No difference in NEFA and glycerol release was observed (Figures 12A and 
12B). Similarly, siRNA mediated knockdown of HILPDA in mature 3T3-L1 adipocytes 
did not alter isoproterenol-induced NEFA and glycerol release (Figures 12C-12E). Thus, 
deletion of HILPDA does not affect the capacity of adipocytes to release fatty acids. 
However, we hypothesized that if HILPDA acts as an inhibitor of lipolysis, its function 
may be better revealed by overexpression. Therefore, we infected 3T3-L1 adipocytes with 
adenovirus to overexpress HILPDA followed by isoproterenol treatment. Consistent with 
our hypothesis, isoproterenol-induced release of NEFAs was significantly lower upon 
HILPDA overexpression (Figure 12F-12H). Taken together, these data suggest that Hilpda 
functions as an inhibitor of adipocyte lipolysis, potentially as part of a feedback mechanism 
induced by β-adrenergic receptor activation.
Discussion
The findings reported in this paper identify HILPDA as a novel regulator of adipocyte 
lipolysis. HILPDA expression was found to be regulated by fasting and high-fat diet feeding. 
Moreover, HILPDA expression was revealed to be under the control of both PPARγ and 
β-adrenergic receptor stimulation. Genetic manipulation of HILPDA expression did not 
affect the differentiation of fibroblasts into mature adipocyte. The metabolic response to 
Chapter 6
150
Figure 10. Adipose tissue-specific Hilpda knockout mice have normal adipose mass upon 
fasting
(A and B) Hilpda (A) and ALPP (B) expression in eWAT and BAT from wild-type and ATHilpda–/– mice (n = 
7-9 animals per group).
(C) Body weight of female and male wild-type or ATHilpda–/– mice (n = 7-9 animals per group).
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fasting in adipose tissue-specific Hilpda knockout mice was comparable to that of wild-type 
mice. However, adenoviral-mediated overexpression of HILPDA reduced NEFA release 
from adipocytes upon β-adrenergic stimulation. 
Central to the induction of adipocyte lipolysis upon stimulation of β-adrenergic 
receptors is the cAMP/protein kinase A (PKA) mediated phosphorylation of hormone 
sensitive lipase (HSL) and perilipin 1 (PLIN1). Consequently, PLIN1 releases comparative 
gene identification-58 (CGI-58) which subsequently serves as a coactivator for ATGL/
PNPLA2. Simultaneously, PLIN1 interacts with and translocates HSL to the surface of 
lipid droplets. Together, these actions lead to increased activity of ATGL and HSL that 
catalyze the hydrolysis of TAG and DAG, respectively. Following the final hydrolysis of 
MAG by MGL, resulting NEFAs are released in to the circulation (35). Despite the presence 
a number of potential phosphorylation sites, as determined by computational analysis 
(34), we found no evidence for phosphorylation of HILPDA upon β-adrenergic receptor 
stimulation using a Phos-tag method. Future experiments will have to address if HILPDA 
may be phosphorylated in response to other stimuli.
Besides causing the phosphorylation of several protein substrates including PLIN1 
and HSL, PKA phosphorylates the transcription factor cAMP response element binding 
protein (CREB), leading to recruitment of several coactivators such as CREB binding 
protein (CBP/p300) and subsequent induction the transcription of numerous target genes 
such as phosphoenolpyruvate carboxykinase (PEPCK) and activating transcription factor 
3 (ATF3) (36-39). siRNA mediated knockdown of CREB modestly decreased the cAMP-
induced increase in Hilpda mRNA (data not shown). However, CREB expression was 
only 40% lower compared to control cells and adenoviral mediated knockdown of CREB 
will have to provide conclusive evidence. It should be noted that in silico analysis did not 
reveal the presence of conserved CREB responsive elements (CREs) in the proximity of 
the Hilpda gene. Thus, additional studies are required to delineate a potential induction 
of Hilpda expression by cAMP/PKA/CREB.
(D) Weight loss in 16-hour fasted female and male wild-type or ATHilpda–/– mice (n = 7-9 animals per 
group).
(E-H) eWAT (E), BAT (F), gastrocnemius (G), and liver (H) weight of 16-hour fasted wild-type and   ATHilpda–/– 
mice (n = 7-9 animals per group).
(I and J) Representative H&E staining of eWAT (I) and BAT (J) of 16-hour fasted wild-type and ATHilpda–/– 
mice.
Data are mean ± SEM. Asterisks and number signs indicate significant differences according to Student’s 
t-test (A and B) or two-way ANOVA with Bonferroni post-hoc test; *P < 0.05, **P < 0.01, ##P < 0.01. *, 
difference between genotype; #, difference between female and male mice.
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Figure 11. Fasting provokes no major alterations in serum parameters of ATHilpda–/– mice
(A-F) Serum from 16-hour fasted wild-type and ATHilpda–/– was analyzed for triglycerides (A), NEFAs (B), 
cholesterol (C), glucose (D), ketone bodies (E), and glycerol (F) (n = 6-9 animals per group).
(G and H) ELISA for adiponectin (G) and insulin (H) on serum samples of wild-type and ATHilpda–/– mice 
fasted for 16 hours (n = 6-9 animals per group).
Data are mean ± SEM. Asterisk and number signs indicate significant differences according to two-way 
ANOVA with Bonferroni post-hoc test; *P < 0.05, ##P < 0.01. *, difference between genotype; #, difference 
between female and male mice.
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Figure 12. Effect of HILPDA on adipocyte lipolysis
(A and B) NEFA (A) and glycerol (B) release in eWAT explants of wild-type and ATHilpda–/– mice upon 
exposure to isoproterenol (n = 4 animals per group).
(C-E) siRNA against HILPDA was applied to mature 3T3-L1 adipocytes replated at 70% confluency leading 
to robust reductions in HILPDA levels (C). Cells were starved for 2 hours and subsequently exposed to 5 
μM isoproterenol for 2 hours. Media were analyzed for NEFAs (D) and glycerol (E) (n = 3).
(F-H) Recombinant adenoviruses expressing GFP or HILPDA under the control of a CMV promoter were 
added to replated 3T3-L1 at an MOI of 750. Three days later the cells were serum starved (DMEM + 1% 
BSA) for 2 hours and subsequently incubated with DMEM supplemented with 5 μM isoproterenol for 
3 hours. Cell lysates were analyzed for HILPDA protein levels (F) and media for NEFAs (G) and glycerol 
(H) content (n = 3).
Data are mean ± SEM. Asterisk and number signs indicate significant differences according to two-way 
ANOVA with Bonferroni post-hoc test; *P < 0.05, ##P < 0.01. *, difference between AV-GFP and AV-HILPDA; 
#, control versus isoproterenol.
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Our experiments in ATHilpda–/– animals revealed no major perturbations in the 
metabolic response to fasting in the absence of adipose tissue HILPDA. Moreover, 
siRNA-mediated knockdown of HILPDA in adipocytes did not result in a change in 
NEFA release induced by catecholamines. By contrast, adenovirus-mediated HILPDA 
overexpression resulted in a significant reduction in NEFA release upon β-adrenergic 
receptor stimulation. Based on these results we postulate that HILPDA functions as a 
negative regulator of adipose tissue lipolysis, and that induction of HILPDA serves as a 
negative feedback mechanism to control the amount of NEFAs released. The mechanism 
behind impairment of adipocyte lipolysis by HILPDA remains elusive and will be studied 
in future experiments. It is tempting to speculate on the potential inhibition of one or 
more lipases such as ATGL or HSL by HILPDA, although evidence provided in chapter 
5 argues against such a mechanism, at least in liver.  
Gimm et al. (34) reported that HILPDA is localized to lipid droplets. Many lipid 
droplet associated proteins are under transcriptional control of PPARγ. Using a variety 
of techniques we firmly establish the direct regulation of HILPDA by PPARγ via at least 
one conserved functional PPRE. Considering the role of PPARγ as master regulator of 
adipogenesis, we expected a substantial increase in HILPDA expression upon adipogenesis. 
However, the inductions we observed were relatively modest compared to other lipid 
droplet proteins such as PLIN1, PLIN2, and G0S2. On the other hand, expression of the 
lipid droplet associated protein PLIN3/TIP47 remains unaltered during adipogenesis 
(22). It can be hypothesized that HILPDA has specific functions at the surface of lipid 
droplets during fasting and β-adrenergic receptor activation but not in the biogenesis of 
lipid droplets.
Compelling evidence suggest that the function of PPARγ goes beyond the anabolic 
lipogenic pathway (4). Indeed, PPARγ was found to regulate many genes involved in the 
lipolytic response upon cathecholamine induced lipolysis, including Adrb3 (β3 adrenergic 
receptor) Atgl, Hsl, and the lipid droplet associated proteins Plin2 and Cidec (40-43). 
Mutations in PPARγ or Pparg2 deletion were found to impair the cathecholamine-
induced lipolytic response (43, 44). Thus, coordinate induction of HILPDA by PPARγ 
and cAMP might be aimed at balancing the amount of NEFAs released from adipocytes 
during fasting. It should be noted that HILPDA appears to be the only gene known to be 
regulated by PPARγ and involved in lipolysis that is also regulated at the transcriptional 
level by β-adrenergic receptor stimulation. 
Despite the absence of clear defects in the response to fasting in ATHilpda–/– animals, we 
did observe a reduction in the number of lipid droplets in brown adipose tissue of some but 
not all ATHilpda–/– animals. Accordingly, analysis of the adipose tissue of a larger number 
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of animals is warranted. Additionally, gene expression data showed increased expression 
of G0s2 and Pnpla3 in the brown adipose tissue of fasted ATHilpda–/– animals (data not 
shown). Thus, in brown adipose tissue HILPDA might play a role in the response to fasting 
potentially via regulation of two known players involved in the lipolytic pathway. In white 
adipose tissue, however, knockdown of Hilpda did not lead to changes in the expression 
of genes involved in lipolysis.
Despite successful adipose tissue HILPDA deletion as determined by PCR and mRNA 
expression of the recombination marker ALPP, the reduction in Hilpda mRNA was 
relatively minor, especially in the white adipose tissue depot. A potential explanation for 
this observation might be increased expression of Hilpda in the macrophage fraction of 
the adipose tissue. Interestingly, experiments performed in our laboratory indicate that 
Hilpda is highly induced upon lipid loading of macrophages. Fractionation of adipose tissue 
from wild-type and ATHilpda–/– animals will be carried out to examine the possibility that 
HILPDA expression is increased in adipose tissue macrophages. 
Taken together, we demonstrate that HILPDA is under positive regulation by PPARγ 
and the β-adrenergic receptor. Induction of HILPDA may be aimed at regulating the 
amount of NEFAs released during β-adrenergic receptor stimulation. Given the induction 
of HILPDA during fasting, we anticipate a similar mechanism of action in vivo.
Methods
Animal studies
For generation of a tissue library, two male wild-type C57BL6 animals were anesthetized with isoflurane 
killed by cervical dislocation and several tissues were excised and snap-frozen. 
Male wild-type C57BL6 animals (4 months old) were fed a chow diet or a high-fat diet containing 
60en% fat (D12492, Research Diet Services, Wijk bij Duurstede, The Netherlands). One week later, 
the animals were anesthetized with isoflurane and killed by cervical dislocation. Epididymal adipose 
tissues were dissected and separated into the adipocyte fraction and stromal vascular fraction (SVF) 
as described below.
For in vivo β3-adrenergic receptor activation, 9-10-week-old female NMRI mice were injected 
intraperitoneally with 1 mg/kg CL316,243 (Tocris Bioscience, Bristol, United Kingdom) in 0.9% saline. 
Control animals were injected with an equal volume of saline. Four hours later, the mice were killed 
by cervical dislocation and the epididymal was WAT dissected and snap-frozen.
Male 4-6-months-old C57BL6 animals were fasted for 18 hours after which the epididymal WAT 
was dissected and snap-frozen in liquid nitrogen.
Heterozygous floxed Hilpda animals on a mixed C57BL/6 and Sv129 background were purchased 
from The Jackson Laboratory (Bar Harbor, ME, USA). LoxP sites were introduced to flank the second 
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exon of Hilpda followed by the open reading frame for membrane-tethered human placental alkaline 
phosphatase (ALPP) after the second loxP site. Following Cre-recombination, ALPP is expressed under 
the control of the HILPDA promoter. Floxed Hilpda mice were crossed with Adiponectin-Cre mice 
(The Jackson Laboratory) on a C57BL6 background. After initial crosses, Hilpdafl/fl mice were crossed 
with Hilpdafl/fl heterozygous for adiponectin-Cre, yielding 50% wild-type animals and 50% adipose 
tissue-specific Hilpda null animals (ATHilpda–/–), equally distributed among males and females. Nine 
to- 13-week-old littermates were used for experiments. 
All animal experiments performed were approved by the local animal welfare committee of 
Wageningen University or Cornell University (Ithaca, NY, USA), respectively.
Recombinant adenoviruses
Adenoviruses (AV) were generated by cloning GFP or Hilpda cDNA in human adenovirus type5 (dE1/
E3). Expression was under the control of the CMV promoter. Viruses were produced and titrated by 
Vector Biolabs (Philadelphia, PA, USA). 
Chemicals
Isoproterenol, norepinephrine, cycloheximide, alpha-amanitin, 3-isobutyl-1-methylxanthine (IBMX), 
insulin, dexamethasone, and rosiglitazone were purchased from Sigma-Aldrich (Schnelldorf, 
Germany). Forskolin, procaterol and CL316,243 were from Tocris (Tocris Bioscience, Bristol, United 
Kingdom).
Collagenase digestion 
Dissected adipose tissue samples from the different experiments were kept on ice in Dulbecco’s 
modified Eagle’s medium (DMEM) (Lonza, Verviers, Belgium) supplemented with 1% bovine serum 
albumin (BSA) (Lonza). Samples were subsequently cut into small 1-2 mm3 pieces and incubated with 
collagenase solution (DMEM, 3.2 mM CaCl2, 15 mM HEPES, 0.5% BSA, 10% fetal calf serum, 1.5 
mg/ml collagenase type II (Sigma-Aldrich #C6885)) at 37°C for 45 minutes. Mixtures were strained 
through a 100 μm cell strainer and centrifuged at 900 rpm for 10 minutes at room temperature. 
Floating adipocytes were collected and snap-frozen for RNA isolation. Stromal vascular cells (SVF) 
were resuspended in red blood cell lysis buffer (155 mM NH4Cl, 12 mM NaHCO3, 0.1 mM EDTA) 
and incubated for 2 minutes at room temperature. Following the addition of 8 ml DMEM, the SVF 
cells were pelleted at 900 rpm for 10 minutes at room temperature. Cell pellets were snap-frozen for 
RNA isolation or counted and plated for differentiation into adipocytes as described below. 
Paired subcutaneous and visceral (omentum) adipose tissue samples were collected according 
to a standardized procedure from patients admitted to the Radboud University Nijmegen Medical 
Centre (Nijmegen, The Netherlands) for laparoscopic cholecystectomy or inguinal hernia surgery. 
Samples were obtained from 7 patients aged between 41-63 years with and a BMI ranging from 
25-28 kg/m2.
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WAT explants
Male wild-type and ATHilpda–/– mice were sacrificed by cervical dislocation. Epididymal fat pads 
were dissected, cut into 20-40 mg pieces, and divided over 6 wells of a 24-well plate per animal. Then, 
explants were incubated in DMEM supplemented with 1% BSA for 30 minutes at 37°C. After thorough 
washing with warm PBS, the explants were incubated in DMEM + 1% BSA with or without 10 μM 
isoproterenol for 3 hours at 37°C. Media were assayed for NEFAs and glycerol using commercially 
available kits from Wako (Wako Chemicals GmbH, Neuss, Germany) and DiaSys (DiaSys Diagnostic 
Systems, Holzheim, Germany), respectively. 
Cell culture
3T3-L1 fibroblasts were maintained in DMEM (Lonza) supplemented with 10% fetal calf serum 
(FCS) (Lonza) and 1% penicillin/streptomycin (P/S) (Lonza). Differentiation was initiated 2 days 
post-confluency by the addition of DMEM + 10% FCS + 1% P/S supplemented with 0.5 mM IBMX, 
5 μg/ml insulin, and 1 μM dexamethasone. Three days later, the medium was replaced by insulin 
medium (DMEM, 10% FCS, 1% P/S, 5 μg/ml insulin). Two days later, the cells were provided with 
fresh DMEM + 10% FCS + 1% P/S and cultured for an additional 2-3 days.  
Dharmacon ON-TARGETplus SMARTpool siRNAs were purchased from Thermo Fisher 
Scientific (Landsmeer, The Netherlands). siRNAs were diluted in Dharmacon siRNA buffer (final 
concentration 20 mM KCl, 6 mM HEPES pH 7.5, 0.2 mM MgCl2). Transfections were performed 
with Lipofectamine RNAiMAX transfection reagent (Life Technologies, Bleiswijk, The Netherlands). 
All siRNA transfections were carried out at a concentration of 40 nM siRNA and 2 μl transfection 
reagent for a 12-well plate well. 
To study the effect of Hilpda knockdown on 3T3-L1 differentiation, siRNAs were added two days 
before initiation of differentiation, at the start of differentiation, and subsequently every 3rd day. To 
knockdown Hilpda or Pparg in mature adipocytes, cells were washed with PBS, trypsinized, and 
collected in 0.5 mg/ml collagenase in PBS. After centrifugation at 400 g for 5 minutes at 4°C, cells were 
strained over a 70 μm cell strainer and plated to 70% confluency. siRNAs were added two hours later, 
and experiments were carried out after an additional 48-72 hours incubation. siCtrl and siHilpda cells 
were incubated in DMEM + 1% BSA for 2 hours followed by 5 μM isoproterenol in DMEM + 1% BSA 
for 2 hours. Medium samples were assayed for NEFAs and glycerol as described above. 
For overexpression experiments in 3T3-L1 adipocytes, recombinant adenoviruses were diluted 
in DMEM (low glucose, 1 g/l) supplemented with 0.5 μg/ml poly-L-lysine and incubated at room 
temperature for 100 minutes. Mixtures were added to the cells and allowed to incubate for 90 minutes 
followed by the addition of normal culture medium. Differentiation was initiated two days later. 
Adenoviruses were used at an MOI of 500. To study isoproterenol induced NEFA and glycerol release, 
mature 3T3-L1 adipocytes were replated to 70% confluency as described above and subsequently 
starved for in DMEM (low glucose) + 1% FCS for 12 hours followed by DMEM (low glucose) + 0.1% 
FCS for an additional 12 hours. Adenoviruses diluted in 0.5 μg/ml poly-L-lysine were added to serum 
starved cells at an MOI of 750. Regular culture medium was added after 90 minutes. Three days later, 
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cells were incubated in DMEM + 1% BSA for 2 hours and subsequently exposed to 5 μM isoproterenol 
for 3 hours. Medium samples were assayed for NEFAs and glycerol as described above.
SVF cells derived from eWAT or iWAT of wild-type mice were plated at a density of 2x104 cells 
per cm2 in DMEM + 10% FCS + 1% P/S. Once cells reached confluency, differentiation was initiated 
using DMEM supplemented with 0.5 mM IBMX, 5 μg/ml insulin, 1 μM dexamethasone, and 0.5 μM 
rosiglitazone. Three days later the medium was replaced with DMEM supplemented with 5 μg/ml 
insulin and 0.5 μM rosiglitazone. Another three days later, the medium was replaced with normal 
growth medium. 
SGBS cells and hMADs cells were cultured and differentiated according to published methods 
(45, 46). For microarray analysis, cells were exposed to 1 μM rosiglitazone for 6 hours as described 
previously (47).
Serum analysis
Triglycerides were determined using a Triglycerides liquicolormono kit (HUMAN, Wiesbaden, Germany), 
NEFAs were measured with a NEFA-HR(2) kit (Wako). Ketone bodies were determined with a Ketone 
bodies Autototal kit (Wako). Glycerol, cholesterol, and glucose were measured with commercially 
available kits from DiaSys. Serum adiponectin was determined using the Mouse Ultrasensitive 
Insulin ELISA (ALPCO Diagnostics, Salem, NH, USA). Serum insulin levels were quantified using 
the Quantikine ELISA (R&D Systems, Abingdon, United Kingdom). 
Oil red O staining
3T3-L1 adipoctyes and primary adipocytes were fixed with 4% formaldehyde in PBS for 20 minutes 
at room temperature. Cells were subsequently washed with PBS and incubated with filtered Oil Red 
O solution (30 mg/ml in 60% isopropanol) for 10 minutes. Cells were washed 2-3 times with ddH2O 
twice before taking pictures.
ChIP-seq experiments
ChIP-seq in 3T3-L1 cells and hMADs cells was performed as described previously (48).
Histology
Adipose tissues were collected, fixated in 4% formaldehyde and embedded in paraffin. WAT was cut 
to 8 μm sections, BAT to 5 μm sections. Haematoxylin and eiosin staining was performed according 
to standard protocols. 
Western blot
Proteins were extracted from adipose tissue samples using homogenization buffer (50 mM Tris, pH 
8.0, 150 mM NaCl, 1% v/v NP-40, 0.5% v/v sodium deoxycholate, 0.1% SDS supplemented with 
Complete EDTA-free protease inhibitor cocktail) and the Qiagen TissueLyser II (Qiagen, Venlo, The 
Netherlands). Lysates were rotated for 15 minutes at 4ºC and subsequently centrifuged at 15,000 g 
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for 15 minutes at 4°C. For extraction of protein from 3T3-L1 cells similar homogenization buffer was 
added to PBS washed cells and the cells were subsequently scraped. 
Equal amounts of protein were diluted with 2x Laemmli sample buffer, boiled, and separated 
on 8-16% gradient Criterion gels. Proteins were transferred to PVDF membrane using a Transblot 
turbo system (BioRad, Veenendaal, The Netherlands). Antibodies to detect HILPDA (1:1000, Santa 
Cruz Biotechnology, Inc, #sc-137518), ACTIN (1:2000, Sigma-Aldrich #A2066), HSP90 (1:4000, Cell 
Signaling Technology, Inc, #4874), TUBULIN (1:5000, Cell Signaling Technology, Inc, #2125), and 
anti-rabbit (1:5000, Jackson ImmunoResearch, #111-035-003) were diluted in PBS-T containing 5% 
w/v skimmed milk powder. Quantification of Western blots was done using the ChemiDoc MP system 
(BioRad, Veenendaal, The Netherlands) and Pierce ECL Plus (Thermo Fisher Scientific, Landsmeer, 
The Netherlands). Analysis of phosphorylation with Phos-tag gels was performed according to 
published methods (49). Phos-tag gels allow for the usage of the same antibody to detect native and 
phosphorylated protein.
RNA isolation and qPCR
RNA was isolated from tissues and cells using TRIzol® (Life Technologies Europe BV, Bleiswijk, The 
Netherlands). Homogenization of tissues was performed using a Qiagen TissueLyser II, whereas cells 
were lysed by pipetting up and down several times. Isolated RNA and RNA from the The FirstChoice 
Human Total RNA Survey Panel (Ambion) was reverse transcribed using the First Strand cDNA 
synthesis kit (Thermo Scientific, Landsmeer, The Netherlands). Gene expression analysis was 
performed on a CFX384 Real-Time PCR platform (BioRad, Veenendaal, The Netherlands). SensiMix 
PCR mix was purchased from Bioline (GC biotech, Alphen aan den Rijn, The Netherlands) Primer 
sequences were derived from the Harvard PrimerBank and synthesized by Eurogentec (Eurogentec 
S.A., Seraing, Belgium).
Microarray analysis
RNA from SGBS and hMADs cells (47) was purified with an RNAeasy Minikit (Qiagen). RNA quality 
was verified with the RNA 6000 Nano assay on an Agilent 2100 Bioanalyzer (Agilent Technologies, 
Amsterdam, the Netherlands). Hybridization, washing, and scanning of the Affymetrix Human 
Gene 1.1 ST array plate was performed according to standard protocols on an Affymetrix GeneTitan 
platform. Bioconductor packages were used to analyze the scans of the arrays (50). Robust multiarray 
(RMA) normalization was applied to obtain raw signal intensities (51). Probe sets were defined using 
remapped chip definition file (CDF, version 15) based on the Entrez gene database using published 
methods (52).
Statistical analysis
Student’s t-tests, two-way ANOVAs with Bonferroni post-hoc test or one-way ANOVAs with Tukey’s 
post-hoc test were performed in GraphPad Prism (GraphPad Software, La Jolla, CA, USA). The 
significance level was set at P < 0.05.
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The angiopoietin-like 4 gene (Angptl4) was identified as a peroxisome proliferator activated 
receptor (PPAR) target gene by three independent groups in 2000 (1-3). Since then, 
interest in ANGPTL4 has increased gradually, partly fueled by the finding that ANGPTL4 
regulates lipoprotein lipase (LPL) and the observation that sequence variants of ANGPTL4 
are associated with changes in plasma triglyceride levels in large human studies(4, 5). In 
this thesis, we uncover ANGPTL4 as an important player in the protection of mesenteric 
lymph node (MLN)-resident macrophages from aberrant lipid accumulation and in the 
regulation of lipid digestion by pancreatic lipase (PL).  
ANGTPL4 as a regulator of lipid digestion
In chapter 4 we provide evidence for regulation of dietary lipid digestion by ANGPTL4 
via inhibition of pancreatic lipase (PL). Although the results clearly point to an effect of 
ANGPTL4 on intraluminal lipase activity, several aspects remain that warrant further 
attention and investigation. Of particular importance is the need to identify the specific 
cell(s) that secrete ANGPTL4 towards the intestinal lumen and to show the presence 
of ANGPTL4 in the lumen. The small intestine contains a multitude of cells such as 
enterocytes, enteroendocrine cells and Goblet cells (6, 7). Recent work from our group 
indicates that C-terminal ANGPTL4 is produced in enteroendocrine cells, suggesting 
secretion into the circulation (8). By contrast, we suspect that N-terminal ANGPTL4 is 
produced by enterocytes, possibly via cell-specific expression of proprotein convertases 
involved in ANGPTL4 processing. Unfortunately, the absence of functional antibodies 
for N-terminal ANGPTL4 has made it very difficult to verify this notion. Accordingly, 
concrete experimental evidence is still lacking that N-terminal ANGPTL4 is secreted 
towards the intestinal lumen. Antibody-based strategies to determine either n- or 
cANGPTL4 in the intestinal lumen did not succeed and it will require more sophisticated 
techniques such as mass spectrometry and peptide sequencing to be able to confirm the 
presence of ANGPTL4. Nevertheless, since we observed increased lipase activity in fecal 
waters of Angptl4–/– mice, inhibition of lipid digestion by ANGPTL4 most likely takes 
place intraluminally. 
In addition to pancreatic lipase and colipase, the pancreas also secretes several proteases. 
The presence of high quantities of proteases in the intestinal lumen raises the question 
whether actual interactions between ANGPTL4 and PL are possible. Indeed, it would 
require significant amounts of ANGPTL4 to be secreted in order to reduce intraluminal 
lipase activity. Alternatively, experiments performed in the late 1980s show that heparin 
binds PL to the brush border which promotes the absorption of fatty acids (9, 10). It is 
167
General discussion
7
therefore tempting to speculate that ANGPTL4 mainly inhibits and/or releases active 
PL that is bound to heparin at the brush border. Consequently, such a mechanism 
could reduce the amount of ANGPTL4 required to inhibit lipid uptake. Experiments to 
delineate potential differences in PL binding capacity of intestinal explants of wild-type 
and Angptl4–/– using radioactively labeled pancreatic lipase would be extremely valuable 
to explore this option. 
The constant rate of appearance of radio-labelled lipid in the circulation in our lipid 
absorption test supports the well-established notion that chylomicron synthesis is saturable 
and rate limiting for fat absorption (11). The lack of difference in tracer appearance 
between wild-type and Angptl4–/– animals suggests that ANGPTL4 does not influence 
chylomicron synthesis. Nevertheless, we did observe enhanced accumulation of lipid in 
the enterocytes of Angptl4–/– animals. Hence, we propose that Angptl4–/– mice produce 
chylomicrons at a similar rate but for a prolonged time, leading to a net increase in 
energy delivery. A potential confounding factor in the interpretation of the effect of PL 
inhibition by ANGPTL4 is the utilization of whole-body knockout. Indeed, ANGPTL4 is 
a known inhibitor of LPL and an increase in the capacity of the adipose tissue in Angptl4–/– 
mice to hydrolyze chylomicrons could lead to increased fat deposition (12). However, it 
should be mentioned that transgenic animals with adipose tissue-specific LPL absence 
or overexpression do not develop a phenotype regarding fat mass or body weight (13, 
14). Also, a change in adipose tissue LPL activity is not expected to affect bodyweight 
gain and fat mass, as it does not influence energy balance. Therefore, we believe that 
the increase in adiposity is mainly attributable to increased harvesting of lipids from the 
ingested food.  
Expression of Angptl4 in the small intestine is known to be regulated by PPARα and it is 
therefore likely that increased lipid accumulation in enterocytes leads to PPARα mediated 
induction of Angptl4 (15). Subsequent secretion of ANGPTL4 results in a reduction of 
lipid digestion and uptake via inhibition of PL. Thus, ANGPTL4 assures a controlled 
uptake of lipid in enterocytes and at the same time reduces the total amount of dietary 
lipid harvested. Interestingly, enterocytes are also capable to take up lipids basolaterally 
(16). Lipid taken up from the circulation is thought to represent a distinct pool of lipid 
from those apically absorbed. Indeed, apical acquired lipid is mainly incorporated into 
chylomicrons whereas basolateral derived lipids are used for β-oxidation or phospholipid 
synthesis (17, 18). Currently, there is no evidence that basolateral uptake of lipids requires 
LPL, which is expressed at very low levels in the small intestine, and uptake likely occurs 
in the form of free fatty acids. Accordingly, it is difficult to envision how ANGPTL4 may 
be involved in the regulation of basolateral lipid accumulation. 
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Macrophage LPL is required for a normal immune response
Chylomicrons mainly transport triglycerides. Upon high-fat diet feeding in rats, TG 
concentrations in the chyle that traverses the mesenteric lymphatics are much higher 
compared to plasma levels and can increase up to 55 mM. Consequently, cells residing in 
the MLNs are exposed to extremely high concentrations of TGs. In chapter 3 we provide 
evidence that MLN-resident macrophages require ANGPTL4-mediated inhibition of LPL 
to protect them from becoming engorged with lipid after a high-fat meal. The reason for 
these MLN-resident macrophages to take up lipids is not completely clear. Interestingly, 
chylomicrons have been described as transporters for dietary antigens such as ovalbumin 
(19). Similarly, LPS produced by the gut microbiota and lipid antigens are incorporated 
into lipoproteins (20, 21). Thus, it is conceivable that chylomicrons transport a variety of 
antigens that can be captured by macrophages in an LPL dependent manner for subsequent 
presentation to lymphocytes. Delivery of antigens to the immune cells that reside within 
the mesenteric lymph node represents an important process in the development of a 
normal immune response (22). 
It has been suggested that under certain circumstances including high-fat feeding, 
bacteria translocate from the intestinal lumen to the circulation during which they are 
partially captured in the mesenteric lymph nodes (23, 24). Previous reports suggest that 
fatty acids are an important energy source to fuel phagocytosis (25, 26). More recently 
it was shown that macrophage β-oxidation and OXPHOS results in the production of 
mitochondria-derived reactive oxygen species (ROS) that contribute to eliminating 
phagocytized bacteria (27). It is therefore possible that the uptake of lipid by MLN-resident 
macrophages is required for efficient phagocytosis of bacteria that otherwise would traverse 
to the circulation. The high levels of chylomicrons that traverse these MLN-resident 
macrophages assures an ample supply of fatty acids to generate ROS but also poses a risk 
for excessive lipid uptake. Indeed, the capacity of macrophages to take up lipid is much 
larger than the amount used in oxidation, leading to storage of the surplus (28). Thus, 
LPL-mediated hydrolysis of chylomicrons by MLN-resident macrophages might be 
aimed at the uptake of antigens and lipid in order to develop a normal immune response. 
Without a tight regulation of this process, inappropriate amounts of antigen and lipid may 
accumulate, ultimately culminating in the development of an uncontrolled inflammatory 
response. Considering a potential deficit in fatty acid supply in macrophages of mice with 
ANGPTL4 overexpression it would be interesting to test if these animals have an impaired 
capacity to phagocytose bacteria in MLNs.
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Saturated fatty acids aff ect chylomicron characteristics
Increased lipid accumulation in cells that are not professional lipid storing cells can lead 
to severe adverse effects such as mitochondrial dysfunction, endoplasmic reticulum 
stress, inflammation, and apoptosis. Hence, lipids can have so-called lipotoxic effects (29). 
Our experiments performed in chapter 3 revealed that the high-fat diet-induced lethal 
phenotype in Angptl4–/– mice was specific for high-fat diets containing mainly saturated 
fatty acids. Moreover, induction of ER stress and inflammation in macrophages was 
observed when they were exposed to saturated fatty acids but not unsaturated fatty acids. 
Indeed, compelling data indicate that saturated fatty acids are highly lipotoxic whereas 
unsaturated fatty acids may prevent lipotoxicity (30-32). The high lipotoxic potential of 
saturated fatty acids is thought to be linked to several mechanisms including a low efficiency 
of esterification into TGs and increased synthesis of ceramides and diacylglycerol (DAG). 
However, in addition to the lipotoxic potential of saturated fatty acids it is important to note 
that the consumption of dietary saturated fat changes the characteristics of chylomicrons 
that are produced in the intestine. Diets rich in saturated fatty acids lead to the production 
of smaller chylomicrons with higher apolipoprotein B to triglyceride ratios compared to 
chylomicrons containing unsaturated fatty acids (33, 34). Consequently, chylomicrons 
containing saturated fat are cleared from the circulation at a faster rate (33). Thus, saturated 
fatty acids not only have the inherent property of being lipotoxic, they also lead to faster 
hydrolysis of lipids from lipoproteins, further challenging the cellular response to lipid 
accumulation. Whether the chylomicrons produced upon consumption of saturated 
or unsaturated fat have divergent capacities for the transport of antigens is not known. 
Nevertheless, it is conceivable that in conjunction with increased delipidation of saturated 
fat based chylomicrons, higher levels of antigens accumulate in macrophages. Finally, it 
should be noted that the inflammatory response in macrophages elicited by chyle could be 
completely blocked by inhibiting LPL indicating that other components that are present 
in chyle such as fibrinogen do not contribute to the observed phenotype. 
Growing family of ANGPTL proteins
ANGPTL4 is part of the family of ANGPTL proteins of which ANGPTL3 and ANGPTL4 are 
known to regulate LPL (35). Recently, a new member of the family was described with the 
identification of ANGPTL8 (36, 37). Interestingly, although the function of these ANGPTL 
proteins seems to be related to the inhibition of LPL, the regulation of these proteins as well 
as their mode of action toward LPL seems to be different. Indeed, ANGPTL3 is exclusively 
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expressed in the liver, mainly active during the fed state and inhibits LPL in a reversible 
manner. ANGPTL4 is expressed in multiple tissues and active in the fed and fasted state 
via non-reversible and reversible inhibition of LPL. ANGPTL8 was found to inhibit LPL 
activity primarily in oxidative tissues upon refeeding. Furthermore, ANGPTL8 would at 
the same time spare adipose tissue LPL in order to preserve uptake of lipid in the adipose 
tissue during the postprandial phase (37). LPL is known to be anchored to the cell surface 
of endothelial cells via several receptors including heparan sulfate proteoglycans (HSPGs) 
and glycosylphosphatidylinositol (GPI)-anchored high density lipoprotein-binding protein 
(GPIHBP1), of which the latter acts as an LPL transporter across endothelial cells (38, 39). 
In vitro experiments suggest that LPL bound to GPIHBP1 but not heparin is prevented 
from being inactivated by ANGPTL4 (40). In contrast, ANGPTL3 is unable to inhibit 
LPL in the presence of both GPIHBP1 and heparin (40). It can be hypothesized that the 
presence of specific anchor proteins that bind LPL prevent ANGPTL8 from inhibiting the 
catalytic function of LPL in adipose tissue. Together, these observations indicate that the 
family of ANGPTL proteins is highly important in the control of the amount of lipid that 
is allowed to enter a specific organ during the fed and fasted state.
Mechanism of HILPDA induced lipid accumulation
In chapter 5 we identified Hilpda as new PPAR target in mouse liver. Hepatic overexpression 
of HILPDA resulted in the induction of fatty liver, which we could attribute to a marked 
inhibition of VLDL-TG secretion. Inhibition of VLDL secretion did not result in a change 
in plasma TG levels. Consequently, it can be hypothesized that TGs secreted from mice 
with increased hepatic HILPDA expression are cleared from the circulation at a slower 
rate. This notion should be verified by plasma TG clearance studies using radiolabeled 
VLDL-like particles. A potential explanation for such an increase in TG clearance may 
be that hepatic HILPDA overexpression affects the apolipoprotein composition of VLDL. 
Indeed, multiple apolipoproteins including APOA5, APOC2, and APOE have been 
implicated in the clearance of lipoprotein-derived TG (41-44). Moreover, it has been 
reported that APOE3 overexpression in livers of APOE deficient mice leads to increased 
VLDL-TG secretion without inducing major changes in plasma TG levels, potentially via 
increased clearance of TG-rich lipoproteins in peripheral tissues (45). Thus, interference 
with the function and/or incorporation of APOE3 into VLDL by HILPDA could be a 
potential explanation for the observed discrepancy between hepatic VLDL production 
and plasma TG levels. In this context, it will be interesting to try to identify the specific 
apolipoproteins that are associated with the VLDL secreted from livers with increased 
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HILPDA expression using a proteomics approach. Many apolipoproteins including those 
of the APOC family are of low molecular weight (46). Given the small size of HILPDA 
it is tempting to speculate that HILPDA itself could represent an apolipoprotein that 
interacts with LPL to modulate the lipolytic activity. However, we did not find HILPDA 
to be secreted suggesting that any possible change in plasma TG clearance is likely to be 
related to perturbations in the liver. 
At this point we have no information on the type of lipids accumulating upon HILPDA 
overexpression or where within the liver the surplus lipids are stored. Delineating this 
riddle would be very helpful in order to identify the function of HILPDA in liver lipid 
metabolism. Changes in the abundance of specific lipids might provide clues about the 
molecular targets of HILPDA involved in VLDL assembly and synthesis (47). 
Important work by Gimm et al. suggests that HILPDA is a novel lipid droplet associated 
protein that colocalizes with PLIN2 and PLIN3 at the surface of some but not all lipid 
droplets (48). Both PLIN2 and HILPDA are regulated by PPARα in the liver and increased 
expression of PLIN2 leads to a reduction in VLDL synthesis (49, 50). Conversely, liver-
specific knockdown of PLIN2 significantly reduces hepatic lipid accumulation, while 
causing no change in plasma TG levels (51, 52). Based on these observations it can be 
hypothesized that HILPDA may function similarly to PLIN2 and increase storage of 
TGs in lipid droplet, thereby preventing them from being incorporated into VLDL. It 
should be noted that incorporation of TG within lipid droplets into VLDL likely requires 
their hydrolysis into fatty acids, followed by re-esterification of the fatty acids to become 
VLDL-TG. Accordingly, it is conceivable that HILPDA may impair the accessibility of lipid 
droplets to cytosolic lipases such as adipose tissue triglyceride lipase (ATGL/PNPLA2), 
without directly impairing ATGL activity. Whether HILPDA and PLIN2 cooperate and/or 
physically interact requires further investigation. In future work, we intend to follow two 
different approaches to unravel the specific function of HILPDA in the VLDL secretory 
pathway: 1) the identification of specific lipids that accumulate, and 2) the pull-down 
assays to characterize proteins that potentially bind to HILPDA. Since we have access 
to floxed Hilpda mice it will be interesting to generate liver-specific knockout mice and 
examine if these animals are protected from hepatic steatosis due to increased VLDL-TG 
secretion. Also, generation of intestine-specific knockout mice would be very helpful to 
study if HILPDA is affecting chylomicron synthesis and secretion, as this process shares 
many similarities with VLDL synthesis. 
Hepatic steatosis is a hallmark of many metabolic disturbances and associated with 
insulin resistance. Based on the plasma lipid and glucose parameters, we have no evidence 
for the development of insulin resistance upon hepatic steatosis following hepatic HILPDA 
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overexpression. Whether HILPDA is associated with accumulation of lipotoxic lipids such 
as ceramides and DAG is not clear (53). Nevertheless, it will be important to elucidate 
the potential effect of HILPDA-induced hepatic steatosis on the development of insulin 
resistance.  
Interestingly, HFD-induced hepatic steatosis did not lead to the induction of HILPDA 
in mice. The unaltered expression of HILPDA upon the development of a fatty liver seems 
to correspond to our observations in the differentiation of fibroblast to adipocytes, in 
which we fail to observe major increases in HILPDA expression. Based on the results 
from these experiments we hypothesize that HILPDA is not directly required for lipid 
droplet biogenesis. Instead, HILPDA probably resides at the surface of lipid droplets 
to perform a specific task under certain conditions such as β-adrenergic stimulation 
(discussed below).
HILPDA regulates adipocyte lipolysis
In chapter 6 we revealed that HILPDA expression is highly induced upon stimulation 
of β-adrenergic receptors. Moreover, fasting resulted in a marked increase in HILPDA 
expression in white adipose tissue (WAT). Activation of β-adrenergic receptors leads to 
the phosphorylation and of numerous downstream targets such as protein kinase A and 
perilipin 1 (PLIN1). As a result, PLIN1 directs hormone sensitive lipase (HSL) to surface 
of lipid droplets. Moreover, comparative gene identification-58 (CGI-58), which is bound 
to PLIN1 under basal conditions, now binds to ATGL serving as a coactivator (54). These 
events increase the activity of ATGL and HSL leading the release of non-esterified fatty 
acids (NEFAs). Given the prominent induction of HILPDA by fasting and β-adrenergic 
receptor stimulation we initially reasoned that HILPDA would serve as an activator 
of lipolysis in adipose tissue, potentially as a cofactor for one of the aforementioned 
lipases. However, experiments with adipose tissue-specific Hilpda knockout mice clearly 
demonstrated that deletion of HILPDA has no major impact on the response to fasting. 
In contrast, overexpression of HILPDA in adipocytes consistently led to reduced NEFA 
release upon β-adrenergic receptor activation. Thus, it is likely that HILPDA is induced 
by β-adrenergic receptor and subsequently inhibits lipolysis to ensure controlled release of 
NEFAs in the circulation. Such feedback mechanisms are not uncommon as exemplified 
by the induction of both LPL and ANGPTL4 by PPAR.
An interesting question based on our data is why there is no increase in NEFA release 
with knockdown of HILPDA during fasting or in cell culture with siRNA? One possible 
answer is that increased lipolysis upon HILPDA knockout leads to increased production of 
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PPAR ligands. Indeed, intracellular lipolysis is known to stimulate the activation of PPARs 
in brown adipose tissue (BAT) (55). In congruence, we observed increased expression of the 
PPAR target G0s2 in BAT of ATHilpda–/– animals (56). G0S2 is an inhibitor of ATGL and 
its increased expression could compensate for increased lipolysis upon HILPDA knockout 
(57). Thus, a potential effect of Hilpda deletion might be obscured via increased PPAR 
activity and subsequent induction of G0S2. Alternatively, a potential increased lipolytic rate 
upon HILPDA knockout may be counteracted by increased re-esterification of NEFAs into 
TGs. Future microarray experiments would provide a good opportunity to characterize 
additional differentially regulated genes upon knockout of adipose tissue HILPDA. 
Experiments in chapter 5 revealed that HILPDA does not directly regulate ATGL or 
HSL activity in liver samples or in an in vitro system. However, this does not exclude a 
possibility for HILPDA to regulate lipolysis and lipase function in adipocytes. As mentioned 
above, PLIN1 plays an important role in the regulation of adipocyte lipolysis. Since PLIN1 
is not expressed in liver it can be speculated that it contributes to a potential tissue-specific 
function of HILPDA in adipose tissue. Consequently, additional experiments will have 
to address a (indirect) inhibitory effect of HILPDA on several key lipases involved in the 
release of NEFAs in adipocytes. 
Expression of HILPDA in macrophages
Unpublished work of our laboratory indicates that HILPDA expression is highly induced 
upon lipid loading of macrophages. In fact, Hilpda is consistently found in the top 15 
of most highly induced genes upon exposure of macrophages to fatty acids or TG-rich 
lipoproteins. Hence, we initially anticipated HILPDA expression in adipose tissue to 
be mainly localized in the SVF, which contains numerous cells including adipocyte 
progenitor cells and macrophages. Moreover, we expected to find major increases in 
HILPDA expression upon high-fat diet intervention or fasting, two challenges that are 
known to increase lipid deposition in adipose tissue macrophages (58, 59). However, 
despite a marked increase in the expression of Cd68 in the SVF fraction upon high-fat diet 
feeding we failed to observe changes in the abundance of Hilpda in the SVF. A potential 
explanation could be that HILPDA is expressed in lipid laden macrophages that separate 
together with adipocytes as has been described in literature (60, 61). Nevertheless, it can 
be expected that a major fraction of macrophages that have accumulated some lipid are 
in the SVF and future experiments will have to address this issue. Immunohistochemistry 
of crown-like structure in adipose tissue of wild-type animals revealed the presence of 
HILPDA positive cells providing evidence for the presence of HILPDA in lipid laden 
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macrophages in vivo. Similar experiments will be performed in adipose tissue of adipose 
tissue-specific Hilpda knockout mice to provide conclusive evidence on the presence 
of HILPDA in macrophages in vivo. Another intriguing observation is the absence of 
induction of Hilpda expression upon exposure of macrophages to potent PPAR ligands. 
In the same experiments the expression of Plin2, a known PPAR target, was increased 
upon exposure to ligands for PPARβ/δ and PPARγ. At this stage it is difficult to explain 
the absence of PPAR induced Hilpda expression in macrophages. Possibly, the PPRE is 
physically not accessible for PPARβ/δ or PPARγ due to occupancy of proximal response 
elements by other transcription factors that bind with higher affinity. Future experiments 
will take advantage of this interesting observation to get a better understanding tissue-
specific induction of target genes by PPARs.
Conclusion
In this thesis we have extended our knowledge on the function of ANGPTL4 in lipid 
metabolism. We demonstrated that ANGPTL4 plays an important role in the protection 
of mesenteric lymph node resident macrophages from becoming engorged with lipid. 
Accumulation of saturated fat in macrophages upon loss of ANGPTL4-mediated 
inhibition of LPL activity elicited an inflammatory process in the lymph nodes ultimately 
culminating in fibrinopurulent peritonitis. Angptl4–/– mice initially gain more weight 
when fed a high-fat diet in the absence of inflammation. We provided evidence for this 
observation being dependent on inhibition of PL by ANGPTL4. As a result, mice lacking 
ANGPTL4 harvest more lipids from dietary sources leading to increased body weight 
and adiposity. We identified HILPDA as a novel PPAR target in mouse liver and adipose 
tissue. Overexpression of HILPDA in liver led to a significant decrease in hepatic VLDL-
TG secretion and the development of a fatty liver. In addition to regulation of HILPDA 
by PPARγ we observed marked inductions in HILPDA expression upon fasting and 
β-adrenergic receptor activation in adipose tissue. Deletion of Hilpda in adipose tissue 
had no major impact on the metabolic response to fasting. In contrast, overexpression 
of HILPDA in adipocytes resulted in a reduction of NEFA release upon β-adrenergic 
receptor stimulation. Thus, HILPDA represents a novel PPAR target involved in hepatic 
and adipose tissue lipid metabolism via regulation of VLDL-TG secretion and adipocyte 
lipolysis, respectively.
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De peroxisoomproliferatorgeactiveerde receptoren (PPARs) omvatten een groep van 
nucleaire receptoren die een belangrijke rol spelen in de regulatie van het vetmetabolisme. 
Verschillende componenten uit onze voeding waaronder onverzadigde vetzuren kunnen 
dergelijke PPARs activeren. Actief PPAR bindt aan specifieke plaatsen op het DNA 
en stimuleert de productie van mRNA, wat leidt tot de productie van een eiwit. Drie 
verschillende PPARs zijn er geïdentificeerd: PPARα, PPARβ/δ en PPARγ. De specifieke 
functies die deze PPARs uitoefenen worden bepaald door zowel de relatieve expressie 
van een PPAR in een cel alsook de set van genen die door de PPAR wordt gereguleerd.  
Angiopoietin-like 4 (ANGPTL4) is één van de vele genen die door deze PPARs wordt 
gereguleerd. ANGPTL4 wordt in verschillende organen geproduceerd waaronder de lever 
en vetweefsel en ondergaat vervolgens verschillende modificaties. Zo wordt ANGPTL4 
in twee delen geknipt: nANGPTL4 en cANGPTL4, die beide verschillende functies 
uitvoeren. nAGPTL4 remt de werking van lipoproteïnelipase (LPL), een belangrijk eiwit 
dat betrokken is bij de afbraak en opname van triglyceriden uit het plasma. cANGPTL4 is 
niet betrokken in het vetmetabolisme maar speelt een rol in tumorgroei en wondheling. 
In dit proefschrift hebben we getracht de huidige kennis over de moleculaire functies van 
ANGPTL4 in het vetmetabolisme verder uit te diepen. Daartoe hebben we verschillende 
technieken gebruikt waaronder dierproeven, celkweek experimenten, biochemische 
experimenten en andere functionele metingen.
Gedurende één van die experimenten hebben we muizen zonder ANGPTL4, zogeheten 
Angptl4 knockout muizen (Angptl4–/–), een hoog-vet dieet gegeven dat voornamelijk uit 
lange-keten verzadigde vetzuren bestond. Hierbij werden de muizen zonder ANGPTL4 
al snel erg ziek en stierven ze aan fibrinopurulente peritonitis, terwijl wild-type dieren 
deze problemen niet ontwikkelden. Wanneer het vet in het dieet werd vervangen door 
lange-keten onverzadigde vetzuren of middellange-keten vetzuren ontstond er ook in de 
Angptl4–/– muizen geen ontstekingsreactie. Dit was een belangrijke aanwijzing in het vinden 
van de oorzaak van het ziek worden van Angptl4–/– dieren bij een dieet bestaande uit lange-
keten verzadigde vetzuren. Daar waar lange-keten vetzuren via het mesenteriaal lymfatisch 
stelsel naar de vena subclavia worden getransporteerd in zogeheten chylomicronen, worden 
korte-keten vetzuren via de poortader naar de lever getransporteerd. Bij nauwkeurige 
inspectie van het mesenteriaal lympfatisch stelsel viel het op dat Angptl4–/– dieren vergrote 
lymfeklieren in het mesenterium ontwikkelden wanneer ze een dieet uit lange-keten 
verzadigde vetzuren kregen aangeboden. Microscopisch onderzoek toonde aan dat deze 
mesenteriale lymfeklieren veel met vet gevulde macrofagen bevatten. Daaropvolgende 
in vitro experimenten toonden aan dat PPARβ/δ de productie van ANGPTL4 in deze 
macrofagen stimuleert wanneer er vet de cel binnenkomt. Vervolgens remt ANGPTL4 
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de werking van LPL om op die manier de vetopname in deze macrofagen te voorkómen. 
Wanneer er geen ANGPTL4 aanwezig is zoals in het geval van de Angptl4–/– muizen, 
nemen macrofagen ongelimiteerd vet op. Uiteindelijk leidt dit tot een verstoring van de 
werking van het endoplasmatisch reticulum en een ongecontroleerde ontstekingsreactie 
die vervolgens uitmondt in fibrinopurulente peritonitis.
Naast de waargenomen ontstekingsreactie die wordt veroorzaakt door lange-keten 
verzadigde vetzuren, komen dieren zonder ANGPTL4 sterker aan in gewicht wanneer 
ze een dieet krijgen aangeboden dat is gebaseerd op lange-keten onverzadigde vetzuren. 
Deze toename in lichaamsgewicht was niet gerelateerd aan een toename in voedselinname, 
lichaamsactiviteit, of een afname in energieverbruik. Echter, Angplt4–/– dieren scheidden 
minder vet uit via de ontlasting in vergelijking met wild-type dieren. Vervolgexperimenten 
lieten zien dat muizen zonder ANGPTL4 zich kenmerken door een verhoogde lipase-
activiteit in hun darminhoud. Pancreatisch lipase is de belangrijkste lipase die door de 
alvleesklier wordt geproduceerd en het grootste gedeelte van het aanwezige vet in voedsel 
verteert. In vitro experimenten toonden vervolgens aan dat ANGPTL4 de werking van 
pancreatisch lipase remt.  
In het tweede deel van dit proefschrift beschrijven we de identificatie en karakterisatie 
van hypoxia inducible lipid droplet associated (HILPDA) als een PPAR gereguleerd gen. 
In initiële experimenten waarbij we dunne plakjes lever van muizen blootstelden aan een 
ligand voor PPARα kwam HILPDA uit de analyse als een mogelijk door PPAR gereguleerd 
gen. Vervolgens observeerden we een substantiële toename in de expressie van HILPDA 
wanneer we normale muizen voerden met een ligand voor PPARα, terwijl deze toename 
niet zichtbaar was wanneer dezelfde ligand aan muizen zonder PPARα werd gegeven. 
Vervolgexperimenten lieten zien dat de regulatie van HILPDA door PPARα is gebaseerd 
op een bindingsplaats voor PPAR op het DNA op ongeveer 1200 basenparen van de plaats 
waar de productie van Hilpda mRNA start. Deze bindingsplaats is zowel in muizen als in 
mensen aanwezig. 
Om een eventuele functie van HILPDA in de lever te onderzoeken hebben we wild-
type muizen met een adeno-geassocieerd virus geïnjecteerd dat specifiek de expressie van 
HILPDA in de lever verhoogt. Muizen met een lever-specifieke overexpressie van HILPDA 
ontwikkelden een vette lever. Daaropvolgende experimenten lieten zien dat muizen met 
een verhoogde HILPDA-expressie in hun lever minder very-low-density-lipoproteïnen 
(VLDL)-triglyceriden produceren, met als gevolg het ontstaan van een vette lever. 
Naast de hierboven bescheven functie van HILPDA in de regulatie van VLDL-
triglyceriden secretie in de lever, observeerden we een susbtantieel expressieniveau van 
HILDPA in vetweefsel van zowel muizen als mensen. In het vetweefsel vonden we dat de 
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expressie van HILPDA wordt gereguleerd door zowel PPARγ en β-adrenerge receptoren. 
Daarnaast was er een toename in de expressie van HILPDA in vetweefsel te zien wanneer 
muizen werden gevast, terwijl er een afname te zien was bij een hoog-vet interventie. 
Meerdere experimenten waarbij gebruik is gemaakt van zowel knockdown als overexpressie 
van HILPDA, hebben laten zien dat HILPDA geen effect heeft op vetceldifferentiatie. 
Muizen die het Hilpda-gen specifiek in het wit en bruin vetweefsel missen vertoonden geen 
metabole afwijking nadat ze werden gevast. Echter, overexpressie van HILPDA in vetcellen 
verlaagde de hoeveelheid vrije vetzuren die werd afgegeven bij activatie van de β-adrenerge 
receptoren. De toename in HILPDA-expressie na stimulatie van β-adrenerge receptoren is 
mogelijk een feedbackmechanisme gericht op het reguleren van de hoeveelheid vetzuren 
die wordt afgegeven.
Samengevat, in dit proefschrift hebben we belangrijke nieuwe kennis vergaard over 
de functie van ANGPTL4. We laten zien dat ANGPTL4 een belangrijke rol speelt in de 
regulatie van het proces van vetvertering en ook in het voorkómen van ongecontroleerde 
vetopname in macrofagen die zich in mesenteriale lymfeklieren bevinden. Vervolgens 
hebben we aangetoond dat HILDPA een nieuw doelgen van PPARα is en betrokken bij de 
regulatie van VLDL-triglyceriden secretie en vetzuurafgifte in het vetweefsel. Toekomstig 
onderzoek richt zich op de mechanistische aspecten die ten grondslag liggen aan de 
regulatie en functies van HILPDA in de lever en vetweefsel
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Daar komen ze dan. De meest gelezen pagina’s van een proefschrift. Vaak ook de enige. 
En dat terwijl hoofdstuk 6 toch echt een aanrader is.
Hoewel het fijn is om dingen af te kunnen ronden, komt met elke letter in dit dankwoord 
mijn vertrek uit Wageningen dichterbij. Waarschijnlijk is dat ook de reden dat ik het 
schrijven ervan zo lang mogelijk heb uitgesteld. Ik heb altijd met veel plezier in Wageningen 
gewerkt en zal met veel goede herinneringen aan deze periode terugdenken. Dit is met 
name te danken aan de prettige werksfeer op het lab.
Allereerst wil ik een paar woorden richten aan mijn promotor, Sander Kersten. Sander, 
zonder jouw kennis, hulp, geduld, maar ook de vrijheid en kansen die je me hebt gegeven, 
had ik de eindstreep nooit gehaald. Je hebt me veel geleerd over het doen van goed en solide 
onderzoek. Het was altijd erg prettig om ’s avonds laat via de mail nog wat ideeën uit te 
wisselen of wat advies te kunnen vragen. Dankzij jouw kritische blik en een discussietje zo 
af en toe heb ik ook veel over mezelf geleerd. Waarschijnlijk zul je niet veel eigenwijzere 
AIO’s meer tegenkomen, dus het ergste heb je maar meteen gehad. Heel erg bedankt voor 
alles. Ik had me geen betere promotor kunnen wensen. 
Michael, erg fijn dat ik binnen jouw NMG-groep onderzoek heb mogen doen. Je 
kritische blik en visie hebben me geleerd dat je je niet altijd maar op je eilandje moet 
blijven focussen. Heel erg bedankt.
Soms kom je iemand tegen waar het meteen mee klikt, zonder al te veel woorden te 
hebben gewisseld. Zo iemand trof ik een tijdje na de start van mijn PhD. Rinke, ik wil je 
bedanken voor al die gezellige koffiepauzes waarin we het laatste wielernieuws bespraken, 
een uitzending van Voetbal International nog eens analyseerden, ideeën uitwisselden 
met betrekking tot het onderzoek en hele ladingen aan slechte grappen aan het adres van 
Sander maakten. Een paar honderd liter koffie later durf ik wel te zeggen dat het zonder 
jouw aanwezigheid in het lab niet hetzelfde zou zijn geweest. Ik wens je veel succes met je 
toekomstige onderzoek. Bedankt dat je naast me gaat staan tijdens de verdediging.
Uiteraard wil ik ook graag mijn kamergenoten bedanken voor de gezellige tijd in 
0049b. Karin, heel erg bedankt voor al die ELISAs, het zijn van een gezellige buurvrouw, 
alle last-minute bestellingen en voor het onderhouden van de plant. Shohreh, I have to 
make an exemption for you, as I am not sure whether I should thank you or not. I mean, 
you are the one who provided all the candy resulting in my occasional weight gain… 
Just kidding, I want to thank you for all your help and for being such a nice roommate. 
Ya, I wish you all the best with the remainder of your time as a PhD student, finding 
‘your compound’, and of course lots of joy with your son. It was always nice to talk about 
the kids. Thanks Fenni for being such a nice roommate and good luck with your thesis. 
I’m sure you will manage. I would also like to thank Sheril for the help with the initial 
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pancreatic lipase assays and for being such a kind roommate. Good luck with your carreer. 
(s)Jenny (s)Jansen, bedankt voor het zijn van een lieve kamergenoot en je humor. Je rust 
en relaxte manier van werken heb ik altijd erg fijn gevonden. Waarschijnlijk ben je ook 
de enige hier op het lab die me ooit heeft verstaan met mijn rare dialect. Super dat je me 
wil bijstaan tijdens m’n promotie. 
Guido (Bontempi) Hooiveld, man naar mijn hart. Altijd behulpzaam en lekker direct. 
Niets meer aan veranderen. Bedankt voor je gezelligheid, enthousiasme en natuurlijk 
het niet te vergeten practicum tijdens het WK voetbal. Eigenlijk zou elk lab een ‘Guido’ 
moeten hebben.
Dan de collega-AIO’s binnen het groepje van Sander. Wieneke, heel veel succes met de 
rest van je PhD. Ik weet zeker dat je er iets moois van gaat maken. Het was erg prettig om 
met je samen te werken. Milène, nog even en je bent de volgende die mag promoveren. 
Je bent al erg goed op weg, dus dat gaat, kinda… wel lukken. Aafke en Lily. Jullie zijn 
nog maar relatief kort geleden toegetreden tot het groepje van Sander maar ik ben er van 
overtuigd dat het allemaal goed komt. Jullie zijn allebei een echte aanwinst die ook veel 
gezelligheid hebben toegevoegd. Veel succes voor de toekomst.
Vervolgens Diederik, Juri, Sophie, en alle eerdere bewoners van kamer 0051. Het was 
erg prettig om zo af en toe bij jullie binnen te vallen om wat slechte grappen en andere 
zaken te kunnen ventileren. Dank hiervoor. Ik wens jullie allemaal veel succes met jullie 
toekomstige onderzoek. Diederik, nog erg bedankt voor al je advies tijdens het afronden 
van mijn proefschrift. 
Uiteraard wil ik nog meer collega’s bedanken. 
Mieke: zonder jou zou de celkweek een puinhoop zijn. Ik wil je bedanken voor al je 
hulp, kunde, en gezelligheid. Carolien, erg bedankt voor de gezellige babbeltjes en veel 
succes nog. Katja, Inge, Jvalini, Neeraj en Nikkie: heel erg bedankt voor de leuke tijd en 
veel succes allemaal nog met het afronden van jullie PhD. Echt super dat onze vis een 
plaatsje krijgt op jullie kantoor. O, Katja, sorry for all my pranks in the hallway. Bedankt 
Mark voor je hulp met de arrays zo af en toe maar vooral voor je humor en alle nutteloze 
feitjes via Wikipedia en al die andere apps. Lydia, Wilma en Mechteld, erg bedankt voor 
jullie gezelligheid. Respect Wilma dat je altijd maar weer zo vroeg op het lab bent. Ik heb 
het een tijdje geprobeerd, maar elke dag om 7 uur beginnen is me toch iets te gortig. Verder 
Philip, Michiel, Parastoo, Marco, Renger, Jocelijn en Klaske allemaal heel veel succes met 
jullie werkzaamheden en bedankt voor de fijne tijd op het lab.
Vervolgens wil ik ook graag de mensen van het CKP bedanken voor al hun hulp en 
kunde. René, Wilma, Judith, Bert, Lisette, Romy, en Rob. Zonder jullie bijdrage was dit 
boekje er zeker niet gekomen en daarom: hartelijk bedankt!
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Mijn zus Bouke met aanhanger Joris en schoonzus Carola met aanhanger Jeroen: ik 
wil jullie bedanken voor jullie interesse, hulp en geduld. 
Marleen, we hebben als familie geen gemakkelijke periode achter de rug met het 
overlijden van Hub. Ik vind het bewonderenswaardig hoe jij je hier doorheen weet te slaan 
en altijd interesse in mijn werk hebt getoond. Heel erg bedankt. 
Pa en Ma, meestal hadden jullie geen flauw idee waar ik me precies mee bezig hield 
anders dan ‘iets in het lab’ of ‘wat muizen opensnijden’. Toch hebben jullie me altijd vrij 
gelaten in mijn keuzes en me hier ook in gesteund. Ik heb dat altijd erg fijn gevonden. Ik 
wil jullie bedanken voor de  onvoorwaardelijke hulp. Zonder jullie aanwezigheid was het 
niet gelukt, zeker niet in de afgelopen 1.5 jaar na de geboorte van Fabian. 
Als laatste wil ik mijn lieve Christel bedanken. Om jou te bedanken Christel zou ik 
eigenlijk een boek moeten schrijven. Al je opofferingen omdat ik zonodig de wetenschapper 
uit wil hangen zijn te gek voor woorden: verhuizen, parttime gaan werken, en veel reizen. 
Ik vind het stoer dat je het ook nu weer aandurft om ‘eens iets anders te doen’. Je bent een 
geweldige moeder en een fantastische vrouw. We hebben samen altijd veel lol en zonder 
jouw ‘schop onder mijn kont’ en liefde ben ik nergens. Ik weet zeker dat we samen met 
Fabian een hele leuke tijd tegemoet gaan in Heidelberg.
Frits
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